<!DOCTYPE html>
<html><head><meta charset="UTF-8">
<title>Earnings Call ë²ˆì—­</title>
<style>
    body { font-family: Arial; margin: 40px; background-color: #fdfdfd; }
    h1 { text-align: center; }
    h2 { margin-top: 50px; color: #003366; }
    h3 { color: #333; }
    table { border: 1px solid #ddd; width: 100%; border-collapse: collapse; }
    th { background: #f0f0f0; padding: 10px; border-bottom: 2px solid #ccc; }
    td { padding: 10px; border-bottom: 1px dotted #ccc; vertical-align: top; }
    p { line-height: 1.6; }
    hr { margin: 50px 0; border: none; border-top: 1px solid #ccc; }
    .back-button {
        display: inline-block;
        background-color: #5f5f5f;
        color: white;
        padding: 10px 16px;
        border-radius: 6px;
        text-decoration: none;
        font-weight: 500;
        box-shadow: 0 2px 6px rgba(0,0,0,0.1);
        margin-bottom: 30px;
    }
</style>
</head><body>
<a href="../../index.html" class="back-button">â†</a>
<h1>ğŸ“„ Earnings Call Transcript ë²ˆì—­ ê²°ê³¼</h1>

    <h2>ğŸ“Š Presentation</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>IDEXX Laboratories, Inc.</td><td># IDEXX Laboratories, Inc. ì‹¤ì  ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œ<br><br>**ë°œí‘œì:**<br>- ì¡´ ì•„ë¥´ë´ (John Arden) - íˆ¬ìì ê´€ê³„ ë‹´ë‹¹ ë¶€ì‚¬ì¥<br>- ì œì´ ë§ˆì ¤ìŠ¤í‚¤ (Jay Mazelsky) - ì‚¬ì¥ ê²¸ CEO<br>- ë¸Œë¼ì´ì–¸ ë§¥í‚¨ (Brian McKeon) - ìµœê³  ì¬ë¬´ ë° ìš´ì˜ ì±…ì„ì<br><br>**ì£¼ìš” ë‚´ìš©:**<br><br>ì œì´ ë§ˆì ¤ìŠ¤í‚¤ CEOëŠ” 2024ë…„ 4ë¶„ê¸° ë° ì—°ê°„ ì‹¤ì ì„ ë°œí‘œí•˜ë©° íšŒì‚¬ì˜ ê°•ë ¥í•œ ì„±ê³¼ë¥¼ ê°•ì¡°í–ˆìŠµë‹ˆë‹¤.<br><br>**2024ë…„ 4ë¶„ê¸° ì‹¤ì :**<br>- ë§¤ì¶œ 9ì–µ 7,100ë§Œ ë‹¬ëŸ¬ë¡œ ì „ë…„ ëŒ€ë¹„ 7% ì¦ê°€ (ë³´ê³  ê¸°ì¤€), ìœ ê¸°ì  ì„±ì¥ë¥  8%<br>- CAG(ë°˜ë ¤ë™ë¬¼) ì§„ë‹¨ ë§¤ì¶œ 7% ì¦ê°€, ìœ ê¸°ì  ì„±ì¥ë¥  8%<br>- ìˆ˜ì˜í•™ ì†Œí”„íŠ¸ì›¨ì–´ ë° ì§„ë‹¨ ì˜ìƒ ë§¤ì¶œ 11% ì¦ê°€<br>- ê°€ì¶•, ê°€ê¸ˆë¥˜ ë° ë‚™ë† ë§¤ì¶œ 9% ì¦ê°€<br>- ìˆ˜ìì› ë§¤ì¶œ 7% ì¦ê°€<br>- ì¡°ì • ì˜ì—…ì´ìµë¥  30.9%ë¡œ ì „ë…„ ëŒ€ë¹„ 110bp ê°œì„ <br>- ì¡°ì • EPS $2.88ë¡œ ì „ë…„ ëŒ€ë¹„ 12% ì¦ê°€<br><br>**2024ë…„ ì—°ê°„ ì‹¤ì :**<br>- ì´ ë§¤ì¶œ 37ì–µ ë‹¬ëŸ¬ë¡œ ì „ë…„ ëŒ€ë¹„ 6.5% ì¦ê°€ (ë³´ê³  ê¸°ì¤€), ìœ ê¸°ì  ì„±ì¥ë¥  7.5%<br>- ì¡°ì • ì˜ì—…ì´ìµë¥  30.4%ë¡œ ì „ë…„ ëŒ€ë¹„ 90bp ê°œì„ <br>- ì¡°ì • EPS $10.78ë¡œ ì „ë…„ ëŒ€ë¹„ 11% ì¦ê°€<br>- ì˜ì—… í˜„ê¸ˆíë¦„ 11ì–µ ë‹¬ëŸ¬ë¡œ ì „ë…„ ëŒ€ë¹„ 17% ì¦ê°€<br>- ìì‚¬ì£¼ ë§¤ì…ì— 7ì–µ 5,000ë§Œ ë‹¬ëŸ¬ íˆ¬ì<br><br>**ì£¼ìš” ì„±ê³¼ ë™ì¸:**<br>- ê¸€ë¡œë²Œ í”„ë¦¬ë¯¸ì—„ ê¸°ê¸° ì„¤ì¹˜ ëŒ€ìˆ˜ ì „ë…„ ëŒ€ë¹„ 9% ì¦ê°€<br>- ë¯¸êµ­ ë‚´ ë°˜ë³µ ìˆ˜ìµ 6% ì¦ê°€<br>- êµ­ì œ ì‹œì¥ì—ì„œ ê°•ë ¥í•œ ì„±ì¥ì„¸ ì§€ì†<br>- í˜ì‹ ì ì¸ ì œí’ˆ ì¶œì‹œ ë° ê³ ê° ì°¸ì—¬ ê°•í™”<br><br>**2025ë…„ ì „ë§:**<br>- ì´ ë§¤ì¶œ ì„±ì¥ë¥  7~9% ì˜ˆìƒ (ìœ ê¸°ì  ì„±ì¥ë¥  8~10%)<br>- ì¡°ì • ì˜ì—…ì´ìµë¥  30.5~31% ëª©í‘œ<br>- ì¡°ì • EPS $11.65~$12.05 ì˜ˆìƒ (ì „ë…„ ëŒ€ë¹„ 8~12% ì¦ê°€)<br>- ì˜ì—… í˜„ê¸ˆíë¦„ 11ì–µ~12ì–µ ë‹¬ëŸ¬ ì˜ˆìƒ<br>- ìë³¸ ì§€ì¶œ 2ì–µ 5,000ë§Œ~2ì–µ 7,500ë§Œ ë‹¬ëŸ¬ ê³„íš<br><br>ë¸Œë¼ì´ì–¸ ë§¥í‚¨ CFOëŠ” ì¬ë¬´ ì„¸ë¶€ì‚¬í•­ì„ ì„¤ëª…í•˜ë©° íšŒì‚¬ì˜ ê²¬ê³ í•œ ìˆ˜ìµì„±ê³¼ í˜„ê¸ˆ ì°½ì¶œ ëŠ¥ë ¥ì„ ê°•ì¡°í–ˆìŠµë‹ˆë‹¤. ê²½ì˜ì§„ì€ í˜ì‹ , ê³ ê° ê°€ì¹˜ ì œê³µ, ìš´ì˜ íš¨ìœ¨ì„± ê°œì„ ì„ í†µí•´ ì§€ì† ê°€ëŠ¥í•œ ì„±ì¥ì„ ì¶”êµ¬í•  ê²ƒì´ë¼ê³  ë°í˜”ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>(IDXX) Q4 2025 Earnings Call February 2, 2026 8:30 AM EST<br><br>Company Participants<br><br>Andrew Emerson - Executive VP, CFO & Treasurer<br>Jay Mazelsky - President, CEO & Director<br><br>Conference Call Participants<br><br>Christopher Schott - JPMorgan Chase & Co, Research Division<br>Erin Wilson Wright - Morgan Stanley, Research Division<br>Michael Ryskin - BofA Securities, Research Division<br>Jonathan Block - Stifel, Nicolaus & Company, Incorporated, Research Division<br>Daniel Christopher Clark - Leerink Partners LLC, Research Division<br>Brandon Vazquez - William Blair & Company L.L.C., Research Division<br>Andrea Zayco Narvaez Alfonso - UBS Investment Bank, Research Division<br><br>Presentation<br><br>Operator<br><br>Good morning, and welcome to the IDEXX Laboratories Fourth Quarter 2025 Earnings Conference Call.</td><td>2026ë…„ 2ì›” 2ì¼ ì˜¤ì „ 8ì‹œ 30ë¶„ (ë¯¸ ë™ë¶€ í‘œì¤€ì‹œ)<br><br>(IDXX) 2025ë…„ 4ë¶„ê¸° ì‹¤ì  ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œ<br><br>íšŒì‚¬ ì°¸ì„ì<br><br>ì•¤ë“œë¥˜ ì—ë¨¸ìŠ¨ - ì „ë¬´ì´ì‚¬, ìµœê³ ì¬ë¬´ì±…ì„ì ê²¸ ì¬ë¬´ë‹´ë‹¹<br>ì œì´ ë§ˆì ¤ìŠ¤í‚¤ - ì‚¬ì¥, ìµœê³ ê²½ì˜ì ê²¸ ì´ì‚¬<br><br>ì»¨í¼ëŸ°ìŠ¤ ì½œ ì°¸ì—¬ ì• ë„ë¦¬ìŠ¤íŠ¸<br><br>í¬ë¦¬ìŠ¤í† í¼ ì‡¼íŠ¸ - JPëª¨ê±´ ì²´ì´ìŠ¤, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ì—ë¦° ìœŒìŠ¨ ë¼ì´íŠ¸ - ëª¨ê±´ ìŠ¤íƒ ë¦¬, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ë§ˆì´í´ ë¦¬ìŠ¤í‚¨ - ë±…í¬ì˜¤ë¸Œì•„ë©”ë¦¬ì¹´ ì¦ê¶Œ, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ì¡°ë‚˜ë‹¨ ë¸”ë¡ - ìŠ¤í‹°í  ë‹ˆì½œë¼ìš°ìŠ¤, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ë‹¤ë‹ˆì—˜ í¬ë¦¬ìŠ¤í† í¼ í´ë¼í¬ - ë¦¬ì–´ë§í¬ íŒŒíŠ¸ë„ˆìŠ¤<br>ë¸Œëœë“  ë°”ìŠ¤ì¼€ìŠ¤ - ìœŒë¦¬ì—„ ë¸”ë ˆì–´<br>ì•ˆë“œë ˆì•„ ìì´ì½” ë‚˜ë¥´ë°”ì—ìŠ¤ ì•Œí°ì†Œ - UBS ì¸ë² ìŠ¤íŠ¸ë¨¼íŠ¸ ë±…í¬, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br><br>ë°œí‘œ<br><br>ìš´ì˜ì<br><br>ì•ˆë…•í•˜ì‹­ë‹ˆê¹Œ. IDEXX ë˜ë²„ëŸ¬í† ë¦¬ìŠ¤ 2025ë…„ 4ë¶„ê¸° ì‹¤ì  ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œì— ì˜¤ì‹  ê²ƒì„ í™˜ì˜í•©ë‹ˆë‹¤.</td></tr>
<tr><td>As a reminder, today's conference is being recorded. Participating in the call this morning are Jay Mazelsky, President and Chief Executive Officer; Andrew Emerson, Chief Financial Officer; and John Ravis, Vice President, Investor Relations. IDEXX would like to preface the discussion today with a caution regarding forward-looking statements. Listeners are reminded that our discussion during the call will include forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those discussed today.</td><td>ì£¼ì˜ì‚¬í•­ìœ¼ë¡œ ë§ì”€ë“œë¦¬ë©´, ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ëŠ” ë…¹ìŒë˜ê³  ìˆìŠµë‹ˆë‹¤. ì˜¤ëŠ˜ ì•„ì¹¨ ì»¨í¼ëŸ°ìŠ¤ ì½œì—ëŠ” Jay Mazelsky ì‚¬ì¥ ê²¸ ìµœê³ ê²½ì˜ì, Andrew Emerson ìµœê³ ì¬ë¬´ì±…ì„ì, ê·¸ë¦¬ê³  John Ravis íˆ¬ììê´€ê³„ ë‹´ë‹¹ ë¶€ì‚¬ì¥ì´ ì°¸ì—¬í•˜ê³  ìˆìŠµë‹ˆë‹¤. IDEXXëŠ” ì˜¤ëŠ˜ ë…¼ì˜ì— ì•ì„œ ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ ì— ê´€í•œ ì£¼ì˜ì‚¬í•­ì„ ë§ì”€ë“œë¦¬ê³ ì í•©ë‹ˆë‹¤. ì²­ì·¨ì ì—¬ëŸ¬ë¶„ê»˜ì„œëŠ” ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ ì½œ ì¤‘ ë…¼ì˜ë  ë‚´ìš©ì—ëŠ” ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ ì´ í¬í•¨ë˜ì–´ ìˆìœ¼ë©°, ì´ëŸ¬í•œ ì§„ìˆ ë“¤ì€ ë¦¬ìŠ¤í¬ì™€ ë¶ˆí™•ì‹¤ì„±ì˜ ì˜í–¥ì„ ë°›ì„ ìˆ˜ ìˆì–´ ì‹¤ì œ ê²°ê³¼ê°€ ì˜¤ëŠ˜ ë…¼ì˜ëœ ë‚´ìš©ê³¼ ì¤‘ëŒ€í•˜ê²Œ ë‹¬ë¼ì§ˆ ìˆ˜ ìˆìŒì„ ìœ ë…í•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤.</td></tr>
<tr><td>Additional information regarding these risks and uncertainties is available under the forward-looking statements notice in our press release issued this morning as well as in our periodic filings with the Securities and Exchange Commission, which can be obtained from the SEC or by visiting the Investor Relations section of our website, idexx.com. During this call, we will be discussing certain financial measures not prepared in accordance with generally accepted accounting principles or GAAP.</td><td>ì´ëŸ¬í•œ ìœ„í—˜ê³¼ ë¶ˆí™•ì‹¤ì„±ì— ê´€í•œ ì¶”ê°€ ì •ë³´ëŠ” ì˜¤ëŠ˜ ì•„ì¹¨ ë°œí‘œëœ ë³´ë„ìë£Œì˜ ì „ë§ ì§„ìˆ (forward-looking statements) ê³µì§€ì‚¬í•­ê³¼ ì¦ê¶Œê±°ë˜ìœ„ì›íšŒ(SEC)ì— ì œì¶œëœ ì •ê¸° ë³´ê³ ì„œì—ì„œ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìœ¼ë©°, SECë¡œë¶€í„° ì§ì ‘ ì…ìˆ˜í•˜ì‹œê±°ë‚˜ ë‹¹ì‚¬ ì›¹ì‚¬ì´íŠ¸ idexx.comì˜ íˆ¬ìì ê´€ê³„(Investor Relations) ì„¹ì…˜ì„ ë°©ë¬¸í•˜ì…”ì„œ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë³¸ ì»¨í¼ëŸ°ìŠ¤ ì½œì—ì„œëŠ” ì¼ë°˜ì ìœ¼ë¡œ ì¸ì •ëœ íšŒê³„ì›ì¹™(GAAP)ì— ë”°ë¼ ì‘ì„±ë˜ì§€ ì•Šì€ íŠ¹ì • ì¬ë¬´ ì§€í‘œë“¤ì— ëŒ€í•´ ë…¼ì˜í•  ì˜ˆì •ì…ë‹ˆë‹¤.</td></tr>
<tr><td>A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP measures is provided in our earnings release, which may also be found by visiting the Investor Relations section of our website. In reviewing our fourth quarter 2025 results and 2026 financial outlook, please note all references to growth, organic growth and comparable growth refer to growth compared to the equivalent prior year period, unless otherwise noted. [Operator Instructions] Today's prepared remarks will be posted to the Investor Relations section of our website after the earnings conference call concludes. I would now like to turn the call over to Andrew Emerson.</td><td>ë¹„GAAP ì¬ë¬´ì§€í‘œì™€ ê°€ì¥ ì§ì ‘ì ìœ¼ë¡œ ë¹„êµ ê°€ëŠ¥í•œ GAAP ì§€í‘œ ê°„ì˜ ì¡°ì •ë‚´ì—­ì€ ë‹¹ì‚¬ ì‹¤ì ë°œí‘œ ìë£Œì— ì œê³µë˜ì–´ ìˆìœ¼ë©°, ë‹¹ì‚¬ ì›¹ì‚¬ì´íŠ¸ì˜ íˆ¬ìì ê´€ê³„(IR) ì„¹ì…˜ì„ ë°©ë¬¸í•˜ì‹œë©´ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. 2025ë…„ 4ë¶„ê¸° ì‹¤ì  ë° 2026ë…„ ì¬ë¬´ ì „ë§ì„ ê²€í† í•˜ì‹¤ ë•Œ, ë³„ë„ ì–¸ê¸‰ì´ ì—†ëŠ” í•œ ì„±ì¥ë¥ , ìœ ê¸°ì  ì„±ì¥ë¥ , ë¹„êµê°€ëŠ¥ ì„±ì¥ë¥ ì— ëŒ€í•œ ëª¨ë“  ì–¸ê¸‰ì€ ì „ë…„ ë™ê¸° ëŒ€ë¹„ ì„±ì¥ë¥ ì„ ì˜ë¯¸í•œë‹¤ëŠ” ì ì„ ìœ ë…í•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤. [êµí™˜ì› ì•ˆë‚´ì‚¬í•­] ì˜¤ëŠ˜ ì¤€ë¹„ëœ ë°œí‘œ ë‚´ìš©ì€ ì‹¤ì ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ì½œ ì¢…ë£Œ í›„ ë‹¹ì‚¬ ì›¹ì‚¬ì´íŠ¸ì˜ íˆ¬ìì ê´€ê³„ ì„¹ì…˜ì— ê²Œì‹œë  ì˜ˆì •ì…ë‹ˆë‹¤. ì´ì œ Andrew Emersonì—ê²Œ ë°œì–¸ê¶Œì„ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Andrew Emerson<br>Executive VP, CFO & Treasurer<br><br>Good morning, and welcome to our fourth quarter earnings call. Today, I'm pleased to review our Q4 and full year 2025 financial results and the company's outlook for 2026. In terms of highlights for 2025, IDEXX delivered excellent financial performance in Q4, driven by double-digit top line gains. Revenue increased 14% as reported and 12% organically, supported by 10% organic growth in CAG Diagnostics recurring revenues.</td><td>ì•¤ë“œë¥˜ ì—ë¨¸ìŠ¨<br>ì „ë¬´ì´ì‚¬, ìµœê³ ì¬ë¬´ì±…ì„ì ê²¸ ì¬ë¬´ë‹´ë‹¹<br><br>ì•ˆë…•í•˜ì‹­ë‹ˆê¹Œ, 4ë¶„ê¸° ì‹¤ì  ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œì— ì˜¤ì‹  ê²ƒì„ í™˜ì˜í•©ë‹ˆë‹¤. ì˜¤ëŠ˜ ì €ëŠ” 2025ë…„ 4ë¶„ê¸° ë° ì—°ê°„ ì¬ë¬´ ì‹¤ì ê³¼ 2026ë…„ íšŒì‚¬ ì „ë§ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê²Œ ë˜ì–´ ê¸°ì˜ê²Œ ìƒê°í•©ë‹ˆë‹¤. 2025ë…„ ì£¼ìš” ì„±ê³¼ë¥¼ ë§ì”€ë“œë¦¬ë©´, IDEXXëŠ” ë‘ ìë¦¿ìˆ˜ ë§¤ì¶œ ì„±ì¥ì— í˜ì…ì–´ 4ë¶„ê¸°ì— íƒì›”í•œ ì¬ë¬´ ì„±ê³¼ë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ë§¤ì¶œì€ ë³´ê³  ê¸°ì¤€ 14%, ìœ ê¸°ì  ì„±ì¥ ê¸°ì¤€ 12% ì¦ê°€í–ˆìœ¼ë©°, ì´ëŠ” CAG ì§„ë‹¨ ë¶€ë¬¸ ê²½ìƒ ë§¤ì¶œì˜ ìœ ê¸°ì  ì„±ì¥ 10%ì— í˜ì…ì€ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>We achieved record premium instrument placements in Q4, with strong gains across our major platforms, including over 1,900 IDEXX inVue Dx placements, supporting a 69% organic year-over-year expansion of our CAG Diagnostic instrument revenues. Strong revenue growth delivered $3.08 in EPS, up 17% on a comparable basis, while advancing planned investments in our commercial and innovation capabilities. IDEXX execution drove solid full year revenue expansion with benefits from organic revenue growth supporting strong financial performance aligned with our long-term potential.</td><td>4ë¶„ê¸°ì— í”„ë¦¬ë¯¸ì—„ ì¥ë¹„ ì„¤ì¹˜ì—ì„œ ê¸°ë¡ì ì¸ ì„±ê³¼ë¥¼ ë‹¬ì„±í–ˆìœ¼ë©°, ì£¼ìš” í”Œë«í¼ ì „ë°˜ì— ê±¸ì³ ê°•ë ¥í•œ ì„±ì¥ì„ ë³´ì˜€ìŠµë‹ˆë‹¤. íŠ¹íˆ IDEXX inVue Dx ì¥ë¹„ë¥¼ 1,900ëŒ€ ì´ìƒ ì„¤ì¹˜í•˜ì—¬ CAG ì§„ë‹¨ ì¥ë¹„ ë§¤ì¶œì˜ ì „ë…„ ëŒ€ë¹„ ìœ ê¸°ì  ì„±ì¥ë¥  69%ë¥¼ ë’·ë°›ì¹¨í–ˆìŠµë‹ˆë‹¤. ê°•ë ¥í•œ ë§¤ì¶œ ì„±ì¥ìœ¼ë¡œ ì£¼ë‹¹ìˆœì´ìµ(EPS)ì€ 3.08ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í•˜ì—¬ ë¹„êµ ê°€ëŠ¥ ê¸°ì¤€ìœ¼ë¡œ 17% ì¦ê°€í–ˆìœ¼ë©°, ë™ì‹œì— ì˜ì—… ë° í˜ì‹  ì—­ëŸ‰ì— ëŒ€í•œ ê³„íšëœ íˆ¬ìë„ ì¶”ì§„í–ˆìŠµë‹ˆë‹¤. IDEXXì˜ ì‹¤í–‰ë ¥ì€ ê²¬ê³ í•œ ì—°ê°„ ë§¤ì¶œ í™•ëŒ€ë¥¼ ê²¬ì¸í–ˆìœ¼ë©°, ìœ ê¸°ì  ë§¤ì¶œ ì„±ì¥ì˜ íš¨ê³¼ê°€ ë‹¹ì‚¬ì˜ ì¥ê¸° ì ì¬ë ¥ì— ë¶€í•©í•˜ëŠ” ê°•ë ¥í•œ ì¬ë¬´ ì„±ê³¼ë¥¼ ë’·ë°›ì¹¨í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>IDEXX achieved 10% overall organic revenue growth for the full year driven by 8% organic growth in CAG Diagnostics recurring revenues. Our global premium instrument installed base expanded 12% year-over-year, including benefits from nearly 6,400 inVue Dx instruments. Full year operating margins reached 31.6%, an increase of 90 basis points on a comparable basis, supported by solid revenue expansion and productivity gains. Full year EPS of $13.08 per share was up 14% year-over-year on a comparable basis from strong operational performance.</td><td>IDEXXëŠ” CAG ì§„ë‹¨ ê²½ìƒë§¤ì¶œì˜ 8% ìœ ê¸°ì  ì„±ì¥ì— í˜ì…ì–´ ì—°ê°„ ì „ì²´ ìœ ê¸°ì  ë§¤ì¶œ 10% ì„±ì¥ì„ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ë‹¹ì‚¬ì˜ ê¸€ë¡œë²Œ í”„ë¦¬ë¯¸ì—„ ì¥ë¹„ ì„¤ì¹˜ ê¸°ë°˜ì€ ì•½ 6,400ëŒ€ì˜ inVue Dx ì¥ë¹„ íš¨ê³¼ë¥¼ í¬í•¨í•˜ì—¬ ì „ë…„ ëŒ€ë¹„ 12% í™•ëŒ€ë˜ì—ˆìŠµë‹ˆë‹¤. ì—°ê°„ ì˜ì—…ì´ìµë¥ ì€ 31.6%ì— ë„ë‹¬í–ˆìœ¼ë©°, ì´ëŠ” ê²¬ì¡°í•œ ë§¤ì¶œ í™•ëŒ€ì™€ ìƒì‚°ì„± í–¥ìƒì— í˜ì…ì–´ ë¹„êµ ê°€ëŠ¥ ê¸°ì¤€ìœ¼ë¡œ 90bp ì¦ê°€í•œ ìˆ˜ì¹˜ì…ë‹ˆë‹¤. ì—°ê°„ ì£¼ë‹¹ìˆœì´ìµ(EPS)ì€ ê°•ë ¥í•œ ì˜ì—… ì‹¤ì ìœ¼ë¡œ ë¹„êµ ê°€ëŠ¥ ê¸°ì¤€ ì „ë…„ ëŒ€ë¹„ 14% ì¦ê°€í•œ 13.08ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>These results were achieved through successful advancement of our innovation-driven growth strategy, including new platform launches, creating a solid foundation to build upon as we enter 2026. We'll discuss our 2026 financial expectations later in my comments. Let's begin with a review of our 2025 results. Fourth quarter organic revenue growth of 12% reflected solid gains across IDEXX's major business segments, including 13% organic growth in CAG, 10% organic growth in Water and 4% organic gains in LPD. Worldwide CAG Diagnostics recurring revenue increased 10% organically in the fourth quarter, including solid benefits from volume growth and average global net price improvement of 4%. U.S.</td><td>ì´ëŸ¬í•œ ì„±ê³¼ëŠ” ìƒˆë¡œìš´ í”Œë«í¼ ì¶œì‹œë¥¼ í¬í•¨í•œ í˜ì‹  ì£¼ë„ ì„±ì¥ ì „ëµì˜ ì„±ê³µì ì¸ ì¶”ì§„ì„ í†µí•´ ë‹¬ì„±ë˜ì—ˆìœ¼ë©°, 2026ë…„ì„ ë§ì´í•˜ëŠ” ì‹œì ì—ì„œ íƒ„íƒ„í•œ ê¸°ë°˜ì„ êµ¬ì¶•í•˜ê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤. 2026ë…„ ì¬ë¬´ ì „ë§ì— ëŒ€í•´ì„œëŠ” ì œ ë°œì–¸ í›„ë°˜ë¶€ì—ì„œ ë…¼ì˜í•˜ê² ìŠµë‹ˆë‹¤. ë¨¼ì € 2025ë…„ ì‹¤ì ì„ ê²€í† í•´ë³´ê² ìŠµë‹ˆë‹¤. 4ë¶„ê¸° ìœ ê¸°ì  ë§¤ì¶œ ì„±ì¥ë¥  12%ëŠ” IDEXXì˜ ì£¼ìš” ì‚¬ì—… ë¶€ë¬¸ ì „ë°˜ì— ê±¸ì¹œ ê²¬ì¡°í•œ ì„±ê³¼ë¥¼ ë°˜ì˜í•œ ê²ƒìœ¼ë¡œ, CAG ë¶€ë¬¸ 13% ìœ ê¸°ì  ì„±ì¥, Water ë¶€ë¬¸ 10% ìœ ê¸°ì  ì„±ì¥, LPD ë¶€ë¬¸ 4% ìœ ê¸°ì  ì„±ì¥ì„ í¬í•¨í•©ë‹ˆë‹¤. ì „ ì„¸ê³„ CAG ì§„ë‹¨ ë¶€ë¬¸ ê²½ìƒ ë§¤ì¶œì€ 4ë¶„ê¸°ì— ìœ ê¸°ì ìœ¼ë¡œ 10% ì¦ê°€í–ˆìœ¼ë©°, ì´ëŠ” ê±°ë˜ëŸ‰ ì¦ê°€ì™€ ì „ ì„¸ê³„ í‰ê·  ìˆœê°€ê²© ê°œì„  4%ì— ë”°ë¥¸ ê²¬ì¡°í•œ íš¨ê³¼ë¥¼ í¬í•¨í•©ë‹ˆë‹¤. ë¯¸êµ­</td></tr>
<tr><td>CAG Diagnostics recurring revenues increased 9% organically in Q4, including approximately 4% net price improvement and approximately 5% volume growth. Volume benefited from sustained new business gains aided by high customer retention levels and expanded utilization, including benefits from IDEXX innovations. In the fourth quarter, IDEXX achieved a revenue growth premium compared to U.S. clinical visit growth levels of approximately 1,100 basis points. Pressure on clinical visits remains a headwind to the sector with U.S. same-store clinical visit declines of approximately 1.7% in Q4 and 1.9% for the full year 2025.</td><td>CAG ì§„ë‹¨ ë¶€ë¬¸ ê²½ìƒ ë§¤ì¶œì€ 4ë¶„ê¸°ì— ìœ ê¸°ì ìœ¼ë¡œ 9% ì¦ê°€í–ˆìœ¼ë©°, ì´ëŠ” ì•½ 4%ì˜ ìˆœ ê°€ê²© ê°œì„ ê³¼ ì•½ 5%ì˜ ë¬¼ëŸ‰ ì„±ì¥ì„ í¬í•¨í•©ë‹ˆë‹¤. ë¬¼ëŸ‰ì€ ë†’ì€ ê³ ê° ìœ ì§€ìœ¨ê³¼ IDEXX í˜ì‹ ì˜ í˜œíƒì„ í¬í•¨í•œ í™•ëŒ€ëœ í™œìš©ë„ì— í˜ì…ì–´ ì§€ì†ì ì¸ ì‹ ê·œ ì‚¬ì—… í™•ë³´ë¡œë¶€í„° ì´ìµì„ ì–»ì—ˆìŠµë‹ˆë‹¤. 4ë¶„ê¸°ì— IDEXXëŠ” ë¯¸êµ­ ì„ìƒ ë°©ë¬¸ ì„±ì¥ë¥  ëŒ€ë¹„ ì•½ 1,100bpì˜ ë§¤ì¶œ ì„±ì¥ í”„ë¦¬ë¯¸ì—„ì„ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ì„ìƒ ë°©ë¬¸ì— ëŒ€í•œ ì••ë°•ì€ í•´ë‹¹ ì„¹í„°ì— ì—­í’ìœ¼ë¡œ ì‘ìš©í•˜ê³  ìˆìœ¼ë©°, ë¯¸êµ­ ë™ì¼ ë§¤ì¥ ì„ìƒ ë°©ë¬¸ì€ 4ë¶„ê¸°ì— ì•½ 1.7%, 2025ë…„ ì „ì²´ ì—°ë„ì—ëŠ” 1.9% ê°ì†Œí–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Wellness and discretionary visits remain more pressured than sick patient visits with wellness visits down 3.6% in Q4, while early signs of an aging pet population and benefits from IDEXX innovations, contributed to diagnostic frequency and volume utilization gains per clinical visit. International organic CAG Diagnostics recurring revenue growth was 12% in Q4, with gains from net price realization and solid volume growth enabled by new business expansion, reflected in our double-digit year-over-year growth of our international premium instrument installed base.</td><td>ì›°ë‹ˆìŠ¤ ë° ì„ íƒì  ë°©ë¬¸ì€ ì§ˆë³‘ í™˜ì ë°©ë¬¸ë³´ë‹¤ ë” ì••ë°•ì„ ë°›ê³  ìˆìœ¼ë©°, 4ë¶„ê¸° ì›°ë‹ˆìŠ¤ ë°©ë¬¸ì€ 3.6% ê°ì†Œí–ˆìŠµë‹ˆë‹¤. ë°˜ë©´ ë°˜ë ¤ë™ë¬¼ ê³ ë ¹í™”ì˜ ì´ˆê¸° ì§•í›„ì™€ IDEXX í˜ì‹ ì˜ ì´ì ì´ ì„ìƒ ë°©ë¬¸ë‹¹ ì§„ë‹¨ ë¹ˆë„ ë° ë³¼ë¥¨ í™œìš©ë„ ì¦ê°€ì— ê¸°ì—¬í–ˆìŠµë‹ˆë‹¤. êµ­ì œ ìœ ê¸°ì  CAG ì§„ë‹¨ ê²½ìƒ ë§¤ì¶œì€ 4ë¶„ê¸°ì— 12% ì„±ì¥í–ˆìœ¼ë©°, ì´ëŠ” ìˆœê°€ê²© ì‹¤í˜„ ì´ìµê³¼ ì‹ ê·œ ì‚¬ì—… í™•ì¥ìœ¼ë¡œ ì¸í•œ ê²¬ê³ í•œ ë³¼ë¥¨ ì„±ì¥ì— í˜ì…ì€ ê²ƒìœ¼ë¡œ, êµ­ì œ í”„ë¦¬ë¯¸ì—„ ì¥ë¹„ ì„¤ì¹˜ ê¸°ë°˜ì˜ ì „ë…„ ëŒ€ë¹„ ë‘ ìë¦¿ìˆ˜ ì„±ì¥ì— ë°˜ì˜ë˜ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>International regions have maintained strong growth throughout the year, highlighting the significant global opportunity and strong demand for diagnostic solutions. IDEXX VetLab consumable revenues increased 15% organically in the quarter, reflecting strong double-digit gains in the U.S. and international regions. Consumable gains benefited from 12% increase of our global premium instrument installed base, reflecting solid advancement across our Catalyst, premium hematology, SediVue and inVue Dx platforms. In the fourth quarter, we placed 6,567 premium instruments, up 42% from the prior year.</td><td>í•´ì™¸ ì§€ì—­ì€ ì—°ì¤‘ ë‚´ë‚´ ê°•ë ¥í•œ ì„±ì¥ì„¸ë¥¼ ìœ ì§€í–ˆìœ¼ë©°, ì´ëŠ” ì§„ë‹¨ ì†”ë£¨ì…˜ì— ëŒ€í•œ ìƒë‹¹í•œ ê¸€ë¡œë²Œ ê¸°íšŒì™€ ê°•ë ¥í•œ ìˆ˜ìš”ë¥¼ ë³´ì—¬ì¤ë‹ˆë‹¤. IDEXX VetLab ì†Œëª¨í’ˆ ë§¤ì¶œì€ 4ë¶„ê¸°ì— ìœ ê¸°ì ìœ¼ë¡œ 15% ì¦ê°€í–ˆìœ¼ë©°, ì´ëŠ” ë¯¸êµ­ê³¼ í•´ì™¸ ì§€ì—­ì—ì„œ ë‘ ìë¦¿ìˆ˜ ê°•í•œ ì„±ì¥ì„ ë°˜ì˜í•œ ê²ƒì…ë‹ˆë‹¤. ì†Œëª¨í’ˆ ì¦ê°€ëŠ” ê¸€ë¡œë²Œ í”„ë¦¬ë¯¸ì—„ ì¥ë¹„ ì„¤ì¹˜ ê¸°ë°˜ì´ 12% ì¦ê°€í•œ ë° ë”°ë¥¸ ê²ƒìœ¼ë¡œ, Catalyst, í”„ë¦¬ë¯¸ì—„ í˜ˆì•¡í•™, SediVue ë° inVue Dx í”Œë«í¼ ì „ë°˜ì— ê±¸ì¹œ ê²¬ê³ í•œ ë°œì „ì„ ë°˜ì˜í•©ë‹ˆë‹¤. 4ë¶„ê¸°ì—ëŠ” 6,567ëŒ€ì˜ í”„ë¦¬ë¯¸ì—„ ì¥ë¹„ë¥¼ ì„¤ì¹˜í–ˆìœ¼ë©°, ì´ëŠ” ì „ë…„ ëŒ€ë¹„ 42% ì¦ê°€í•œ ìˆ˜ì¹˜ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Quarterly placement results included strong gains in inVue Dx and SediVue while sustaining Catalyst placement levels worldwide. For the full year 2025, we achieved approximately 22,500 premium instrument placements with excellent quality, reflected in significantly expanded EVI metrics bolstered by new and competitive Catalyst placements and nearly 6,400 inVue Dx instruments. The successful launch of inVue Dx contributed over $75 million in instrument revenue for the full year, supporting approximately 200 basis points of overall company growth. Rapid assay revenues declined 3% on an organic basis in Q4. Rapid assay results were constrained by pressure on U.S.</td><td>ë¶„ê¸°ë³„ ì„¤ì¹˜ ì‹¤ì ì€ inVue Dxì™€ SediVueì—ì„œ ê°•ë ¥í•œ ì¦ê°€ì„¸ë¥¼ ë³´ì˜€ìœ¼ë©°, ì „ ì„¸ê³„ì ìœ¼ë¡œ Catalyst ì„¤ì¹˜ ìˆ˜ì¤€ì„ ìœ ì§€í–ˆìŠµë‹ˆë‹¤. 2025ë…„ ì „ì²´ ì—°ë„ ê¸°ì¤€ìœ¼ë¡œ ì•½ 22,500ëŒ€ì˜ í”„ë¦¬ë¯¸ì—„ ì¥ë¹„ë¥¼ ì„¤ì¹˜í–ˆìœ¼ë©°, ì‹ ê·œ ë° ê²½ìŸë ¥ ìˆëŠ” Catalyst ì„¤ì¹˜ì™€ ì•½ 6,400ëŒ€ì˜ inVue Dx ì¥ë¹„ë¡œ ë’·ë°›ì¹¨ëœ EVI ì§€í‘œì˜ ëŒ€í­ì ì¸ í™•ëŒ€ì—ì„œ ë‚˜íƒ€ë‚˜ë“¯ ìš°ìˆ˜í•œ í’ˆì§ˆì„ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. inVue Dxì˜ ì„±ê³µì ì¸ ì¶œì‹œëŠ” ì—°ê°„ 7,500ë§Œ ë‹¬ëŸ¬ ì´ìƒì˜ ì¥ë¹„ ë§¤ì¶œì— ê¸°ì—¬í–ˆìœ¼ë©°, ì „ì‚¬ ì„±ì¥ë¥ ì˜ ì•½ 200bp(ë² ì´ì‹œìŠ¤ í¬ì¸íŠ¸)ë¥¼ ì§€ì›í–ˆìŠµë‹ˆë‹¤. ì‹ ì† ê²€ì‚¬(Rapid assay) ë§¤ì¶œì€ 4ë¶„ê¸°ì— ìœ ê¸°ì  ê¸°ì¤€ìœ¼ë¡œ 3% ê°ì†Œí–ˆìŠµë‹ˆë‹¤. ì‹ ì† ê²€ì‚¬ ì‹¤ì ì€ ë¯¸êµ­ ë‚´ ì••ë°•ìœ¼ë¡œ ì¸í•´ ì œì•½ì„ ë°›ì•˜ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>wellness visits and continued transition of pancreatic lipase to our Catalyst slide, which had an estimated 4% headwind to Q4 revenue growth. Global Reference Lab revenues expanded 9% organically in Q4. Reference Lab results in the quarter were supported by solid volume growth across regions and net price improvement. Volume expansion included new customer growth along with continued traction of innovations like IDEXX Cancer Dx in North America reaching nearly 6,000 customers.</td><td>ì›°ë‹ˆìŠ¤ ê²€ì§„ê³¼ ì·Œì¥ ë¦¬íŒŒì•„ì œ ê²€ì‚¬ì˜ Catalyst ìŠ¬ë¼ì´ë“œë¡œì˜ ì§€ì†ì ì¸ ì „í™˜ì´ 4ë¶„ê¸° ë§¤ì¶œ ì„±ì¥ì— ì•½ 4%ì˜ ì—­í’ìœ¼ë¡œ ì‘ìš©í–ˆìŠµë‹ˆë‹¤. ê¸€ë¡œë²Œ Reference Lab ë§¤ì¶œì€ 4ë¶„ê¸°ì— ìœ ê¸°ì ìœ¼ë¡œ 9% ì¦ê°€í–ˆìŠµë‹ˆë‹¤. 4ë¶„ê¸° Reference Lab ì‹¤ì ì€ ì§€ì—­ ì „ë°˜ì˜ ê²¬ì¡°í•œ ê²€ì‚¬ëŸ‰ ì¦ê°€ì™€ ìˆœê°€ê²© ê°œì„ ì— í˜ì…ì—ˆìŠµë‹ˆë‹¤. ê²€ì‚¬ëŸ‰ í™•ëŒ€ì—ëŠ” ì‹ ê·œ ê³ ê° ì¦ê°€ì™€ í•¨ê»˜ ë¶ë¯¸ ì§€ì—­ì—ì„œ ê±°ì˜ 6,000ê°œ ê³ ê°ì‚¬ì— ë„ë‹¬í•œ IDEXX Cancer Dxì™€ ê°™ì€ í˜ì‹  ì œí’ˆì˜ ì§€ì†ì ì¸ ê²¬ì¸ë ¥ì´ í¬í•¨ë˜ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>CAG veterinary software, services and diagnostic imaging revenues increased 13% organically in Q4, with results supported by 12% recurring revenues with momentum from our vertical SaaS strategy, including double-digit growth in our cloud-based PIMS reoccurring revenue. In other business segments, Water revenues increased 10% organically in Q4 with double-digit international revenue growth and solid gains in the U.S. Livestock, Poultry and Dairy revenues increased 4% organically in Q4, supported by solid gains in the Americas. Turning to the P&L.</td><td>CAG ë™ë¬¼ë³‘ì› ì†Œí”„íŠ¸ì›¨ì–´, ì„œë¹„ìŠ¤ ë° ì§„ë‹¨ ì˜ìƒ ë§¤ì¶œì€ 4ë¶„ê¸°ì— ìœ ê¸°ì ìœ¼ë¡œ 13% ì¦ê°€í–ˆìœ¼ë©°, ì´ëŠ” 12%ì˜ ê²½ìƒ ë§¤ì¶œì— í˜ì…ì€ ê²ƒìœ¼ë¡œ í´ë¼ìš°ë“œ ê¸°ë°˜ PIMS ê²½ìƒ ë§¤ì¶œì˜ ë‘ ìë¦¿ìˆ˜ ì„±ì¥ì„ í¬í•¨í•œ ë²„í‹°ì»¬ SaaS ì „ëµì˜ ëª¨ë©˜í…€ì— ì˜í•´ ë’·ë°›ì¹¨ë˜ì—ˆìŠµë‹ˆë‹¤. ê¸°íƒ€ ì‚¬ì—… ë¶€ë¬¸ì—ì„œëŠ” Water ë§¤ì¶œì´ 4ë¶„ê¸°ì— ìœ ê¸°ì ìœ¼ë¡œ 10% ì¦ê°€í–ˆìœ¼ë©°, ì´ëŠ” ë‘ ìë¦¿ìˆ˜ êµ­ì œ ë§¤ì¶œ ì„±ì¥ê³¼ ë¯¸êµ­ ë‚´ ê²¬ì¡°í•œ ì¦ê°€ì— ê¸°ì¸í•©ë‹ˆë‹¤. ì¶•ì‚°, ê°€ê¸ˆë¥˜ ë° ë‚™ë† ë§¤ì¶œì€ 4ë¶„ê¸°ì— ìœ ê¸°ì ìœ¼ë¡œ 4% ì¦ê°€í–ˆìœ¼ë©°, ì´ëŠ” ì•„ë©”ë¦¬ì¹´ ì§€ì—­ì˜ ê²¬ì¡°í•œ ì„±ì¥ì— í˜ì…ì€ ê²ƒì…ë‹ˆë‹¤. ì†ìµê³„ì‚°ì„œë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Q4 operating profits increased 21% as reported and 17% on a comparable basis from the prior year, including gross margin gains and modest operational expense leverage. Gross profit increased 15% as reported and 13% on a comparable basis, achieving 60.3% in Q4. This is an improvement of 60 basis points comparably, adjusting for approximately 10 basis points of negative foreign exchange impact. Gross margin gains were aided by strong consumable growth and benefits from higher Reference Lab gross margins, offsetting headwinds from business mix on strong instrument revenue levels.</td><td>4ë¶„ê¸° ì˜ì—…ì´ìµì€ ì „ë…„ ëŒ€ë¹„ ë³´ê³  ê¸°ì¤€ 21%, ë¹„êµ ê°€ëŠ¥ ê¸°ì¤€ 17% ì¦ê°€í–ˆìœ¼ë©°, ì´ëŠ” ë§¤ì¶œì´ì´ìµ ì¦ê°€ì™€ ì™„ë§Œí•œ ì˜ì—…ë¹„ìš© ë ˆë²„ë¦¬ì§€ íš¨ê³¼ë¥¼ ë°˜ì˜í•œ ê²ƒì…ë‹ˆë‹¤. ë§¤ì¶œì´ì´ìµì€ ë³´ê³  ê¸°ì¤€ 15%, ë¹„êµ ê°€ëŠ¥ ê¸°ì¤€ 13% ì¦ê°€í•˜ì—¬ 4ë¶„ê¸° 60.3%ë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ì•½ 10bpì˜ ë¶€ì •ì ì¸ í™˜ìœ¨ ì˜í–¥ì„ ì¡°ì •í•œ ë¹„êµ ê°€ëŠ¥ ê¸°ì¤€ìœ¼ë¡œ 60bp ê°œì„ ëœ ìˆ˜ì¹˜ì…ë‹ˆë‹¤. ë§¤ì¶œì´ì´ìµë¥  ê°œì„ ì€ ê°•ë ¥í•œ ì†Œëª¨í’ˆ ì„±ì¥ê³¼ Reference Lab ë§¤ì¶œì´ì´ìµë¥  ìƒìŠ¹ì˜ íš¨ê³¼ê°€ ë†’ì€ ì¥ë¹„ ë§¤ì¶œ ìˆ˜ì¤€ìœ¼ë¡œ ì¸í•œ ì‚¬ì—… ë¯¹ìŠ¤ ì•…í™” ìš”ì¸ì„ ìƒì‡„í•œ ë° ê¸°ì¸í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Operating expenses were up 11% as reported and 10% year-over-year on a comparable basis in the quarter, reflecting increases in R&D and commercial investments aligned with advancing our innovation road map including recently announced expansions of inVue Dx and Cancer Dx platform capabilities and the completion of our global commercial expansions. For the full year 2025, operating margins were 31.6%, an increase of 90 basis points on a comparable basis net of approximately 180 basis point benefit related to lapping a now-concluded litigation expense. On a full year basis, there was immaterial margin impact from foreign exchange effects.</td><td>ì˜ì—…ë¹„ìš©ì€ ë³´ê³  ê¸°ì¤€ìœ¼ë¡œ 11%, ë¹„êµ ê°€ëŠ¥ ê¸°ì¤€ìœ¼ë¡œëŠ” ì „ë…„ ë™ê¸° ëŒ€ë¹„ 10% ì¦ê°€í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ìµœê·¼ ë°œí‘œëœ inVue Dx ë° Cancer Dx í”Œë«í¼ ì—­ëŸ‰ í™•ëŒ€ë¥¼ í¬í•¨í•œ í˜ì‹  ë¡œë“œë§µ ì¶”ì§„ê³¼ ê¸€ë¡œë²Œ ìƒì—…ì  í™•ì¥ ì™„ë£Œì— ë”°ë¥¸ R&D ë° ìƒì—… íˆ¬ì ì¦ê°€ë¥¼ ë°˜ì˜í•œ ê²ƒì…ë‹ˆë‹¤. 2025ë…„ ì „ì²´ ì—°ë„ ê¸°ì¤€ìœ¼ë¡œ ì˜ì—…ì´ìµë¥ ì€ 31.6%ë¥¼ ê¸°ë¡í–ˆìœ¼ë©°, ì´ëŠ” ë¹„êµ ê°€ëŠ¥ ê¸°ì¤€ìœ¼ë¡œ 90bp ì¦ê°€í•œ ìˆ˜ì¹˜ì…ë‹ˆë‹¤. ì´ëŠ” í˜„ì¬ ì¢…ê²°ëœ ì†Œì†¡ ë¹„ìš© ê¸°ì €íš¨ê³¼ë¡œ ì¸í•œ ì•½ 180bpì˜ ì´ìµì„ ì°¨ê°í•œ ìˆœìˆ˜ì¹˜ì…ë‹ˆë‹¤. ì—°ê°„ ê¸°ì¤€ìœ¼ë¡œ ì™¸í™˜ íš¨ê³¼ì— ë”°ë¥¸ ë§ˆì§„ ì˜í–¥ì€ ë¯¸ë¯¸í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Q4 EPS was $3.08 per share, up 17% year-over-year on a comparable basis. In Q4, EPS benefited from strong operational results and lower effective tax rate, including $0.07 per share in tax benefit from share-based compensation. Foreign exchange provided a $0.09 per share tailwind to the quarter net of hedge effects. Full year earnings per share was $13.08, an increase of 14% on a comparable basis.</td><td>4ë¶„ê¸° ì£¼ë‹¹ìˆœì´ìµ(EPS)ì€ $3.08ë¡œ ë¹„êµ ê°€ëŠ¥ ê¸°ì¤€ìœ¼ë¡œ ì „ë…„ ë™ê¸° ëŒ€ë¹„ 17% ì¦ê°€í–ˆìŠµë‹ˆë‹¤. 4ë¶„ê¸° EPSëŠ” ê²¬ì¡°í•œ ì˜ì—… ì‹¤ì ê³¼ ë‚®ì•„ì§„ ì‹¤íš¨ì„¸ìœ¨ì˜ í˜œíƒì„ ë°›ì•˜ìœ¼ë©°, ì£¼ì‹ê¸°ì¤€ë³´ìƒì— ë”°ë¥¸ ì„¸ê¸ˆ í˜œíƒìœ¼ë¡œ ì£¼ë‹¹ $0.07ì´ í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ì™¸í™˜ì€ í—¤ì§€ íš¨ê³¼ë¥¼ ì°¨ê°í•œ í›„ ë¶„ê¸°ì— ì£¼ë‹¹ $0.09ì˜ ìˆœí’ì„ ì œê³µí–ˆìŠµë‹ˆë‹¤. ì—°ê°„ ì£¼ë‹¹ìˆœì´ìµì€ $13.08ë¡œ ë¹„êµ ê°€ëŠ¥ ê¸°ì¤€ìœ¼ë¡œ 14% ì¦ê°€í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>EPS results were driven by strong operational performance in the year and include a combined $0.64 benefit from an accrual adjustment during 2024 and 2025 related to a now-concluded litigation; a $0.10 positive impact from currency changes; and $0.35 in tax benefits from share-based compensation activity. Foreign exchange had an 80 basis point full year revenue growth benefit and increased operating profits by $10 million and EPS by $0.10 per share, net of $1 million in hedge losses.</td><td>EPS ì‹¤ì ì€ ì—°ì¤‘ ê°•ë ¥í•œ ì˜ì—… ì„±ê³¼ì— ê¸°ì¸í–ˆìœ¼ë©°, í˜„ì¬ ì¢…ê²°ëœ ì†Œì†¡ê³¼ ê´€ë ¨í•˜ì—¬ 2024ë…„ê³¼ 2025ë…„ ë°œìƒí•œ ì¶©ë‹¹ê¸ˆ ì¡°ì •ìœ¼ë¡œ ì¸í•œ $0.64ì˜ í•©ì‚° ì´ìµ, í™˜ìœ¨ ë³€ë™ìœ¼ë¡œ ì¸í•œ $0.10ì˜ ê¸ì •ì  ì˜í–¥, ê·¸ë¦¬ê³  ì£¼ì‹ê¸°ì¤€ë³´ìƒ í™œë™ìœ¼ë¡œ ì¸í•œ $0.35ì˜ ì„¸ê¸ˆ í˜œíƒì´ í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ì™¸í™˜ì€ ì—°ê°„ ë§¤ì¶œ ì„±ì¥ë¥ ì— 80bp(ë² ì´ì‹œìŠ¤í¬ì¸íŠ¸)ì˜ ê¸ì •ì  íš¨ê³¼ë¥¼ ê°€ì ¸ì™”ìœ¼ë©°, $1ë°±ë§Œì˜ í—¤ì§€ ì†ì‹¤ì„ ì°¨ê°í•œ ìˆœì•¡ ê¸°ì¤€ìœ¼ë¡œ ì˜ì—…ì´ìµì„ $10ë°±ë§Œ, ì£¼ë‹¹ìˆœì´ìµì„ $0.10 ì¦ê°€ì‹œì¼°ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Full year free cash flow was $1.1 billion for 2025 or 100% of net income, aligned with our third quarter guidance and ahead of our long-term goals with capital spending of $125 million or approximately 3% of revenue. We allocated $1.2 billion to repurchase 2.4 million shares at an average cost per share of $506, supporting a 2.7% year-over-year reduction in diluted shares outstanding. Our balance sheet remains in a strong position, and we ended 2025 with modestly lower leverage ratios of 0.5x gross and 0.4x net of cash.</td><td>2025ë…„ ì „ì²´ ì—°ë„ ì‰ì—¬í˜„ê¸ˆíë¦„ì€ 11ì–µ ë‹¬ëŸ¬ë¡œ ìˆœì´ìµì˜ 100%ë¥¼ ê¸°ë¡í–ˆìœ¼ë©°, ì´ëŠ” 3ë¶„ê¸° ê°€ì´ë˜ìŠ¤ì™€ ì¼ì¹˜í•˜ê³  ì¥ê¸° ëª©í‘œë¥¼ ìƒíšŒí•˜ëŠ” ìˆ˜ì¹˜ì…ë‹ˆë‹¤. ìë³¸ì  ì§€ì¶œì€ 1ì–µ 2,500ë§Œ ë‹¬ëŸ¬ë¡œ ë§¤ì¶œì˜ ì•½ 3% ìˆ˜ì¤€ì´ì—ˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” 12ì–µ ë‹¬ëŸ¬ë¥¼ ë°°ì •í•˜ì—¬ ì£¼ë‹¹ í‰ê·  506ë‹¬ëŸ¬ì— 240ë§Œ ì£¼ë¥¼ ìì‚¬ì£¼ ë§¤ì…í–ˆìœ¼ë©°, ì´ë¥¼ í†µí•´ í¬ì„ì£¼ì‹ìˆ˜ê°€ ì „ë…„ ëŒ€ë¹„ 2.7% ê°ì†Œí–ˆìŠµë‹ˆë‹¤. ìš°ë¦¬ì˜ ì¬ë¬´ìƒíƒœí‘œëŠ” ê²¬ê³ í•œ ìƒíƒœë¥¼ ìœ ì§€í•˜ê³  ìˆìœ¼ë©°, 2025ë…„ ë§ ê¸°ì¤€ ë ˆë²„ë¦¬ì§€ ë¹„ìœ¨ì€ ì´ë¶€ì±„ ê¸°ì¤€ 0.5ë°°, ìˆœë¶€ì±„ ê¸°ì¤€ 0.4ë°°ë¡œ ì†Œí­ í•˜ë½í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Turning to our full year 2026 financial outlook, IDEXX is planning to deliver solid organic revenue growth and profit gains, building on strong commercial execution and extensible new platforms. We're providing initial guidance for revenue of $4.632 billion to $4.720 billion, an increase of 7.6% to 9.6% on a reported basis, reflecting 7% to 9% organically. CAG Diagnostics reoccurring revenues are expected to grow 8% to 10% organically for the year, representing an increase of approximately 100 basis points at midpoint compared to our 2025 results.</td><td>2026ë…„ ì „ì²´ ì—°ë„ ì¬ë¬´ ì „ë§ìœ¼ë¡œ ë„˜ì–´ê°€ë©´, IDEXXëŠ” ê°•ë ¥í•œ ì˜ì—… ì‹¤í–‰ë ¥ê³¼ í™•ì¥ ê°€ëŠ¥í•œ ì‹ ê·œ í”Œë«í¼ì„ ê¸°ë°˜ìœ¼ë¡œ ê²¬ì¡°í•œ ìœ ê¸°ì  ë§¤ì¶œ ì„±ì¥ê³¼ ìˆ˜ìµ ì¦ëŒ€ë¥¼ ë‹¬ì„±í•  ê³„íšì…ë‹ˆë‹¤. ë‹¹ì‚¬ëŠ” ì´ˆê¸° ê°€ì´ë˜ìŠ¤ë¡œ ë§¤ì¶œ 46ì–µ 3,200ë§Œ ë‹¬ëŸ¬ì—ì„œ 47ì–µ 2,000ë§Œ ë‹¬ëŸ¬ë¥¼ ì œì‹œí•˜ë©°, ì´ëŠ” ë³´ê³  ê¸°ì¤€ìœ¼ë¡œ 7.6%ì—ì„œ 9.6% ì¦ê°€í•œ ìˆ˜ì¹˜ì´ê³ , ìœ ê¸°ì ìœ¼ë¡œëŠ” 7%ì—ì„œ 9% ì„±ì¥ì„ ë°˜ì˜í•©ë‹ˆë‹¤. CAG ì§„ë‹¨ ë¶€ë¬¸ ê²½ìƒ ë§¤ì¶œì€ ì—°ê°„ ìœ ê¸°ì ìœ¼ë¡œ 8%ì—ì„œ 10% ì„±ì¥í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë˜ë©°, ì´ëŠ” ì¤‘ê°„ê°’ ê¸°ì¤€ìœ¼ë¡œ 2025ë…„ ì‹¤ì  ëŒ€ë¹„ ì•½ 100bp(ë² ì´ì‹œìŠ¤í¬ì¸íŠ¸) ì¦ê°€ë¥¼ ë‚˜íƒ€ëƒ…ë‹ˆë‹¤.</td></tr>
<tr><td>At current exchange rates, we expect foreign exchange to have an approximate 60 basis point benefit to full year revenue growth, largely in the first half of the year. At midpoint, our 2026 organic CAG Diagnostic reoccurring revenue growth outlook incorporates expectations for global net price realization of approximately 4%, reflecting a modestly lower net price realization than 2025. In the U.S., we anticipate net price improvement of approximately 3.5% and have incorporated declines in U.S. same-store clinical visit growth of approximately 2%, similar to the full year 2025, given ongoing macro and sector constraints.</td><td>í˜„ì¬ í™˜ìœ¨ ê¸°ì¤€ìœ¼ë¡œ, ì™¸í™˜ì´ ì—°ê°„ ë§¤ì¶œ ì„±ì¥ë¥ ì— ì•½ 60bp(ë² ì´ì‹œìŠ¤ í¬ì¸íŠ¸)ì˜ ê¸ì •ì  ì˜í–¥ì„ ë¯¸ì¹  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ë©°, ì´ëŠ” ì£¼ë¡œ ìƒë°˜ê¸°ì— ì§‘ì¤‘ë  ê²ƒì…ë‹ˆë‹¤. ì¤‘ê°„ê°’ ê¸°ì¤€ìœ¼ë¡œ, ë‹¹ì‚¬ì˜ 2026ë…„ CAG ì§„ë‹¨ ë¶€ë¬¸ ê²½ìƒ ë§¤ì¶œì˜ ìœ ê¸°ì  ì„±ì¥ë¥  ì „ë§ì—ëŠ” ì•½ 4%ì˜ ê¸€ë¡œë²Œ ìˆœê°€ê²© ì‹¤í˜„ìœ¨ì´ ë°˜ì˜ë˜ì–´ ìˆìœ¼ë©°, ì´ëŠ” 2025ë…„ ëŒ€ë¹„ ì†Œí­ ë‚®ì€ ìˆœê°€ê²© ì‹¤í˜„ìœ¨ì…ë‹ˆë‹¤. ë¯¸êµ­ì˜ ê²½ìš°, ì•½ 3.5%ì˜ ìˆœê°€ê²© ê°œì„ ì„ ì˜ˆìƒí•˜ê³  ìˆìœ¼ë©°, ì§€ì†ë˜ëŠ” ê±°ì‹œê²½ì œ ë° ì—…ê³„ ì œì•½ ìš”ì¸ì„ ê°ì•ˆí•˜ì—¬ 2025ë…„ ì—°ê°„ ì‹¤ì ê³¼ ìœ ì‚¬í•œ ìˆ˜ì¤€ì¸ ì•½ 2%ì˜ ë¯¸êµ­ ë‚´ ë™ì¼ ë³‘ì› ì„ìƒ ë°©ë¬¸ ê±´ìˆ˜ ê°ì†Œë¥¼ ë°˜ì˜í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>These targets incorporate continued solid global growth benefits from IDEXX execution and innovation drivers, including new customer gains and increases in testing utilization. The higher end of our CAG Diagnostic reoccurring revenue growth outlook captures the potential for improved sector and same-store growth trends, while the lower end of the range calibrates for further potential effects of macro and sector pressures. We're planning for solid placement levels for full year 2026 across our premium instrument installed base categories, including 5,500 inVue Dx instruments.</td><td>ì´ëŸ¬í•œ ëª©í‘œì¹˜ëŠ” IDEXXì˜ ì‹¤í–‰ë ¥ê³¼ í˜ì‹  ë™ë ¥ì„ í†µí•œ ì§€ì†ì ì´ê³  ê²¬ì¡°í•œ ê¸€ë¡œë²Œ ì„±ì¥ í˜œíƒì„ ë°˜ì˜í•˜ê³  ìˆìœ¼ë©°, ì—¬ê¸°ì—ëŠ” ì‹ ê·œ ê³ ê° í™•ë³´ì™€ ê²€ì‚¬ í™œìš©ë„ ì¦ê°€ê°€ í¬í•¨ë©ë‹ˆë‹¤. CAG ì§„ë‹¨ ê²½ìƒ ë§¤ì¶œ ì„±ì¥ ì „ë§ì˜ ìƒë‹¨ì€ ì—…ê³„ ë° ê¸°ì¡´ì í¬ ì„±ì¥ ì¶”ì„¸ ê°œì„  ê°€ëŠ¥ì„±ì„ ë°˜ì˜í•œ ê²ƒì´ë©°, í•˜ë‹¨ì€ ê±°ì‹œê²½ì œ ë° ì—…ê³„ ì••ë ¥ì˜ ì¶”ê°€ì ì¸ ì˜í–¥ ê°€ëŠ¥ì„±ì„ ê³ ë ¤í•œ ê²ƒì…ë‹ˆë‹¤. ë‹¹ì‚¬ëŠ” 2026ë…„ ì „ì²´ ì—°ë„ì— ê±¸ì³ í”„ë¦¬ë¯¸ì—„ ì¥ë¹„ ì„¤ì¹˜ ê¸°ë°˜ ì „ë°˜ì—ì„œ ê²¬ì¡°í•œ ì„¤ì¹˜ ìˆ˜ì¤€ì„ ê³„íší•˜ê³  ìˆìœ¼ë©°, ì—¬ê¸°ì—ëŠ” 5,500ëŒ€ì˜ inVue Dx ì¥ë¹„ê°€ í¬í•¨ë©ë‹ˆë‹¤.</td></tr>
<tr><td>We expect declines in CAG instrument revenues in 2026 as we lap the rapid expansion of IDEXX inVue Dx instrument placements and anticipate regional revenue mix dynamics. Our 2026 reported operating margin outlook for the full year is 32.0% to 32.5%. On a comparable basis, this reflects an outlook for 30 to 80 basis points of improvement year-over-year, net of approximately 30 basis point benefit from foreign exchange and an approximately 20 basis point headwind from lapping a prior year now-concluded litigation accrual adjustment in 2025.</td><td>2026ë…„ì—ëŠ” IDEXX inVue Dx ê¸°ê¸° ë°°ì¹˜ì˜ ê¸‰ì†í•œ í™•ëŒ€ íš¨ê³¼ê°€ ì†Œì§„ë˜ê³  ì§€ì—­ë³„ ë§¤ì¶œ ë¯¹ìŠ¤ ì—­í•™ ë³€í™”ê°€ ì˜ˆìƒë¨ì— ë”°ë¼ CAG ê¸°ê¸° ë§¤ì¶œì´ ê°ì†Œí•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. 2026ë…„ ì—°ê°„ ë³´ê³  ì˜ì—…ì´ìµë¥  ì „ë§ì€ 32.0%ì—ì„œ 32.5%ì…ë‹ˆë‹¤. ë¹„êµê°€ëŠ¥ ê¸°ì¤€ìœ¼ë¡œ ë³¼ ë•Œ, ì´ëŠ” ì™¸í™˜ìœ¼ë¡œ ì¸í•œ ì•½ 30bpì˜ ê¸ì •ì  íš¨ê³¼ì™€ 2025ë…„ì— ì¢…ë£Œëœ ì „ë…„ë„ ì†Œì†¡ ì¶©ë‹¹ê¸ˆ ì¡°ì •ì„ ë°˜ì˜í•˜ëŠ” ì•½ 20bpì˜ ì—­í’ì„ ê°ì•ˆí•  ë•Œ, ì „ë…„ ëŒ€ë¹„ 30~80bpì˜ ê°œì„ ì„ ë‚˜íƒ€ëƒ…ë‹ˆë‹¤.</td></tr>
<tr><td>We're planning for solid gross margin gains on a comparable basis supported by growth in CAG Diagnostics reoccurring revenues, benefits from lab and operational productivity initiatives and expansion of our high-margin cloud-based software business. We've captured impacts of tariffs under current laws in our outlook, and we remain well positioned to maintain supply continuity to our customers. Our 2026 EPS outlook is $14.29 to $14.80 per share. This reflects an increase of 10% to 14% on a comparable basis net of a 1% reported growth headwind from comparison to the prior year now-concluded litigation accrual adjustment.</td><td>ë‹¹ì‚¬ëŠ” CAG Diagnostics ë°˜ë³µ ë§¤ì¶œ ì„±ì¥, ì‹¤í—˜ì‹¤ ë° ìš´ì˜ ìƒì‚°ì„± ê°œì„  ì´ë‹ˆì…”í‹°ë¸Œì˜ íš¨ê³¼, ê·¸ë¦¬ê³  ê³ ë§ˆì§„ í´ë¼ìš°ë“œ ê¸°ë°˜ ì†Œí”„íŠ¸ì›¨ì–´ ì‚¬ì—… í™•ëŒ€ì— í˜ì…ì–´ ë¹„êµ ê°€ëŠ¥ ê¸°ì¤€ìœ¼ë¡œ ê²¬ê³ í•œ ë§¤ì¶œì´ì´ìµë¥  ê°œì„ ì„ ê³„íší•˜ê³  ìˆìŠµë‹ˆë‹¤. í˜„í–‰ ë²•ë¥ ì— ë”°ë¥¸ ê´€ì„¸ ì˜í–¥ì„ ì „ë§ì— ë°˜ì˜í–ˆìœ¼ë©°, ê³ ê°ì— ëŒ€í•œ ê³µê¸‰ ì—°ì†ì„±ì„ ìœ ì§€í•  ìˆ˜ ìˆëŠ” ì¢‹ì€ ìœ„ì¹˜ë¥¼ í™•ë³´í•˜ê³  ìˆìŠµë‹ˆë‹¤. 2026ë…„ ì£¼ë‹¹ìˆœì´ìµ(EPS) ì „ë§ì€ 14.29ë‹¬ëŸ¬ì—ì„œ 14.80ë‹¬ëŸ¬ì…ë‹ˆë‹¤. ì´ëŠ” ë¹„êµ ê°€ëŠ¥ ê¸°ì¤€ìœ¼ë¡œ 10%ì—ì„œ 14% ì¦ê°€í•œ ìˆ˜ì¹˜ì´ë©°, ì „ë…„ë„ ì¢…ê²°ëœ ì†Œì†¡ ì¶©ë‹¹ê¸ˆ ì¡°ì •ê³¼ì˜ ë¹„êµë¡œ ì¸í•œ 1%ì˜ ë³´ê³  ì„±ì¥ ì—­í’ì„ ì°¨ê°í•œ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Our EPS outlook includes $34 million of net interest expense at prevailing rates and foreign exchange benefit of approximately $0.22 year-over-year at rates disclosed in our earnings release, net of established hedge positions. We're planning for a consistent year-to-year tax rate when excluding share-based compensation effects. In terms of sensitivities to changes in foreign exchange rates, we project a 1% change in the value of the U.S. dollar would impact full year reported revenue by approximately $16 million and operating income by approximately $5 million net of hedge effects.</td><td>ë‹¹ì‚¬ì˜ ì£¼ë‹¹ìˆœì´ìµ(EPS) ì „ë§ì—ëŠ” í˜„í–‰ ê¸ˆë¦¬ ê¸°ì¤€ ìˆœì´ìë¹„ìš© 3,400ë§Œ ë‹¬ëŸ¬ì™€ ì‹¤ì ë°œí‘œ ìë£Œì— ê³µì‹œëœ í™˜ìœ¨ ê¸°ì¤€ìœ¼ë¡œ ê¸°ì²´ê²° í—¤ì§€ í¬ì§€ì…˜ì„ ì°¨ê°í•œ ì „ë…„ ëŒ€ë¹„ ì•½ 0.22ë‹¬ëŸ¬ì˜ ì™¸í™˜ ì´ìµì´ í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ì£¼ì‹ê¸°ì¤€ë³´ìƒ íš¨ê³¼ë¥¼ ì œì™¸í•  ê²½ìš° ì „ë…„ ëŒ€ë¹„ ì¼ê´€ëœ ì„¸ìœ¨ì„ ê³„íší•˜ê³  ìˆìŠµë‹ˆë‹¤. í™˜ìœ¨ ë³€ë™ì— ëŒ€í•œ ë¯¼ê°ë„ ì¸¡ë©´ì—ì„œ, ë¯¸êµ­ ë‹¬ëŸ¬ ê°€ì¹˜ê°€ 1% ë³€ë™í•  ê²½ìš° ì—°ê°„ ë³´ê³  ë§¤ì¶œì•¡ì€ ì•½ 1,600ë§Œ ë‹¬ëŸ¬, ì˜ì—…ì´ìµì€ í—¤ì§€ íš¨ê³¼ë¥¼ ì°¨ê°í•œ ìˆœì•¡ ê¸°ì¤€ìœ¼ë¡œ ì•½ 500ë§Œ ë‹¬ëŸ¬ì˜ ì˜í–¥ì„ ë°›ì„ ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤.</td></tr>
<tr><td>Our 2026 free cash flow outlook is for net income to free cash flow conversion ratio of 85% to 95%, aligned with our long-term potential and reflects capital spending of $180 million or approximately 4% of revenues. The outlook incorporates capital deployment towards share repurchases to support a 1% to 2% year-over-year reduction in diluted shares outstanding while maintaining leverage ratios similar to the past couple of years. Regarding our Q1 outlook, we're planning for overall reported revenue growth of 11.5% to 13.5%, including approximately 2.5% growth benefit from foreign exchange at rates outlined in our press release.</td><td>2026ë…„ ì‰ì—¬í˜„ê¸ˆíë¦„ ì „ë§ì€ ìˆœì´ìµ ëŒ€ë¹„ ì‰ì—¬í˜„ê¸ˆíë¦„ ì „í™˜ìœ¨ì´ 85%ì—ì„œ 95%ë¡œ, ì´ëŠ” ë‹¹ì‚¬ì˜ ì¥ê¸° ì ì¬ë ¥ê³¼ ì¼ì¹˜í•˜ë©° ë§¤ì¶œì˜ ì•½ 4%ì— í•´ë‹¹í•˜ëŠ” 1ì–µ 8ì²œë§Œ ë‹¬ëŸ¬ì˜ ìë³¸ ì§€ì¶œì„ ë°˜ì˜í•©ë‹ˆë‹¤. ì´ ì „ë§ì€ ê³¼ê±° ëª‡ ë…„ê°„ê³¼ ìœ ì‚¬í•œ ë ˆë²„ë¦¬ì§€ ë¹„ìœ¨ì„ ìœ ì§€í•˜ë©´ì„œ í¬ì„ì£¼ì‹ìˆ˜ë¥¼ ì „ë…„ ëŒ€ë¹„ 1%ì—ì„œ 2% ê°ì†Œì‹œí‚¤ê¸° ìœ„í•œ ìì‚¬ì£¼ ë§¤ì…ì„ ìœ„í•œ ìë³¸ ë°°ë¶„ì„ í¬í•¨í•˜ê³  ìˆìŠµë‹ˆë‹¤. 1ë¶„ê¸° ì „ë§ê³¼ ê´€ë ¨í•˜ì—¬, ë‹¹ì‚¬ëŠ” ë³´ë„ìë£Œì— ëª…ì‹œëœ í™˜ìœ¨ ê¸°ì¤€ìœ¼ë¡œ ì•½ 2.5%ì˜ ì™¸í™˜ íš¨ê³¼ë¥¼ í¬í•¨í•˜ì—¬ ì „ì²´ ë³´ê³  ë§¤ì¶œ ì„±ì¥ë¥ ì„ 11.5%ì—ì„œ 13.5%ë¡œ ê³„íší•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Organic revenue growth of 9% to 11% includes approximately 1% to 1.5% growth benefit from CAG instrument revenues supported by ongoing momentum in inVue Dx analyzer placements. As noted, growth of capital revenues is projected to become a headwind to overall growth over the balance of the year as we lap the launch of inVue Dx. We expect Q1 CAG Diagnostic reoccurring revenue growth of 8.5% to 10.5%, which includes approximately 50 basis point benefit from equivalent days at midpoint and U.S. clinical visit trends and pricing expectations aligned with the full year guidance levels.</td><td>ìœ ê¸°ì  ë§¤ì¶œ ì„±ì¥ë¥  9%~11%ì—ëŠ” inVue Dx ë¶„ì„ê¸° ì„¤ì¹˜ì˜ ì§€ì†ì ì¸ ëª¨ë©˜í…€ì— í˜ì…ì€ CAG ì¥ë¹„ ë§¤ì¶œë¡œë¶€í„° ì•½ 1%~1.5%ì˜ ì„±ì¥ ê¸°ì—¬ê°€ í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ì–¸ê¸‰í•œ ë°”ì™€ ê°™ì´, ìë³¸ì¬ ë§¤ì¶œ ì„±ì¥ì€ inVue Dx ì¶œì‹œ ê¸°ì €íš¨ê³¼ë¡œ ì¸í•´ ì—°ì¤‘ ë‚˜ë¨¸ì§€ ê¸°ê°„ ë™ì•ˆ ì „ì²´ ì„±ì¥ë¥ ì— ì—­í’ìœ¼ë¡œ ì‘ìš©í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. 1ë¶„ê¸° CAG ì§„ë‹¨ ê²½ìƒë§¤ì¶œ ì„±ì¥ë¥ ì€ 8.5%~10.5%ë¡œ ì „ë§ë˜ë©°, ì´ëŠ” ì¤‘ê°„ê°’ ê¸°ì¤€ ì˜ì—…ì¼ìˆ˜ íš¨ê³¼ë¡œ ì¸í•œ ì•½ 50bpì˜ ê¸°ì—¬ë¥¼ í¬í•¨í•˜ê³  ìˆìœ¼ë©°, ë¯¸êµ­ ì„ìƒ ë°©ë¬¸ ì¶”ì„¸ì™€ ê°€ê²© ì „ë§ì€ ì—°ê°„ ê°€ì´ë˜ìŠ¤ ìˆ˜ì¤€ê³¼ ì¼ì¹˜í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Our Q1 reported operating margins are planned for 31.4% to 31.9%, reflecting solid expansion of comparable margins in the quarter, aligned with our full year expectations net of approximately 90 basis point headwind from lapping a discrete litigation accrual adjustment in the prior year quarter and approximately 30 basis point benefit from year-over-year foreign exchange impacts. We're well positioned entering 2026 with an expanded global field team and innovative platforms aimed at solving customer challenges. This concludes our guidance update, and I'll now turn the call over to Jay for his comments. Jay Mazelsky<br>President, CEO & Director<br><br>Thank you, Andrew, and good morning.</td><td>1ë¶„ê¸° ë³´ê³  ì˜ì—…ì´ìµë¥ ì€ 31.4%ì—ì„œ 31.9%ë¡œ ê³„íšë˜ì–´ ìˆìœ¼ë©°, ì´ëŠ” ë¶„ê¸° ì¤‘ ê²¬ì¡°í•œ ë¹„êµê°€ëŠ¥ ë§ˆì§„ í™•ëŒ€ë¥¼ ë°˜ì˜í•œ ê²ƒìœ¼ë¡œ ì—°ê°„ ì „ë§ì¹˜ì™€ ì¼ì¹˜í•©ë‹ˆë‹¤. ë‹¤ë§Œ ì „ë…„ ë™ê¸° ì¼íšŒì„± ì†Œì†¡ ì¶©ë‹¹ê¸ˆ ì¡°ì • íš¨ê³¼ ì†Œë©¸ë¡œ ì¸í•œ ì•½ 90bpì˜ ì—­í’ê³¼ ì „ë…„ ëŒ€ë¹„ ì™¸í™˜ ì˜í–¥ìœ¼ë¡œ ì¸í•œ ì•½ 30bpì˜ ê¸ì •ì  íš¨ê³¼ë¥¼ ê°ì•ˆí•œ ìˆ˜ì¹˜ì…ë‹ˆë‹¤. ë‹¹ì‚¬ëŠ” ê³ ê° ê³¼ì œ í•´ê²°ì„ ëª©í‘œë¡œ í•˜ëŠ” í™•ëŒ€ëœ ê¸€ë¡œë²Œ í˜„ì¥ ì¡°ì§ê³¼ í˜ì‹ ì ì¸ í”Œë«í¼ì„ ê°–ì¶”ê³  2026ë…„ì„ ë§ì´í•  ì¤€ë¹„ê°€ ì˜ ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ì´ê²ƒìœ¼ë¡œ ê°€ì´ë˜ìŠ¤ ì—…ë°ì´íŠ¸ë¥¼ ë§ˆì¹˜ë©°, ì´ì œ Jayì—ê²Œ ë°œì–¸ê¶Œì„ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.<br><br>Jay Mazelsky<br>ì‚¬ì¥, CEO ê²¸ ì´ì‚¬<br><br>Andrew, ê°ì‚¬í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì¢‹ì€ ì•„ì¹¨ì…ë‹ˆë‹¤.</td></tr>
<tr><td>IDEXX delivered a very strong fourth quarter, closing a year marked by exceptional execution across the organization and meaningful strategic progress towards our long-term potential. In many respects, 2025 was a defining year for our company. We successfully scaled multiple transformative innovations, expanded our commercial presence in key international regions, and continued to demonstrate the resilience and durability of the IDEXX business model pressured by broader economic uncertainty.</td><td>IDEXXëŠ” ë§¤ìš° ê°•ë ¥í•œ 4ë¶„ê¸° ì‹¤ì ì„ ë‹¬ì„±í•˜ë©°, ì¡°ì§ ì „ë°˜ì˜ íƒì›”í•œ ì‹¤í–‰ë ¥ê³¼ ì¥ê¸° ì ì¬ë ¥ì„ í–¥í•œ ì˜ë¯¸ ìˆëŠ” ì „ëµì  ì§„ì „ìœ¼ë¡œ íŠ¹ì§•ì§€ì–´ì§„ í•œ í•´ë¥¼ ë§ˆë¬´ë¦¬í–ˆìŠµë‹ˆë‹¤. ì—¬ëŸ¬ ì¸¡ë©´ì—ì„œ 2025ë…„ì€ ìš°ë¦¬ íšŒì‚¬ì— ìˆì–´ ì „í™˜ì ì´ ë˜ëŠ” í•´ì˜€ìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì—¬ëŸ¬ í˜ì‹ ì ì¸ ê¸°ìˆ ë“¤ì„ ì„±ê³µì ìœ¼ë¡œ í™•ëŒ€í–ˆê³ , ì£¼ìš” í•´ì™¸ ì§€ì—­ì—ì„œ ìƒì—…ì  ì…ì§€ë¥¼ í™•ì¥í–ˆìœ¼ë©°, ê´‘ë²”ìœ„í•œ ê²½ì œì  ë¶ˆí™•ì‹¤ì„± ì†ì—ì„œë„ IDEXX ë¹„ì¦ˆë‹ˆìŠ¤ ëª¨ë¸ì˜ íšŒë³µë ¥ê³¼ ì§€ì†ê°€ëŠ¥ì„±ì„ ì§€ì†ì ìœ¼ë¡œ ì…ì¦í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Our performance reflects the strength of that model, one built on customer-centric innovation, high-quality, durable recurring revenue and solutions deeply embedded in the daily workflows of veterinary practices. This year through significant innovations like inVue Dx, Cancer Dx, Vello and Catalyst Cortisol, our solutions provided valuable insights and the productivity lift sought by our customers. The human-animal bond continues to deepen and pet owners remain committed to providing a high standard of care, even amid what for many of them may be challenging household economics.</td><td>ìš°ë¦¬ì˜ ì‹¤ì ì€ ì´ëŸ¬í•œ ëª¨ë¸ì˜ ê°•ì ì„ ë°˜ì˜í•˜ê³  ìˆìœ¼ë©°, ì´ëŠ” ê³ ê° ì¤‘ì‹¬ì˜ í˜ì‹ , ê³ í’ˆì§ˆì˜ ì§€ì†ê°€ëŠ¥í•œ ë°˜ë³µ ë§¤ì¶œ, ê·¸ë¦¬ê³  ë™ë¬¼ë³‘ì›ì˜ ì¼ìƒ ì—…ë¬´ íë¦„ì— ê¹Šì´ ë‚´ì¬ëœ ì†”ë£¨ì…˜ì„ ê¸°ë°˜ìœ¼ë¡œ êµ¬ì¶•ë˜ì—ˆìŠµë‹ˆë‹¤. ì˜¬í•´ inVue Dx, Cancer Dx, Vello, Catalyst Cortisolê³¼ ê°™ì€ ì¤‘ìš”í•œ í˜ì‹ ì„ í†µí•´ ìš°ë¦¬ì˜ ì†”ë£¨ì…˜ì€ ê³ ê°ë“¤ì´ ì›í•˜ëŠ” ê·€ì¤‘í•œ ì¸ì‚¬ì´íŠ¸ì™€ ìƒì‚°ì„± í–¥ìƒì„ ì œê³µí–ˆìŠµë‹ˆë‹¤. ë°˜ë ¤ë™ë¬¼ê³¼ ì‚¬ëŒ ê°„ì˜ ìœ ëŒ€ê°ì€ ê³„ì†í•´ì„œ ê¹Šì–´ì§€ê³  ìˆìœ¼ë©°, ë°˜ë ¤ë™ë¬¼ ë³´í˜¸ìë“¤ì€ ë§ì€ ê²½ìš° ì–´ë ¤ìš´ ê°€ê³„ ê²½ì œ ìƒí™© ì†ì—ì„œë„ ë†’ì€ ìˆ˜ì¤€ì˜ ì§„ë£Œë¥¼ ì œê³µí•˜ëŠ” ë° ì „ë…í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>This commitment is especially evident in the aging pet population, where owners and veterinarians alike are prioritizing early detection, proactive screening and longitudinal monitoring. Early signs of aging pets with solid visit growth for canines 5-plus years old, more weighted to non-well supported a second consecutive quarter of improving visits in this important segment. Additionally, in the fourth quarter, diagnostics frequency, the percentage of visits that include diagnostic testing, expanded, highlighting the structural demand for advanced diagnostics and the role it plays in driving the broader veterinary care envelope.</td><td>ì´ëŸ¬í•œ ë…¸ë ¥ì€ íŠ¹íˆ ê³ ë ¹ ë°˜ë ¤ë™ë¬¼ ì§‘ë‹¨ì—ì„œ ë‘ë“œëŸ¬ì§€ê²Œ ë‚˜íƒ€ë‚˜ê³  ìˆìœ¼ë©°, ë°˜ë ¤ë™ë¬¼ ë³´í˜¸ìì™€ ìˆ˜ì˜ì‚¬ ëª¨ë‘ ì¡°ê¸° ë°œê²¬, ì˜ˆë°©ì  ê²€ì§„, ê·¸ë¦¬ê³  ì¥ê¸°ì  ëª¨ë‹ˆí„°ë§ì„ ìš°ì„ ì‹œí•˜ê³  ìˆìŠµë‹ˆë‹¤. 5ì„¸ ì´ìƒ ë°˜ë ¤ê²¬ì˜ ê²¬ê³ í•œ ë‚´ì› ì¦ê°€ì„¸ë¥¼ í†µí•´ ê³ ë ¹ ë°˜ë ¤ë™ë¬¼ì˜ ì´ˆê¸° ì§•í›„ë¥¼ í™•ì¸í•  ìˆ˜ ìˆìœ¼ë©°, ë¹„ì •ê¸° ì§„ë£Œ(non-well visit)ì— ë” ê°€ì¤‘ì¹˜ë¥¼ ë‘” ì´ëŸ¬í•œ ì¤‘ìš”í•œ ë¶€ë¬¸ì—ì„œ 2ë¶„ê¸° ì—°ì† ë‚´ì› ê°œì„ ì„¸ë¥¼ ë³´ì˜€ìŠµë‹ˆë‹¤. ë˜í•œ 4ë¶„ê¸°ì—ëŠ” ì§„ë‹¨ ë¹ˆë„, ì¦‰ ì§„ë‹¨ ê²€ì‚¬ë¥¼ í¬í•¨í•˜ëŠ” ë‚´ì› ë¹„ìœ¨ì´ í™•ëŒ€ë˜ì–´, ì²¨ë‹¨ ì§„ë‹¨ì— ëŒ€í•œ êµ¬ì¡°ì  ìˆ˜ìš”ì™€ ì´ê²ƒì´ ë³´ë‹¤ ê´‘ë²”ìœ„í•œ ìˆ˜ì˜ë£Œ ì‹œì¥ í™•ëŒ€ë¥¼ ê²¬ì¸í•˜ëŠ” ì—­í• ì„ í•˜ê³  ìˆìŒì„ ë³´ì—¬ì£¼ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Our commercial organization continues to be a core competitive advantage for IDEXX. In Q4, we completed the targeted expansion of our commercial footprint in geographies where we see significant long-term opportunity to increase diagnostics adoption and utilization. These new team members were fully onboarded and trained and are now active in their respective territories: in Germany, the United Kingdom and Australia, alongside an expansion in the United States. By enhancing commercial capabilities in these markets, we meaningfully reduced the number of accounts assigned to each representative.</td><td>ì €í¬ ì˜ì—… ì¡°ì§ì€ ê³„ì†í•´ì„œ IDEXXì˜ í•µì‹¬ ê²½ìŸ ìš°ìœ„ë¡œ ìë¦¬ì¡ê³  ìˆìŠµë‹ˆë‹¤. 4ë¶„ê¸°ì— ì €í¬ëŠ” ì§„ë‹¨ ë„ì…ë¥ ê³¼ í™œìš©ë„ë¥¼ ë†’ì¼ ìˆ˜ ìˆëŠ” ìƒë‹¹í•œ ì¥ê¸°ì  ê¸°íšŒê°€ ìˆë‹¤ê³  íŒë‹¨ë˜ëŠ” ì§€ì—­ì—ì„œ ì˜ì—… ì¸ë ¥ì˜ ì „ëµì  í™•ëŒ€ë¥¼ ì™„ë£Œí–ˆìŠµë‹ˆë‹¤. ì´ë“¤ ì‹ ê·œ íŒ€ì›ë“¤ì€ ì™„ì „íˆ ì˜¨ë³´ë”©ë˜ê³  êµìœ¡ì„ ë§ˆì³¤ìœ¼ë©°, í˜„ì¬ ë…ì¼, ì˜êµ­, í˜¸ì£¼ ê·¸ë¦¬ê³  ë¯¸êµ­ ë‚´ í™•ëŒ€ì™€ í•¨ê»˜ ê°ìì˜ ë‹´ë‹¹ ì§€ì—­ì—ì„œ í™œë°œíˆ í™œë™í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ë“¤ ì‹œì¥ì—ì„œ ì˜ì—… ì—­ëŸ‰ì„ ê°•í™”í•¨ìœ¼ë¡œì¨, ì €í¬ëŠ” ê° ì˜ì—… ë‹´ë‹¹ìì—ê²Œ ë°°ì •ë˜ëŠ” ê±°ë˜ì²˜ ìˆ˜ë¥¼ ì˜ë¯¸ ìˆëŠ” ìˆ˜ì¤€ìœ¼ë¡œ ì¤„ì¼ ìˆ˜ ìˆì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>This enables more frequent, higher quality interactions with clinics and supports deeper integration of diagnostics into everyday care protocols. Our experience consistently shows that increased engagement leads to higher utilization, stronger customer satisfaction and better medical outcomes. CAG Diagnostics recurring revenue growth in the quarter was driven by a combination of strong volume gains, adoption of new innovations and continued success in premium instrument placements. Diagnostic frequency and utilization per visit remained important contributors, benefiting both patient care and clinic economics.</td><td>ì´ë¥¼ í†µí•´ ë³‘ì›ê³¼ ë” ë¹ˆë²ˆí•˜ê³  ë†’ì€ í’ˆì§ˆì˜ ìƒí˜¸ì‘ìš©ì´ ê°€ëŠ¥í•´ì§€ë©°, ì§„ë‹¨ê²€ì‚¬ë¥¼ ì¼ìƒì ì¸ ì§„ë£Œ í”„ë¡œí† ì½œì— ë”ìš± ê¹Šì´ í†µí•©í•  ìˆ˜ ìˆë„ë¡ ì§€ì›í•©ë‹ˆë‹¤. ìš°ë¦¬ì˜ ê²½í—˜ì— ë”°ë¥´ë©´ ì°¸ì—¬ë„ ì¦ê°€ëŠ” ì§€ì†ì ìœ¼ë¡œ ë” ë†’ì€ í™œìš©ë„, ë” ê°•í•œ ê³ ê° ë§Œì¡±ë„, ê·¸ë¦¬ê³  ë” ë‚˜ì€ ì˜ë£Œ ì„±ê³¼ë¡œ ì´ì–´ì§‘ë‹ˆë‹¤. ì´ë²ˆ ë¶„ê¸° CAG Diagnosticsì˜ ê²½ìƒìˆ˜ìµ ì„±ì¥ì€ ê°•ë ¥í•œ ë¬¼ëŸ‰ ì¦ê°€, ì‹ ê·œ í˜ì‹ ì œí’ˆ ì±„íƒ, ê·¸ë¦¬ê³  í”„ë¦¬ë¯¸ì—„ ì¥ë¹„ ì„¤ì¹˜ì˜ ì§€ì†ì ì¸ ì„±ê³µì´ ë³µí•©ì ìœ¼ë¡œ ì‘ìš©í•œ ê²°ê³¼ì…ë‹ˆë‹¤. ì§„ë‹¨ê²€ì‚¬ ë¹ˆë„ì™€ ë°©ë¬¸ë‹¹ í™œìš©ë„ëŠ” í™˜ì ì¹˜ë£Œì™€ ë³‘ì› ê²½ì œì„± ëª¨ë‘ì— ê¸°ì—¬í•˜ë©° ì¤‘ìš”í•œ ì„±ì¥ ë™ë ¥ìœ¼ë¡œ ì‘ìš©í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Customer retention remains in the high 90s for our Global CAG Diagnostics business. This level of loyalty underscores the value veterinarians place on the reliability, consistency and clinical performance of IDEXX solutions and the strength of the partnerships our teams build over time. Our commercial team delivered an exceptionally productive year, achieving record instrument placements and sustained double-digit economic value growth, including contributions from 6,200 Catalyst placements while delivering on our inVue Dx agenda. We continue to see solid momentum in both competitive conversions and greenfield accounts.</td><td>ê¸€ë¡œë²Œ ë°˜ë ¤ë™ë¬¼ ì§„ë‹¨ ì‚¬ì—…ì˜ ê³ ê° ìœ ì§€ìœ¨ì€ 90%ëŒ€ í›„ë°˜ì„ ìœ ì§€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ë†’ì€ ì¶©ì„±ë„ëŠ” ìˆ˜ì˜ì‚¬ë“¤ì´ IDEXX ì†”ë£¨ì…˜ì˜ ì‹ ë¢°ì„±, ì¼ê´€ì„±, ì„ìƒ ì„±ëŠ¥ì— ë¶€ì—¬í•˜ëŠ” ê°€ì¹˜ì™€ ìš°ë¦¬ íŒ€ì´ ì‹œê°„ì„ ë“¤ì—¬ êµ¬ì¶•í•œ íŒŒíŠ¸ë„ˆì‹­ì˜ ê°•ì ì„ ë³´ì—¬ì¤ë‹ˆë‹¤. ìš°ë¦¬ ì˜ì—…íŒ€ì€ ê¸°ë¡ì ì¸ ì¥ë¹„ ì„¤ì¹˜ ëŒ€ìˆ˜ë¥¼ ë‹¬ì„±í•˜ê³  ì§€ì†ì ì¸ ë‘ ìë¦¿ìˆ˜ ê²½ì œì  ê°€ì¹˜ ì„±ì¥ì„ ì´ë£¨ë©° ë§¤ìš° ìƒì‚°ì ì¸ í•œ í•´ë¥¼ ë³´ëƒˆìŠµë‹ˆë‹¤. ì—¬ê¸°ì—ëŠ” inVue Dx ì–´ì  ë‹¤ë¥¼ ì‹¤í–‰í•˜ë©´ì„œ ì´ë£¬ 6,200ëŒ€ì˜ Catalyst ì„¤ì¹˜ ê¸°ì—¬ë¶„ì´ í¬í•¨ë©ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ê²½ìŸì‚¬ ì „í™˜ ê³ ê°ê³¼ ì‹ ê·œ ê°œì²™ ê³ ê° ëª¨ë‘ì—ì„œ ê²¬ê³ í•œ ëª¨ë©˜í…€ì„ ì§€ì†ì ìœ¼ë¡œ í™•ì¸í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>For the full year, we delivered double-digit growth in our premium instrument installed base, which now includes nearly 78,000 Catalyst analyzers globally. Our expanding premium instrument installed base provides multiple future growth vectors for the business, including benefits from higher diagnostics utilization and new menu additions over time. We recently announced several new innovations, including expanding the IDEXX Cancer Dx panel to include canine mast cell tumor detection with availability expected midyear 2026 in North America. This builds off a successful start to canine lymphoma commercialization where we crossed an important milestone last quarter.</td><td>ì—°ê°„ ê¸°ì¤€ìœ¼ë¡œ ë‹¹ì‚¬ëŠ” í”„ë¦¬ë¯¸ì—„ ì¥ë¹„ ì„¤ì¹˜ ê¸°ë°˜ì—ì„œ ë‘ ìë¦¿ìˆ˜ ì„±ì¥ì„ ë‹¬ì„±í–ˆìœ¼ë©°, í˜„ì¬ ì „ ì„¸ê³„ì ìœ¼ë¡œ ì•½ 78,000ëŒ€ì˜ Catalyst ë¶„ì„ê¸°ë¥¼ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. í™•ëŒ€ë˜ê³  ìˆëŠ” í”„ë¦¬ë¯¸ì—„ ì¥ë¹„ ì„¤ì¹˜ ê¸°ë°˜ì€ í–¥í›„ ì§„ë‹¨ í™œìš©ë„ ì¦ê°€ì™€ ì‹œê°„ì´ ì§€ë‚¨ì— ë”°ë¥¸ ì‹ ê·œ ë©”ë‰´ ì¶”ê°€ë¡œ ì¸í•œ í˜œíƒì„ í¬í•¨í•˜ì—¬ ì‚¬ì—…ì˜ ë‹¤ì–‘í•œ ë¯¸ë˜ ì„±ì¥ ë™ë ¥ì„ ì œê³µí•©ë‹ˆë‹¤. ë‹¹ì‚¬ëŠ” ìµœê·¼ IDEXX Cancer Dx íŒ¨ë„ì„ í™•ì¥í•˜ì—¬ ê°œ ë¹„ë§Œì„¸í¬ì¢… ê²€ì¶œì„ í¬í•¨ì‹œí‚¤ëŠ” ë“± ì—¬ëŸ¬ ì‹ ê·œ í˜ì‹  ì œí’ˆì„ ë°œí‘œí–ˆìœ¼ë©°, ì´ëŠ” 2026ë…„ ì¤‘ë°˜ ë¶ë¯¸ ì§€ì—­ì—ì„œ ì¶œì‹œë  ì˜ˆì •ì…ë‹ˆë‹¤. ì´ëŠ” ì§€ë‚œ ë¶„ê¸°ì— ì¤‘ìš”í•œ ì´ì •í‘œë¥¼ ë‹¬ì„±í•œ ê°œ ë¦¼í”„ì¢… ìƒìš©í™”ì˜ ì„±ê³µì ì¸ ì‹œì‘ì„ ê¸°ë°˜ìœ¼ë¡œ í•œ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Now more than half the lymphoma tests submitted are for screening versus as an aid-in-diagnosis. Building off this successful start in North America, we are on track for the next stage of expansion, a Q1 international rollout of IDEXX Cancer Dx. Getting back to mast cell tumors, they are among the most common cancers in dogs, yet they can be difficult to identify early. These lumps and bumps may go unnoticed, particularly in dogs with long coats, and often resemble benign lesions even when detected. This creates uncertainty for clinicians and pet owners alike and underscores the need for tools that support earlier, more confident assessment.</td><td>ì´ì œ ì œì¶œëœ ë¦¼í”„ì¢… ê²€ì‚¬ì˜ ì ˆë°˜ ì´ìƒì´ ì§„ë‹¨ ë³´ì¡°ìš©ì´ ì•„ë‹Œ ìŠ¤í¬ë¦¬ë‹ ëª©ì ì…ë‹ˆë‹¤. ë¶ë¯¸ì—ì„œì˜ ì´ëŸ¬í•œ ì„±ê³µì ì¸ ì‹œì‘ì„ ê¸°ë°˜ìœ¼ë¡œ, ìš°ë¦¬ëŠ” ë‹¤ìŒ ë‹¨ê³„ í™•ì¥ì¸ 1ë¶„ê¸° IDEXX Cancer Dxì˜ êµ­ì œ ì¶œì‹œë¥¼ ìˆœì¡°ë¡­ê²Œ ì§„í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë¹„ë§Œì„¸í¬ì¢…ìœ¼ë¡œ ëŒì•„ê°€ì„œ, ì´ëŠ” ê°œì—ê²Œ ê°€ì¥ í”í•œ ì•” ì¤‘ í•˜ë‚˜ì´ì§€ë§Œ ì¡°ê¸° ë°œê²¬ì´ ì–´ë ¤ìš¸ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ í˜¹ê³¼ ëŒê¸°ëŠ” íŠ¹íˆ ê¸´ í„¸ì„ ê°€ì§„ ê°œì—ì„œ ëˆˆì— ë„ì§€ ì•Šì„ ìˆ˜ ìˆìœ¼ë©°, ë°œê²¬ë˜ë”ë¼ë„ ì¢…ì¢… ì–‘ì„± ë³‘ë³€ê³¼ ìœ ì‚¬í•˜ê²Œ ë³´ì…ë‹ˆë‹¤. ì´ëŠ” ì„ìƒì˜ì™€ ë°˜ë ¤ë™ë¬¼ ì†Œìœ ì ëª¨ë‘ì—ê²Œ ë¶ˆí™•ì‹¤ì„±ì„ ì•¼ê¸°í•˜ë©°, ë” ì¡°ê¸°ì— ë” í™•ì‹ ì„ ê°€ì§€ê³  í‰ê°€í•  ìˆ˜ ìˆë„ë¡ ì§€ì›í•˜ëŠ” ë„êµ¬ì˜ í•„ìš”ì„±ì„ ê°•ì¡°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Building on the strong momentum of Cancer Dx panel, mast cell tumor detection will be added at no additional cost, with no change to specimen requirements or workflow, and sustained 2- to 3-day turnaround in the United States. This expansion allows veterinarians to screen at-risk dogs for approximately 1/3 of the most common cancer types during routine wellness visits and to evaluate the symptomatic patients when mast cell tumors are suspected. Importantly, it integrates seamlessly into existing workflows, reducing friction while expanding clinical insight. We believe this enhancement further strengthens Cancer Dx as a foundational tool for early detection and informed decision-making.</td><td>ì•” ì§„ë‹¨ íŒ¨ë„ì˜ ê°•ë ¥í•œ ëª¨ë©˜í…€ì„ ê¸°ë°˜ìœ¼ë¡œ, ë¹„ë§Œì„¸í¬ì¢… ê²€ì¶œì´ ì¶”ê°€ ë¹„ìš© ì—†ì´ ì¶”ê°€ë  ì˜ˆì •ì´ë©°, ê²€ì²´ ìš”êµ¬ì‚¬í•­ì´ë‚˜ ì›Œí¬í”Œë¡œìš°ì˜ ë³€ê²½ ì—†ì´, ë¯¸êµ­ ë‚´ 2~3ì¼ì˜ ì²˜ë¦¬ ê¸°ê°„ì„ ìœ ì§€í•  ê²ƒì…ë‹ˆë‹¤. ì´ë²ˆ í™•ì¥ì„ í†µí•´ ìˆ˜ì˜ì‚¬ë“¤ì€ ì •ê¸° ê±´ê°•ê²€ì§„ ì‹œ ìœ„í—˜êµ° ë°˜ë ¤ê²¬ë“¤ì— ëŒ€í•´ ê°€ì¥ í”í•œ ì•” ìœ í˜•ì˜ ì•½ 1/3ì„ ìŠ¤í¬ë¦¬ë‹í•  ìˆ˜ ìˆìœ¼ë©°, ë¹„ë§Œì„¸í¬ì¢…ì´ ì˜ì‹¬ë˜ëŠ” ì¦ìƒì´ ìˆëŠ” í™˜ìë“¤ì„ í‰ê°€í•  ìˆ˜ ìˆê²Œ ë©ë‹ˆë‹¤. ì¤‘ìš”í•œ ì ì€, ì´ê²ƒì´ ê¸°ì¡´ ì›Œí¬í”Œë¡œìš°ì— ì›í™œí•˜ê²Œ í†µí•©ë˜ì–´ ë§ˆì°°ì„ ì¤„ì´ë©´ì„œë„ ì„ìƒì  í†µì°°ë ¥ì„ í™•ëŒ€í•œë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì´ëŸ¬í•œ ê°œì„ ì´ ì¡°ê¸° ë°œê²¬ê³¼ ì •ë³´ì— ê¸°ë°˜í•œ ì˜ì‚¬ê²°ì •ì„ ìœ„í•œ ê¸°ì´ˆ ë„êµ¬ë¡œì„œ Cancer Dxë¥¼ ë”ìš± ê°•í™”í•  ê²ƒìœ¼ë¡œ ë¯¿ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We have also seen exciting new developments with the first Cancer Dx marker for canine lymphoma. Evidence shows that we can detect a lymphoma signal up to 8 months prior to clinical manifestation of disease. This means crucial months of earlier detection and treatment potential. As patients undergo treatment, the lymphoma test has also been proven to be useful for repeated testing to monitor remission during CHOP chemotherapy, a common treatment for canine lymphoma. With this treatment monitoring use case using reasonable assumptions, we see an addressable opportunity for canine lymphoma monitoring with Cancer Dx at approximately 130,000 tests per year in North America alone.</td><td>ë˜í•œ ê°œ ë¦¼í”„ì¢…ì„ ìœ„í•œ ìµœì´ˆì˜ Cancer Dx ë§ˆì»¤ì™€ ê´€ë ¨í•˜ì—¬ í¥ë¯¸ë¡œìš´ ìƒˆë¡œìš´ ë°œì „ì„ ëª©ê²©í–ˆìŠµë‹ˆë‹¤. ì¦ê±°ì— ë”°ë¥´ë©´ ì„ìƒì ìœ¼ë¡œ ì§ˆë³‘ì´ ë‚˜íƒ€ë‚˜ê¸° ìµœëŒ€ 8ê°œì›” ì „ì— ë¦¼í”„ì¢… ì‹ í˜¸ë¥¼ ê°ì§€í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ì¡°ê¸° ë°œê²¬ê³¼ ì¹˜ë£Œ ê°€ëŠ¥ì„±ì— ìˆì–´ ë§¤ìš° ì¤‘ìš”í•œ ìˆ˜ê°œì›”ì„ ì˜ë¯¸í•©ë‹ˆë‹¤. í™˜ìê°€ ì¹˜ë£Œë¥¼ ë°›ëŠ” ë™ì•ˆ, ë¦¼í”„ì¢… ê²€ì‚¬ëŠ” ê°œ ë¦¼í”„ì¢…ì˜ ì¼ë°˜ì ì¸ ì¹˜ë£Œë²•ì¸ CHOP í™”í•™ìš”ë²• ì¤‘ ê´€í•´ ìƒíƒœë¥¼ ëª¨ë‹ˆí„°ë§í•˜ê¸° ìœ„í•œ ë°˜ë³µ ê²€ì‚¬ì—ë„ ìœ ìš©í•œ ê²ƒìœ¼ë¡œ ì…ì¦ë˜ì—ˆìŠµë‹ˆë‹¤. í•©ë¦¬ì ì¸ ê°€ì •ì„ ì ìš©í•œ ì´ëŸ¬í•œ ì¹˜ë£Œ ëª¨ë‹ˆí„°ë§ ì‚¬ìš© ì‚¬ë¡€ë¥¼ í†µí•´, ë¶ë¯¸ ì§€ì—­ì—ì„œë§Œ Cancer Dxë¥¼ í™œìš©í•œ ê°œ ë¦¼í”„ì¢… ëª¨ë‹ˆí„°ë§ì˜ ì ì¬ ì‹œì¥ ê¸°íšŒê°€ ì—°ê°„ ì•½ 130,000ê±´ì˜ ê²€ì‚¬ ê·œëª¨ì„ì„ í™•ì¸í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>As is the case with the broader diagnostics category, the more we test, the more we learn. IDEXX inVue Dx continues to be a transformational platform, redefining point-of-care cell cytology across several high-volume use cases. The rollout of inVue Dx represents one of the most successful product launches in IDEXX history. In the fourth quarter reinforced that trajectory, bringing inVue Dx placements for the year to nearly 6,400. This performance was driven by strong customer demand, operational readiness and highly positive clinician feedback, exceeding our initial expectations.</td><td>ê´‘ë²”ìœ„í•œ ì§„ë‹¨ ì¹´í…Œê³ ë¦¬ì˜ ê²½ìš°ì™€ ë§ˆì°¬ê°€ì§€ë¡œ, ê²€ì‚¬ë¥¼ ë§ì´ í• ìˆ˜ë¡ ë” ë§ì€ ê²ƒì„ ë°°ìš°ê²Œ ë©ë‹ˆë‹¤. IDEXX inVue DxëŠ” ì—¬ëŸ¬ ê³ ë¹ˆë„ ì‚¬ìš© ì‚¬ë¡€ì—ì„œ í˜„ì¥ì§„ë£Œ(point-of-care) ì„¸í¬ ì„¸í¬í•™ì„ ì¬ì •ì˜í•˜ë©° í˜ì‹ ì ì¸ í”Œë«í¼ìœ¼ë¡œ ìë¦¬ì¡ê³  ìˆìŠµë‹ˆë‹¤. inVue Dxì˜ ì¶œì‹œëŠ” IDEXX ì—­ì‚¬ìƒ ê°€ì¥ ì„±ê³µì ì¸ ì œí’ˆ ì¶œì‹œ ì¤‘ í•˜ë‚˜ì…ë‹ˆë‹¤. 4ë¶„ê¸°ëŠ” ì´ëŸ¬í•œ ê¶¤ì ì„ ë”ìš± ê°•í™”í•˜ì—¬, ì—°ê°„ inVue Dx ì„¤ì¹˜ ëŒ€ìˆ˜ê°€ ê±°ì˜ 6,400ëŒ€ì— ë‹¬í–ˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì„±ê³¼ëŠ” ê°•ë ¥í•œ ê³ ê° ìˆ˜ìš”, ìš´ì˜ ì¤€ë¹„íƒœì„¸, ê·¸ë¦¬ê³  ë§¤ìš° ê¸ì •ì ì¸ ì„ìƒì˜ í”¼ë“œë°±ì— í˜ì…ì€ ê²ƒìœ¼ë¡œ, ë‹¹ì´ˆ ê¸°ëŒ€ì¹˜ë¥¼ ì´ˆê³¼í•˜ëŠ” ì‹¤ì ì…ë‹ˆë‹¤.</td></tr>
<tr><td>In December, we reached an important milestone with the controlled launch of fine needle aspirate or FNA on inVue Dx. While the initial menu is for mast cell tumor detection, we view the FNA capability as a platform of its own. As with new platforms, this will be a controlled launch that builds over time, ensuring that the testing performance and customer experience are exceptional within the real-world environment of a veterinary practice. FNA is a critical diagnostic technique used daily to evaluate masses and skin lesions. Historically, this process has been manual, time-intensive and dependent on specialized expertise and external lab interpretation.</td><td>12ì›”ì— ìš°ë¦¬ëŠ” inVue Dxì—ì„œ ì„¸ì¹¨í¡ì¸(FNA, Fine Needle Aspirate) ì œí•œì  ì¶œì‹œë¼ëŠ” ì¤‘ìš”í•œ ì´ì •í‘œë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ì´ˆê¸° ë©”ë‰´ëŠ” ë¹„ë§Œì„¸í¬ì¢… ê²€ì¶œìš©ì´ì§€ë§Œ, ìš°ë¦¬ëŠ” FNA ê¸°ëŠ¥ì„ ê·¸ ìì²´ë¡œ í•˜ë‚˜ì˜ í”Œë«í¼ìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ìƒˆë¡œìš´ í”Œë«í¼ì´ ê·¸ë ‡ë“¯ì´, ì´ëŠ” ì‹œê°„ì„ ë‘ê³  êµ¬ì¶•ë˜ëŠ” ì œí•œì  ì¶œì‹œê°€ ë  ê²ƒì´ë©°, ì‹¤ì œ ë™ë¬¼ë³‘ì› í™˜ê²½ì—ì„œ ê²€ì‚¬ ì„±ëŠ¥ê³¼ ê³ ê° ê²½í—˜ì´ íƒì›”í•¨ì„ ë³´ì¥í•  ê²ƒì…ë‹ˆë‹¤. FNAëŠ” ì¢…ê´´ì™€ í”¼ë¶€ ë³‘ë³€ì„ í‰ê°€í•˜ê¸° ìœ„í•´ ë§¤ì¼ ì‚¬ìš©ë˜ëŠ” ì¤‘ìš”í•œ ì§„ë‹¨ ê¸°ë²•ì…ë‹ˆë‹¤. ì—­ì‚¬ì ìœ¼ë¡œ ì´ ê³¼ì •ì€ ìˆ˜ì‘ì—…ìœ¼ë¡œ ì§„í–‰ë˜ì—ˆê³ , ì‹œê°„ì´ ë§ì´ ì†Œìš”ë˜ë©°, ì „ë¬¸ ì§€ì‹ê³¼ ì™¸ë¶€ ê²€ì‚¬ì‹¤ íŒë…ì— ì˜ì¡´í•´ ì™”ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>By automating key steps and applying AI-powered analysis, inVue Dx allows technicians to prepare a sample and receive results within minutes while the patient is still in the clinic with the option of a one-click pathologist evaluation for additional expertise and review of FNA images and results. The initial FNA rollout focuses on mast cell tumor detection, one of the most clinically significant canine cancers. Together with Cancer Dx, these innovations will give clinicians confidence at every step, from screening to diagnosis, so they can act sooner and faster, ruling cancer in or out with certainty.</td><td>AI ê¸°ë°˜ ë¶„ì„ì„ ì ìš©í•˜ê³  ì£¼ìš” ë‹¨ê³„ë¥¼ ìë™í™”í•¨ìœ¼ë¡œì¨, inVue DxëŠ” ê¸°ìˆ ìê°€ í™˜ìê°€ ì—¬ì „íˆ í´ë¦¬ë‹‰ì— ìˆëŠ” ë™ì•ˆ ëª‡ ë¶„ ë‚´ì— ìƒ˜í”Œì„ ì¤€ë¹„í•˜ê³  ê²°ê³¼ë¥¼ ë°›ì„ ìˆ˜ ìˆë„ë¡ í•˜ë©°, FNA ì´ë¯¸ì§€ ë° ê²°ê³¼ì— ëŒ€í•œ ì¶”ê°€ ì „ë¬¸ ì§€ì‹ê³¼ ê²€í† ë¥¼ ìœ„í•´ ì›í´ë¦­ ë³‘ë¦¬í•™ì í‰ê°€ ì˜µì…˜ì„ ì œê³µí•©ë‹ˆë‹¤. ì´ˆê¸° FNA ì¶œì‹œëŠ” ì„ìƒì ìœ¼ë¡œ ê°€ì¥ ì¤‘ìš”í•œ ê°œ ì•” ì¤‘ í•˜ë‚˜ì¸ ë¹„ë§Œì„¸í¬ì¢… ê²€ì¶œì— ì¤‘ì ì„ ë‘ê³  ìˆìŠµë‹ˆë‹¤. Cancer Dxì™€ í•¨ê»˜, ì´ëŸ¬í•œ í˜ì‹ ë“¤ì€ ì„ìƒì˜ë“¤ì´ ìŠ¤í¬ë¦¬ë‹ë¶€í„° ì§„ë‹¨ê¹Œì§€ ëª¨ë“  ë‹¨ê³„ì—ì„œ í™•ì‹ ì„ ê°€ì§€ê³ , ë” ë¹ ë¥´ê³  ì‹ ì†í•˜ê²Œ í–‰ë™í•˜ì—¬ ì•”ì„ í™•ì‹¤í•˜ê²Œ íŒë³„í•˜ê±°ë‚˜ ë°°ì œí•  ìˆ˜ ìˆë„ë¡ í•  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Our Catalyst platform continues to reflect IDEXX's Technology for Life strategy, delivering sustained value through disciplined menu expansions that enhance diagnostic confidence and efficiency at the point of care. In 2025, we built on this strategy with growing adoption of Catalyst Pancreatic Lipase and the launch of Catalyst Cortisol, both of which enable veterinarians to make faster, more informed decisions during the patient visit. Catalyst Pancreatic Lipase, introduced in late 2024, saw broad uptake throughout 2025 as practices incorporated it into routine workflows to support timely pancreatitis assessment.</td><td>ì €í¬ Catalyst í”Œë«í¼ì€ IDEXXì˜ Technology for Life ì „ëµì„ ì§€ì†ì ìœ¼ë¡œ ë°˜ì˜í•˜ë©°, ì§„ë£Œ í˜„ì¥ì—ì„œ ì§„ë‹¨ ì‹ ë¢°ë„ì™€ íš¨ìœ¨ì„±ì„ í–¥ìƒì‹œí‚¤ëŠ” ì²´ê³„ì ì¸ ë©”ë‰´ í™•ì¥ì„ í†µí•´ ì§€ì†ì ì¸ ê°€ì¹˜ë¥¼ ì œê³µí•˜ê³  ìˆìŠµë‹ˆë‹¤. 2025ë…„ì—ëŠ” Catalyst Pancreatic Lipaseì˜ ì±„íƒ í™•ëŒ€ì™€ Catalyst Cortisolì˜ ì¶œì‹œë¥¼ í†µí•´ ì´ëŸ¬í•œ ì „ëµì„ ë”ìš± ê°•í™”í–ˆìœ¼ë©°, ë‘ ì œí’ˆ ëª¨ë‘ ìˆ˜ì˜ì‚¬ë“¤ì´ í™˜ì ì§„ë£Œ ì¤‘ ë” ë¹ ë¥´ê³  ì •í™•í•œ ì˜ì‚¬ê²°ì •ì„ ë‚´ë¦´ ìˆ˜ ìˆë„ë¡ ì§€ì›í•©ë‹ˆë‹¤. 2024ë…„ ë§ ì¶œì‹œëœ Catalyst Pancreatic LipaseëŠ” 2025ë…„ ë‚´ë‚´ í­ë„“ê²Œ ì±„íƒë˜ì—ˆìœ¼ë©°, ë™ë¬¼ë³‘ì›ë“¤ì´ ì‹ ì†í•œ ì·Œì¥ì—¼ í‰ê°€ë¥¼ ì§€ì›í•˜ê¸° ìœ„í•´ ì¼ìƒì ì¸ ì§„ë£Œ í”„ë¡œì„¸ìŠ¤ì— ì´ë¥¼ í†µí•©í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>The test provides rapid quantitative results for both dogs and cats, with Reference Lab quality, helping veterinarians address a clinically challenging condition with greater confidence. Adoption across tens of thousands of practices supported diagnostic frequency gains and improved patient outcomes. We extended this momentum with the launch of Catalyst Cortisol in the third quarter, making the third Catalyst menu expansion in under a year when including Catalyst SmartQC. This test delivers real-time cortisol measurements to support endocrine diagnosis and ongoing disease management, allowing clinicians to move quickly from testing to action.</td><td>ì´ ê²€ì‚¬ëŠ” ê°œì™€ ê³ ì–‘ì´ ëª¨ë‘ì— ëŒ€í•´ ì‹ ì†í•œ ì •ëŸ‰ì  ê²°ê³¼ë¥¼ ì œê³µí•˜ë©°, ë ˆí¼ëŸ°ìŠ¤ ë© ìˆ˜ì¤€ì˜ í’ˆì§ˆë¡œ ìˆ˜ì˜ì‚¬ë“¤ì´ ì„ìƒì ìœ¼ë¡œ ê¹Œë‹¤ë¡œìš´ ìƒíƒœë¥¼ ë” í° í™•ì‹ ì„ ê°€ì§€ê³  ë‹¤ë£° ìˆ˜ ìˆë„ë¡ ì§€ì›í•©ë‹ˆë‹¤. ìˆ˜ë§Œ ê°œì˜ ë™ë¬¼ë³‘ì›ì—ì„œì˜ ë„ì…ì€ ì§„ë‹¨ ë¹ˆë„ ì¦ê°€ì™€ í™˜ì ì¹˜ë£Œ ê²°ê³¼ ê°œì„ ì„ ë’·ë°›ì¹¨í–ˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” 3ë¶„ê¸°ì— Catalyst Cortisolì„ ì¶œì‹œí•˜ë©° ì´ëŸ¬í•œ ëª¨ë©˜í…€ì„ í™•ëŒ€í–ˆëŠ”ë°, ì´ëŠ” Catalyst SmartQCë¥¼ í¬í•¨í•  ê²½ìš° 1ë…„ ì´ë‚´ì— ì„¸ ë²ˆì§¸ Catalyst ë©”ë‰´ í™•ì¥ì´ ë©ë‹ˆë‹¤. ì´ ê²€ì‚¬ëŠ” ë‚´ë¶„ë¹„ ì§„ë‹¨ê³¼ ì§€ì†ì ì¸ ì§ˆë³‘ ê´€ë¦¬ë¥¼ ì§€ì›í•˜ê¸° ìœ„í•´ ì‹¤ì‹œê°„ ì½”ë¥´í‹°ì†” ì¸¡ì •ì¹˜ë¥¼ ì œê³µí•˜ë©°, ì„ìƒì˜ë“¤ì´ ê²€ì‚¬ì—ì„œ ì¡°ì¹˜ë¡œ ì‹ ì†í•˜ê²Œ ì´ë™í•  ìˆ˜ ìˆë„ë¡ í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Early adoption exceeded expectations and contributed to solid consumable growth in the second half. Together these high-impact menu addition underscores the platform benefits of our robust installed base and Technology for Life strategy. We are able to rapidly expand new specialty tests like these across a large global installed base of approximately 78,000 Catalysts. For example, in North America, over 50% of Catalyst users adopted the Pancreatic Lipase Test in the first 12 months. Our software ecosystem remains an important growth driver and a source of strategic differentiation.</td><td>ì¡°ê¸° ë„ì…ì´ ì˜ˆìƒì„ ì´ˆê³¼í•˜ë©° í•˜ë°˜ê¸° ì†Œëª¨í’ˆ ì„±ì¥ì— í¬ê²Œ ê¸°ì—¬í–ˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì˜í–¥ë ¥ ë†’ì€ ë©”ë‰´ ì¶”ê°€ëŠ” ìš°ë¦¬ì˜ ê²¬ê³ í•œ ì„¤ì¹˜ ê¸°ë°˜ê³¼ Technology for Life ì „ëµì˜ í”Œë«í¼ ì´ì ì„ ì˜ ë³´ì—¬ì¤ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì•½ 78,000ëŒ€ì˜ Catalystë¡œ êµ¬ì„±ëœ ëŒ€ê·œëª¨ ê¸€ë¡œë²Œ ì„¤ì¹˜ ê¸°ë°˜ ì „ë°˜ì— ê±¸ì³ ì´ëŸ¬í•œ ìƒˆë¡œìš´ íŠ¹ìˆ˜ ê²€ì‚¬ë¥¼ ì‹ ì†í•˜ê²Œ í™•ëŒ€í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì˜ˆë¥¼ ë“¤ì–´, ë¶ë¯¸ì—ì„œëŠ” Catalyst ì‚¬ìš©ìì˜ 50% ì´ìƒì´ ì²« 12ê°œì›” ë‚´ì— ì·Œì¥ ë¦¬íŒŒì•„ì œ ê²€ì‚¬(Pancreatic Lipase Test)ë¥¼ ë„ì…í–ˆìŠµë‹ˆë‹¤. ìš°ë¦¬ì˜ ì†Œí”„íŠ¸ì›¨ì–´ ìƒíƒœê³„ëŠ” ì—¬ì „íˆ ì¤‘ìš”í•œ ì„±ì¥ ë™ë ¥ì´ì ì „ëµì  ì°¨ë³„í™”ì˜ ì›ì²œìœ¼ë¡œ ë‚¨ì•„ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>IDEXX software is deeply integrated across diagnostics, imaging, client communication and practice operations, helping clinics fully realize the value of their diagnostic investments. In 2025, we saw strong performance across our practice information management systems as well as continued momentum in pet owner engagement tools such as Vello. Our ezyVet and Neo platforms delivered double-digit installed base growth, with particular strength among multi-location practices and corporate customers. We closed the year with record quarterly bookings, reflecting contracted future ARR, signaling strong momentum for IDEXX's software solutions.</td><td>IDEXX ì†Œí”„íŠ¸ì›¨ì–´ëŠ” ì§„ë‹¨, ì˜ìƒ, ê³ ê° ì»¤ë®¤ë‹ˆì¼€ì´ì…˜ ë° ì§„ë£Œ ìš´ì˜ ì „ë°˜ì— ê±¸ì³ ê¸´ë°€í•˜ê²Œ í†µí•©ë˜ì–´ ìˆì–´, ë™ë¬¼ë³‘ì›ë“¤ì´ ì§„ë‹¨ íˆ¬ìì˜ ê°€ì¹˜ë¥¼ ì™„ì „íˆ ì‹¤í˜„í•  ìˆ˜ ìˆë„ë¡ ì§€ì›í•©ë‹ˆë‹¤. 2025ë…„ì—ëŠ” ì§„ë£Œì •ë³´ê´€ë¦¬ì‹œìŠ¤í…œ(PIMS)ì—ì„œ ê°•ë ¥í•œ ì„±ê³¼ë¥¼ ê±°ë‘ì—ˆìœ¼ë©°, Velloì™€ ê°™ì€ ë°˜ë ¤ë™ë¬¼ ë³´í˜¸ì ì°¸ì—¬ ë„êµ¬ì—ì„œë„ ì§€ì†ì ì¸ ëª¨ë©˜í…€ì„ ë³´ì˜€ìŠµë‹ˆë‹¤. ezyVetê³¼ Neo í”Œë«í¼ì€ ì„¤ì¹˜ ê¸°ë°˜ì—ì„œ ë‘ ìë¦¿ìˆ˜ ì„±ì¥ì„ ë‹¬ì„±í–ˆìœ¼ë©°, íŠ¹íˆ ë‹¤ì¤‘ ì§€ì  ë³‘ì›ê³¼ ê¸°ì—… ê³ ê°ë“¤ ì‚¬ì´ì—ì„œ ê°•ì„¸ë¥¼ ë³´ì˜€ìŠµë‹ˆë‹¤. ê³„ì•½ëœ ë¯¸ë˜ ARRì„ ë°˜ì˜í•˜ëŠ” ë¶„ê¸° ì‹ ê·œ ê³„ì•½ ê±´ìˆ˜ê°€ ì‚¬ìƒ ìµœê³ ì¹˜ë¥¼ ê¸°ë¡í•˜ë©° í•œ í•´ë¥¼ ë§ˆê°í–ˆìœ¼ë©°, ì´ëŠ” IDEXX ì†Œí”„íŠ¸ì›¨ì–´ ì†”ë£¨ì…˜ì˜ ê°•ë ¥í•œ ëª¨ë©˜í…€ì„ ë‚˜íƒ€ëƒ…ë‹ˆë‹¤.</td></tr>
<tr><td>Clinics continue to choose our cloud-native platforms for their modern interfaces, diagnostics interpretation and ability to scale efficiently across locations with centralized workflows and data. Vello continues to expand, growing its users over 40% from last quarter, and nearly tripling last year. Clinics using Vello report improved communication with pet owners, increased visit frequency and better compliance with diagnostics and treatment plans compared to practices relying on more basic engaged tools. We see Vello as a powerful complement to diagnostics, helping clinics translate clinical insight into action.</td><td>ë³‘ì›ë“¤ì€ í˜„ëŒ€ì ì¸ ì¸í„°í˜ì´ìŠ¤, ì§„ë‹¨ í•´ì„ ê¸°ëŠ¥, ê·¸ë¦¬ê³  ì¤‘ì•™í™”ëœ ì›Œí¬í”Œë¡œìš°ì™€ ë°ì´í„°ë¥¼ í†µí•´ ì—¬ëŸ¬ ì§€ì ì— ê±¸ì³ íš¨ìœ¨ì ìœ¼ë¡œ í™•ì¥í•  ìˆ˜ ìˆëŠ” ëŠ¥ë ¥ì„ ê°–ì¶˜ ë‹¹ì‚¬ì˜ í´ë¼ìš°ë“œ ë„¤ì´í‹°ë¸Œ í”Œë«í¼ì„ ì§€ì†ì ìœ¼ë¡œ ì„ íƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. VelloëŠ” ì§€ì†ì ìœ¼ë¡œ í™•ì¥ë˜ê³  ìˆìœ¼ë©°, ì§€ë‚œ ë¶„ê¸° ëŒ€ë¹„ ì‚¬ìš©ìê°€ 40% ì´ìƒ ì¦ê°€í–ˆê³ , ì‘ë…„ ëŒ€ë¹„ë¡œëŠ” ê±°ì˜ 3ë°° ì¦ê°€í–ˆìŠµë‹ˆë‹¤. Velloë¥¼ ì‚¬ìš©í•˜ëŠ” ë³‘ì›ë“¤ì€ ë³´ë‹¤ ê¸°ë³¸ì ì¸ ì°¸ì—¬ ë„êµ¬ì— ì˜ì¡´í•˜ëŠ” ë³‘ì›ë“¤ê³¼ ë¹„êµí–ˆì„ ë•Œ, ë°˜ë ¤ë™ë¬¼ ë³´í˜¸ìì™€ì˜ ì»¤ë®¤ë‹ˆì¼€ì´ì…˜ ê°œì„ , ë‚´ì› ë¹ˆë„ ì¦ê°€, ê·¸ë¦¬ê³  ì§„ë‹¨ ë° ì¹˜ë£Œ ê³„íšì— ëŒ€í•œ ìˆœì‘ë„ í–¥ìƒì„ ë³´ê³ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë‹¹ì‚¬ëŠ” Velloë¥¼ ì§„ë‹¨ ì„œë¹„ìŠ¤ì˜ ê°•ë ¥í•œ ë³´ì™„ì¬ë¡œ ë³´ê³  ìˆìœ¼ë©°, ë³‘ì›ë“¤ì´ ì„ìƒì  ì¸ì‚¬ì´íŠ¸ë¥¼ ì‹¤í–‰ìœ¼ë¡œ ì „í™˜í•˜ëŠ” ë° ë„ì›€ì„ ì£¼ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We also made exciting progress in our diagnostic imaging business where we launched in early January the most advanced radiography system in veterinary medicine, one that combines superb image quality at the lowest dose of radiation, an important consideration where 75% of technicians are women of child-bearing age. Our solution enables a connected diagnostic imaging workflow for veterinary professionals, where our AI-powered viewer automates key clinical measurements and customers can now submit and review telemedicine cases directly through Web PACS. As we close out 2025, IDEXX remains firmly committed to creating long-term value for our customers, employees and shareholders.</td><td>ë˜í•œ ì§„ë‹¨ ì˜ìƒ ì‚¬ì—…ì—ì„œë„ ê³ ë¬´ì ì¸ ì§„ì „ì„ ì´ë£¨ì—ˆìŠµë‹ˆë‹¤. 1ì›” ì´ˆ ìˆ˜ì˜í•™ ë¶„ì•¼ì—ì„œ ê°€ì¥ ì§„ë³´ëœ ë°©ì‚¬ì„  ì´¬ì˜ ì‹œìŠ¤í…œì„ ì¶œì‹œí–ˆëŠ”ë°, ì´ëŠ” ìµœì € ë°©ì‚¬ì„  í”¼í­ëŸ‰ìœ¼ë¡œ íƒì›”í•œ ì˜ìƒ í’ˆì§ˆì„ ì œê³µí•˜ëŠ” ì œí’ˆì…ë‹ˆë‹¤. ì´ëŠ” ê¸°ìˆ ìì˜ 75%ê°€ ê°€ì„ê¸° ì—¬ì„±ì´ë¼ëŠ” ì ì„ ê³ ë ¤í•  ë•Œ ë§¤ìš° ì¤‘ìš”í•œ ìš”ì†Œì…ë‹ˆë‹¤. ë‹¹ì‚¬ì˜ ì†”ë£¨ì…˜ì€ ìˆ˜ì˜í•™ ì „ë¬¸ê°€ë“¤ì„ ìœ„í•œ ì—°ê²°ëœ ì§„ë‹¨ ì˜ìƒ ì›Œí¬í”Œë¡œìš°ë¥¼ êµ¬í˜„í•˜ë©°, AI ê¸°ë°˜ ë·°ì–´ê°€ ì£¼ìš” ì„ìƒ ì¸¡ì •ì„ ìë™í™”í•˜ê³  ê³ ê°ë“¤ì´ ì´ì œ Web PACSë¥¼ í†µí•´ ì§ì ‘ ì›ê²©ì§„ë£Œ ì‚¬ë¡€ë¥¼ ì œì¶œí•˜ê³  ê²€í† í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. 2025ë…„ì„ ë§ˆë¬´ë¦¬í•˜ë©´ì„œ, IDEXXëŠ” ê³ ê°, ì§ì› ë° ì£¼ì£¼ë“¤ì„ ìœ„í•œ ì¥ê¸°ì  ê°€ì¹˜ ì°½ì¶œì— í™•ê³ íˆ ì „ë…í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Over the past year, we strengthened our commercial foundation, scaled impactful innovations and reinforced our leadership in diagnostics and software. We enter 2026 with confidence in our strategy, our teams and the opportunities ahead. The human-animal bond continues to deepen and expectations for quality veterinary care continue to rise. IDEXX is uniquely positioned to support this evolution by delivering diagnostic and digital tools that enhance productivity, improve outcomes, and support sustainable practice growth. I want to close by thanking our 11,000 employees around the world.</td><td>ì§€ë‚œ 1ë…„ê°„ ìš°ë¦¬ëŠ” ìƒì—…ì  ê¸°ë°˜ì„ ê°•í™”í•˜ê³ , ì˜í–¥ë ¥ ìˆëŠ” í˜ì‹ ì„ í™•ëŒ€í–ˆìœ¼ë©°, ì§„ë‹¨ ë° ì†Œí”„íŠ¸ì›¨ì–´ ë¶„ì•¼ì—ì„œì˜ ë¦¬ë”ì‹­ì„ ê³µê³ íˆ í–ˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ìš°ë¦¬ì˜ ì „ëµê³¼ íŒ€, ê·¸ë¦¬ê³  ì•ìœ¼ë¡œì˜ ê¸°íšŒì— ëŒ€í•œ í™•ì‹ ì„ ê°€ì§€ê³  2026ë…„ì„ ë§ì´í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì¸ê°„ê³¼ ë°˜ë ¤ë™ë¬¼ ê°„ì˜ ìœ ëŒ€ê°ì€ ê³„ì†í•´ì„œ ê¹Šì–´ì§€ê³  ìˆìœ¼ë©°, ì–‘ì§ˆì˜ ìˆ˜ì˜í•™ì  ì§„ë£Œì— ëŒ€í•œ ê¸°ëŒ€ì¹˜ë„ ê³„ì† ë†’ì•„ì§€ê³  ìˆìŠµë‹ˆë‹¤. IDEXXëŠ” ìƒì‚°ì„±ì„ í–¥ìƒì‹œí‚¤ê³ , ì¹˜ë£Œ ê²°ê³¼ë¥¼ ê°œì„ í•˜ë©°, ì§€ì† ê°€ëŠ¥í•œ ë³‘ì› ì„±ì¥ì„ ì§€ì›í•˜ëŠ” ì§„ë‹¨ ë° ë””ì§€í„¸ ë„êµ¬ë¥¼ ì œê³µí•¨ìœ¼ë¡œì¨ ì´ëŸ¬í•œ ë³€í™”ë¥¼ ë’·ë°›ì¹¨í•  ìˆ˜ ìˆëŠ” ë…ë³´ì ì¸ ìœ„ì¹˜ì— ìˆìŠµë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ ì „ ì„¸ê³„ 11,000ëª…ì˜ ì„ì§ì›ë“¤ì—ê²Œ ê°ì‚¬ì˜ ë§ì”€ì„ ì „í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Your dedication to innovation, quality and customer partnership is what enables IDEXX to deliver consistent performance year after year. We're excited about the year ahead and look forward to continuing to build on this momentum. With that, I'll open the line for Q&A. Thank you.</td><td>í˜ì‹ , í’ˆì§ˆ, ê·¸ë¦¬ê³  ê³ ê° íŒŒíŠ¸ë„ˆì‹­ì— ëŒ€í•œ ì—¬ëŸ¬ë¶„ì˜ í—Œì‹ ì´ IDEXXê°€ í•´ë§ˆë‹¤ ì¼ê´€ëœ ì„±ê³¼ë¥¼ ì œê³µí•  ìˆ˜ ìˆê²Œ í•˜ëŠ” ì›ë™ë ¥ì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì•ìœ¼ë¡œì˜ í•œ í•´ê°€ ê¸°ëŒ€ë˜ë©°, ì´ëŸ¬í•œ ëª¨ë©˜í…€ì„ ì§€ì†ì ìœ¼ë¡œ êµ¬ì¶•í•´ ë‚˜ê°€ê¸°ë¥¼ ê¸°ëŒ€í•©ë‹ˆë‹¤. ê·¸ëŸ¼ ì´ì œ ì§ˆì˜ì‘ë‹µ ì‹œê°„ì„ ê°–ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤. ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;"># IDEXX Laboratories Q4 2025 ì‹¤ì  ìš”ì•½<br><br>## ì£¼ìš” ì¬ë¬´ ì„±ê³¼<br>- **Q4 2025**: ë§¤ì¶œ 14% ì¦ê°€(ìœ ê¸°ì  12%), CAG ì§„ë‹¨ ë°˜ë³µë§¤ì¶œ 10% ìœ ê¸°ì  ì„±ì¥. EPS $3.08(ì „ë…„ë¹„ 17% ì¦ê°€)<br>- **ì—°ê°„ 2025**: ìœ ê¸°ì  ë§¤ì¶œ 10% ì„±ì¥, CAG ì§„ë‹¨ ë°˜ë³µë§¤ì¶œ 8% ì¦ê°€. ì˜ì—…ì´ìµë¥  31.6%(90bp ê°œì„ ), EPS $13.08(14% ì¦ê°€). í”„ë¦¬ë¯¸ì—„ ì¥ë¹„ ì„¤ì¹˜ ê¸°ë°˜ 12% í™•ëŒ€, inVue Dx 6,400ëŒ€ í¬í•¨<br>- **2026 ê°€ì´ë˜ìŠ¤**: ë§¤ì¶œ $4.63~4.72B(ìœ ê¸°ì  7~9% ì„±ì¥), CAG ì§„ë‹¨ ë°˜ë³µë§¤ì¶œ 8~10% ì„±ì¥ ì „ë§. ì˜ì—…ì´ìµë¥  32.0~32.5%, EPS $14.29~14.80(10~14% ì¦ê°€). ì™¸í™˜ íš¨ê³¼ ì•½ 60bp ê¸ì •ì  ê¸°ì—¬ ì˜ˆìƒ<br><br>## ê²½ì˜ì§„ í†¤ ë° ì „ëµ<br>- **ê¸ì •ì  í†¤**: 2025ë…„ì„ "ì „í™˜ì "ìœ¼ë¡œ í‰ê°€í•˜ë©° inVue Dx, Cancer Dx ë“± í˜ì‹  í”Œë«í¼ì˜ ì„±ê³µì  í™•ì¥ ê°•ì¡°. ìƒì—… ì¡°ì§ í™•ëŒ€ ì™„ë£Œ(ë…ì¼, ì˜êµ­, í˜¸ì£¼, ë¯¸êµ­)ë¡œ ê³ ê° ì ‘ì  ê°•í™”<br>- **ì„±ì¥ ë™ë ¥**: ê³ ë ¹ ë°˜ë ¤ë™ë¬¼ ì¦ê°€ë¡œ ì§„ë‹¨ ë¹ˆë„ ìƒìŠ¹, ê³ ê° ìœ ì§€ìœ¨ 90% í›„ë°˜ ìœ ì§€. Catalyst í”Œë«í¼ ë©”ë‰´ í™•ì¥(Pancreatic Lipase,</p>
    <hr style="margin:50px 0;">
    

    <h2>â“ Q&A</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Operator: [Operator Instructions] And our first question is going to come from Chris Schott.</td><td>**Operator:** <budget:token_used>5000</budget:token_used><br><br>[ìš´ì˜ì ì•ˆë‚´] ì²« ë²ˆì§¸ ì§ˆë¬¸ì€ Chris Schottë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Christopher Schott: JPMorgan Chase & Co, Research Division I just want to start on the vet visit side. We're obviously seeing a pretty wide divergence between wellness and non-wellness visits. It sounds like part of that from your perspective is the pandemic puppy starting to age here. But I was just interested to see how you're thinking about this evolving in 2026 as we think about wellness versus non-wellness visits in that negative 2% overall number? And maybe just related to that, on price, I know you're targeting a bit less price this year. What are you seeing at the vet practice level in terms of price increases? I guess are you seeing any signs of some of these corporate practices starting to moderate price at all this year as well? I'm just trying to get some -- my hands around some of those dynamics.</td><td>**Christopher Schott:** ìˆ˜ì˜ì‚¬ ë°©ë¬¸ ì¸¡ë©´ì—ì„œ ì‹œì‘í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤. ì›°ë‹ˆìŠ¤ ë°©ë¬¸ê³¼ ë¹„ì›°ë‹ˆìŠ¤ ë°©ë¬¸ ê°„ì— ìƒë‹¹íˆ í° ì°¨ì´ê°€ ë‚˜íƒ€ë‚˜ê³  ìˆìŠµë‹ˆë‹¤. ê·€ì‚¬ì˜ ê´€ì ì—ì„œëŠ” íŒ¬ë°ë¯¹ ì‹œê¸°ì— ì…ì–‘ëœ ë°˜ë ¤ë™ë¬¼ë“¤ì´ ì´ì œ ë‚˜ì´ë¥¼ ë¨¹ì–´ê°€ëŠ” ê²ƒì´ ì¼ë¶€ ì›ì¸ì¸ ê²ƒìœ¼ë¡œ ë“¤ë¦½ë‹ˆë‹¤. ë‹¤ë§Œ ì „ì²´ ë§ˆì´ë„ˆìŠ¤ 2%ë¼ëŠ” ìˆ˜ì¹˜ë¥¼ ê³ ë ¤í•  ë•Œ, 2026ë…„ì— ì›°ë‹ˆìŠ¤ ëŒ€ë¹„ ë¹„ì›°ë‹ˆìŠ¤ ë°©ë¬¸ì´ ì–´ë–»ê²Œ ë³€í™”í•  ê²ƒìœ¼ë¡œ ë³´ì‹œëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ê´€ë ¨í•´ì„œ ê°€ê²© ì¸¡ë©´ì—ì„œ, ì˜¬í•´ëŠ” ê°€ê²© ì¸ìƒí­ì„ ë‹¤ì†Œ ì¤„ì¼ ê³„íšì¸ ê²ƒìœ¼ë¡œ ì•Œê³  ìˆëŠ”ë°ìš”. ì‹¤ì œ ë™ë¬¼ë³‘ì› í˜„ì¥ì—ì„œëŠ” ê°€ê²© ì¸ìƒì´ ì–´ë–»ê²Œ ë‚˜íƒ€ë‚˜ê³  ìˆìŠµë‹ˆê¹Œ? ì¼ë¶€ ëŒ€í˜• ì²´ì¸ ë™ë¬¼ë³‘ì›ë“¤ì´ ì˜¬í•´ ê°€ê²© ì¸ìƒì„ ìì œí•˜ëŠ” ì¡°ì§ì´ ë³´ì´ëŠ”ì§€ìš”? ì´ëŸ¬í•œ ì—­í•™ê´€ê³„ë¥¼ ì¢€ ë” ëª…í™•íˆ íŒŒì•…í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Jay Mazelsky: President, CEO & Director Yes, just in terms of -- let me start with the vet visit profile first. We have seen some headwinds more on the wellness side. We think that's, at this point, really macro, probably in the lower end economic demographic households where there's obviously some financial pressures. Less so on the non-wellness side, obviously, and we have seen some green shoots now 2 quarters in a row with those pets 5 years plus starting to grow. So we think that's positive. We think that likely reflects the pandemic adoption boom and these pets aging and will likely continue going forward. In terms of 2026, we just -- we kept that baseline of about 2% decline until -- I think until we have clear evidence that, that's going to improve, we thought that was an appropriate path to take. From a vet inflation standpoint, maybe on the vet services side, more from the corporate perspective, we have seen some moderation. It's still running hotter than CPI. And I think that will come down over time. What we've seen is, I think the corporate practices recognize that, that may be an obstacle to getting care with some of their clients, and they're interested in being more aggressive in driving demand and patient traffic into their practices. So I think more to come as that develops.</td><td>**Jay Mazelsky:** ë„¤, ë¨¼ì € ë™ë¬¼ë³‘ì› ë°©ë¬¸ í”„ë¡œí•„ë¶€í„° ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì›°ë‹ˆìŠ¤ ë¶€ë¬¸ì—ì„œ ì¼ë¶€ ì—­í’ì„ ê²½í—˜í•˜ê³  ìˆìŠµë‹ˆë‹¤. í˜„ ì‹œì ì—ì„œ ì´ëŠ” ì‹¤ì§ˆì ìœ¼ë¡œ ê±°ì‹œê²½ì œì  ìš”ì¸ìœ¼ë¡œ ë³´ì´ë©°, íŠ¹íˆ ì €ì†Œë“ì¸µ ê°€êµ¬ì—ì„œ ì¬ì •ì  ì••ë°•ì´ ìˆëŠ” ê²ƒìœ¼ë¡œ íŒë‹¨ë©ë‹ˆë‹¤. ë°˜ë©´ ë¹„ì›°ë‹ˆìŠ¤ ë¶€ë¬¸ì—ì„œëŠ” ê·¸ ì •ë„ê°€ ëœí•˜ê³ , 5ì„¸ ì´ìƒ ë°˜ë ¤ë™ë¬¼ì´ 2ë¶„ê¸° ì—°ì† ì„±ì¥ì„¸ë¥¼ ë³´ì´ëŠ” ê¸ì •ì ì¸ ì‹ í˜¸ë¥¼ í™•ì¸í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ê¸ì •ì ì¸ í˜„ìƒì…ë‹ˆë‹¤. íŒ¬ë°ë¯¹ ì‹œê¸° ì…ì–‘ ë¶ìœ¼ë¡œ ì¸í•œ ë°˜ë ¤ë™ë¬¼ë“¤ì´ ë‚˜ì´ë¥¼ ë¨¹ì–´ê°€ëŠ” ê²ƒì„ ë°˜ì˜í•˜ëŠ” ê²ƒìœ¼ë¡œ ë³´ì´ë©°, ì´ëŸ¬í•œ ì¶”ì„¸ëŠ” ì•ìœ¼ë¡œë„ ì§€ì†ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. 2026ë…„ ê´€ë ¨í•´ì„œëŠ” ê¸°ì¤€ì„ ì„ ì•½ 2% ê°ì†Œë¡œ ìœ ì§€í–ˆìŠµë‹ˆë‹¤. ëª…í™•í•œ ê°œì„  ì¦ê±°ê°€ ë‚˜ì˜¬ ë•Œê¹Œì§€ëŠ” ì´ê²ƒì´ ì ì ˆí•œ ì ‘ê·¼ ë°©ì‹ì´ë¼ê³  íŒë‹¨í–ˆìŠµë‹ˆë‹¤. ìˆ˜ì˜ ì¸í”Œë ˆì´ì…˜ ì¸¡ë©´ì—ì„œ ë³´ë©´, íŠ¹íˆ ìˆ˜ì˜ ì„œë¹„ìŠ¤ ë¶€ë¬¸ì—ì„œ ê¸°ì—… ê´€ì ìœ¼ë¡œ ë³¼ ë•Œ ì–´ëŠ ì •ë„ ì™„í™”ì„¸ë¥¼ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. ì—¬ì „íˆ ì†Œë¹„ìë¬¼ê°€ì§€ìˆ˜(CPI)ë³´ë‹¤ëŠ” ë†’ê²Œ ì›€ì§ì´ê³  ìˆì§€ë§Œ, ì‹œê°„ì´ ì§€ë‚˜ë©´ì„œ í•˜ë½í•  ê²ƒìœ¼ë¡œ ë´…ë‹ˆë‹¤. ê¸°ì—…í˜• ë™ë¬¼ë³‘ì›ë“¤ì´ ì´ëŸ¬í•œ ê°€ê²© ìƒìŠ¹ì´ ê³ ê°ë“¤ì˜ ì§„ë£Œ ì ‘ê·¼ì— ì¥ì• ë¬¼ì´ ë  ìˆ˜ ìˆë‹¤ëŠ” ì ì„ ì¸ì‹í•˜ê³  ìˆìœ¼ë©°, ë³‘ì›ìœ¼ë¡œì˜ ìˆ˜ìš”ì™€ í™˜ì ìœ ì…ì„ ë” ì ê·¹ì ìœ¼ë¡œ ìœ ë„í•˜ëŠ” ë° ê´€ì‹¬ì„ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ìƒí™©ì´ ì „ê°œë˜ë©´ì„œ ë” ë§ì€ ë³€í™”ê°€ ìˆì„ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤.</td></tr>
<tr><td>Andrew Emerson: Executive VP, CFO & Treasurer Yes. And Chris, I'd just add on the visit dynamic just in terms of both the non-well and the wellness visits, we continue to see a really nice quality of visits overall. The frequency and utilization continues to expand in both categories. And so even in those groups in terms of the wellness and discretionary types of visits, when they are coming into the clinic, we're continuing to see really positive momentum for the use of diagnostics, which I think is a key part of our strategy overall.</td><td>**Andrew Emerson:** ë„¤, ê·¸ë¦¬ê³  í¬ë¦¬ìŠ¤, ë°©ë¬¸ ë™í–¥ì— ëŒ€í•´ í•œ ê°€ì§€ ë§ë¶™ì´ìë©´, ì¼ë°˜ ì§„ë£Œì™€ ì›°ë‹ˆìŠ¤ ë°©ë¬¸ ëª¨ë‘ì—ì„œ ì „ë°˜ì ìœ¼ë¡œ ë§¤ìš° ì–‘í˜¸í•œ ë°©ë¬¸ í’ˆì§ˆì„ ì§€ì†ì ìœ¼ë¡œ í™•ì¸í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë‘ ì¹´í…Œê³ ë¦¬ ëª¨ë‘ì—ì„œ ë°©ë¬¸ ë¹ˆë„ì™€ ì´ìš©ë¥ ì´ ê³„ì† ì¦ê°€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì›°ë‹ˆìŠ¤ë‚˜ ì„ íƒì  ë°©ë¬¸ ê·¸ë£¹ì—ì„œë„ ê³ ê°ë“¤ì´ ë³‘ì›ì„ ë°©ë¬¸í•  ë•Œ ì§„ë‹¨ê²€ì‚¬ ì´ìš©ì´ ì§€ì†ì ìœ¼ë¡œ ê¸ì •ì ì¸ ëª¨ë©˜í…€ì„ ë³´ì´ê³  ìˆìœ¼ë©°, ì´ëŠ” ìš°ë¦¬ì˜ ì „ì²´ ì „ëµì—ì„œ í•µì‹¬ì ì¸ ë¶€ë¶„ì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Jay Mazelsky: President, CEO & Director Yes. Keep in mind, the non-wellness visits represent about 60% of the visits, but 70% to 75% of the diagnostics revenue. So this combination of what Andrew put his finger on, which is they're using more diagnostics when they come in. So we call that frequency, but also it's more intensive, I think, is an important factor to keep in mind just from a -- through a diagnostic lens.</td><td>**Jay Mazelsky:** ë„¤, ëª…ì‹¬í•˜ì…”ì•¼ í•  ì ì€ ë¹„ì›°ë‹ˆìŠ¤ ë°©ë¬¸ì´ ì „ì²´ ë°©ë¬¸ì˜ ì•½ 60%ë¥¼ ì°¨ì§€í•˜ì§€ë§Œ, ì§„ë‹¨ê²€ì‚¬ ë§¤ì¶œì˜ 70~75%ë¥¼ ì°¨ì§€í•œë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ë”°ë¼ì„œ Andrewê°€ ì§€ì í•œ ë¶€ë¶„, ì¦‰ í™˜ìë“¤ì´ ë‚´ì› ì‹œ ë” ë§ì€ ì§„ë‹¨ê²€ì‚¬ë¥¼ ì´ìš©í•œë‹¤ëŠ” ì ê³¼ ê²°í•©ë˜ëŠ” ê²ƒì´ì£ . ìš°ë¦¬ëŠ” ì´ê²ƒì„ ë¹ˆë„(frequency)ë¼ê³  ë¶€ë¥´ì§€ë§Œ, ë™ì‹œì— ë” ì§‘ì¤‘ì ì´ë¼ëŠ” ì ë„ ì§„ë‹¨ê²€ì‚¬ ê´€ì ì—ì„œ ë³¼ ë•Œ ì¤‘ìš”í•œ ìš”ì†Œì…ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: And our next question is going to come from Erin Wright from Morgan Stanley.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ ëª¨ê±´ìŠ¤íƒ ë¦¬ì˜ ì—ë¦° ë¼ì´íŠ¸ë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Erin Wilson Wright: Morgan Stanley, Research Division So could you speak a little bit about the underlying drivers of the consumables growth? How should we be thinking about continuing mid-teens growth into 2026 or the cadence that we should be thinking about things here? What are the components of this? What will you lap? And then also, I assume that inVue isn't necessarily directly contributing all that much in terms of meaningful consumables flow-through as yet. So is there more to come on that front? What are you seeing in terms of that consumables flow-through? And then if not, like how do you think about when you enter into these contracts with placing inVue, how is that translating into consumables growth across the entire portfolio?</td><td>**Erin Wilson Wright:** ì†Œëª¨í’ˆ ì„±ì¥ì˜ ê·¼ë³¸ì ì¸ ë™ì¸ì— ëŒ€í•´ ì¢€ ë” ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. 2026ë…„ê¹Œì§€ 10%ëŒ€ ì¤‘ë°˜ ì„±ì¥ì„ ì–´ë–»ê²Œ ìƒê°í•´ì•¼ í• ì§€, ë˜ëŠ” ì—¬ê¸°ì„œ ì–´ë–¤ íë¦„ì„ ì˜ˆìƒí•´ì•¼ í• ì§€ì— ëŒ€í•œ ì§ˆë¬¸ì´ì‹œì£ ? ì´ê²ƒì˜ êµ¬ì„± ìš”ì†ŒëŠ” ë¬´ì—‡ì´ê³ , ë¬´ì—‡ì„ ê¸°ì €íš¨ê³¼ë¡œ ë„˜ê¸°ê²Œ ë ê¹Œìš”? ê·¸ë¦¬ê³  inVueê°€ ì•„ì§ì€ ì˜ë¯¸ ìˆëŠ” ì†Œëª¨í’ˆ ë§¤ì¶œ ì¦ê°€ì— ì§ì ‘ì ìœ¼ë¡œ í¬ê²Œ ê¸°ì—¬í•˜ê³  ìˆì§€ëŠ” ì•Šë‹¤ê³  ê°€ì •í•©ë‹ˆë‹¤. ê·¸ë ‡ë‹¤ë©´ ê·¸ ë¶€ë¶„ì—ì„œ ë” ë‚˜ì˜¬ ì—¬ì§€ê°€ ìˆëŠ” ê±´ê°€ìš”? ì†Œëª¨í’ˆ ì—°ê³„ ë§¤ì¶œ ì¸¡ë©´ì—ì„œ ì–´ë–¤ ê²ƒë“¤ì„ ë³´ê³  ê³„ì‹ ê°€ìš”? ê·¸ë¦¬ê³  ë§Œì•½ ê·¸ë ‡ì§€ ì•Šë‹¤ë©´, inVueë¥¼ ì„¤ì¹˜í•˜ëŠ” ê³„ì•½ì„ ì²´ê²°í•  ë•Œ ì´ê²ƒì´ ì „ì²´ í¬íŠ¸í´ë¦¬ì˜¤ì— ê±¸ì³ ì†Œëª¨í’ˆ ì„±ì¥ìœ¼ë¡œ ì–´ë–»ê²Œ ì „í™˜ë˜ëŠ”ì§€ ì–´ë–»ê²Œ ìƒê°í•˜ê³  ê³„ì‹ ê°€ìš”?</td></tr>
<tr><td>Jay Mazelsky: President, CEO & Director Yes. Let me just maybe set this up from an innovation standpoint, and then I'll hand it off to Andrew, who can provide some additional specifics. The approach that we take with putting platforms out in the market and growing our installed base with this overlay of Technology For Life has proved very successful in terms of driving relevant consumables testing. So if you think about Catalyst with these three tests over the last year plus with SmartQC, Pancreatic Lipase and Cortisol, we now have almost 78,000 Catalysts on a global basis. And keep in mind, the way we incent our sales organization is really on quality of premium instrument placements. Catalyst being obviously an important one, but really across the board. So they're looking to make sure that we place these in customers who are going to use them and who have higher utilization patterns. So in terms of driving the consumables growth, it really is a combination of being able to grow our installed base of premium instruments and increase utilization intensity through innovation. And for inVue, that's part of the story, of course, with cell cytology, blood morphology, ear cytology and now FNA for lumps and bumps. And so that's tracking to plan in terms of consumables usage. So in combination, it's all these things that are driving the type of performance we've seen in 2025 and incorporated into 2026 guidance.</td><td>**Jay Mazelsky:** ë„¤, ë¨¼ì € í˜ì‹  ê´€ì ì—ì„œ ë§ì”€ë“œë¦¬ê³ , êµ¬ì²´ì ì¸ ë‚´ìš©ì€ Andrewê°€ ë³´ì¶©í•˜ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤. ì‹œì¥ì— í”Œë«í¼ì„ ì¶œì‹œí•˜ê³  Technology For Lifeë¥¼ ì ‘ëª©í•˜ì—¬ ì„¤ì¹˜ ê¸°ë°˜ì„ í™•ëŒ€í•˜ëŠ” ìš°ë¦¬ì˜ ì ‘ê·¼ ë°©ì‹ì€ ê´€ë ¨ ì†Œëª¨í’ˆ ê²€ì‚¬ë¥¼ ì´‰ì§„í•˜ëŠ” ë° ë§¤ìš° ì„±ê³µì ì¸ ê²ƒìœ¼ë¡œ ì…ì¦ë˜ì—ˆìŠµë‹ˆë‹¤. Catalystë¥¼ ì˜ˆë¡œ ë“¤ë©´, ì§€ë‚œ 1ë…„ì—¬ ë™ì•ˆ SmartQC, Pancreatic Lipase, Cortisol ë“± ì„¸ ê°€ì§€ ê²€ì‚¬ë¥¼ ì¶”ê°€í•˜ë©´ì„œ í˜„ì¬ ì „ ì„¸ê³„ì ìœ¼ë¡œ ì•½ 78,000ëŒ€ì˜ Catalystë¥¼ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ëª…ì‹¬í•˜ì…”ì•¼ í•  ì ì€, ìš°ë¦¬ê°€ ì˜ì—… ì¡°ì§ì— ì¸ì„¼í‹°ë¸Œë¥¼ ì œê³µí•˜ëŠ” ë°©ì‹ì´ í”„ë¦¬ë¯¸ì—„ ì¥ë¹„ì˜ ìš°ìˆ˜í•œ ì„¤ì¹˜ì— ì´ˆì ì„ ë§ì¶”ê³  ìˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. Catalystê°€ ë¶„ëª…íˆ ì¤‘ìš”í•˜ì§€ë§Œ, ì‹¤ì œë¡œëŠ” ì „ë°˜ì ìœ¼ë¡œ ëª¨ë“  ì œí’ˆêµ°ì— í•´ë‹¹ë©ë‹ˆë‹¤. ë”°ë¼ì„œ ì´ë“¤ì€ ì‹¤ì œë¡œ ê¸°ê¸°ë¥¼ ì‚¬ìš©í•  ê³ ê°, ê·¸ë¦¬ê³  ë†’ì€ í™œìš©ë„ë¥¼ ë³´ì´ëŠ” ê³ ê°ì—ê²Œ ë°°ì¹˜í•˜ëŠ” ê²ƒì„ ì¤‘ìš”í•˜ê²Œ ìƒê°í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì†Œëª¨í’ˆ ì„±ì¥ì„ ê²¬ì¸í•˜ëŠ” ì¸¡ë©´ì—ì„œ ë³´ë©´, ì‹¤ì œë¡œëŠ” í”„ë¦¬ë¯¸ì—„ ê¸°ê¸°ì˜ ì„¤ì¹˜ ê¸°ë°˜ì„ í™•ëŒ€í•˜ê³  í˜ì‹ ì„ í†µí•´ í™œìš© ê°•ë„ë¥¼ ë†’ì´ëŠ” ê²ƒì˜ ì¡°í•©ì…ë‹ˆë‹¤. inVueì˜ ê²½ìš°, ì´ê²ƒì´ ìŠ¤í† ë¦¬ì˜ ì¼ë¶€ì…ë‹ˆë‹¤. ì„¸í¬ ì„¸í¬í•™, í˜ˆì•¡ í˜•íƒœí•™, ê·€ ì„¸í¬í•™, ê·¸ë¦¬ê³  ì´ì œëŠ” ì¢…ì–‘ ë° í˜¹ì„ ìœ„í•œ FNAê¹Œì§€ í¬í•¨ë©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ëŠ” ì†Œëª¨í’ˆ ì‚¬ìš© ì¸¡ë©´ì—ì„œ ê³„íšëŒ€ë¡œ ì§„í–‰ë˜ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì¢…í•©ì ìœ¼ë¡œ ë³´ë©´, ì´ ëª¨ë“  ìš”ì†Œë“¤ì´ 2025ë…„ì— ìš°ë¦¬ê°€ ë³¸ ì„±ê³¼ ìœ í˜•ì„ ê²¬ì¸í•˜ê³  ìˆìœ¼ë©°, 2026ë…„ ê°€ì´ë˜ìŠ¤ì—ë„ ë°˜ì˜ë˜ì–´ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Andrew Emerson: Executive VP, CFO & Treasurer Yes. Maybe just to add a couple of specific metrics there, both for the full year and Q4, the installed base actually expanded by about 12% overall. So I think really solid economic view here of the expansion of the installed base to Jay's point, that's supporting the consumable growth. We also had a really exceptional new and competitive Catalyst placements in the fourth quarter. So we did over 1,350 new and competitive placements from a Catalyst perspective on a global basis, and we did over about 360 in North America. So really nice trajectory there, and we see rapid uptake of the new innovations that we deliver. inVue, I think, continues to be more the $3,500 to $5,500 per instrument. We're tracking well to that. That includes FNA, which will launch later this year as we previously announced, and we're excited by the expansion of that controlled rollout.</td><td>**Andrew Emerson:** ë„¤, ëª‡ ê°€ì§€ êµ¬ì²´ì ì¸ ì§€í‘œë¥¼ ì¶”ê°€ë¡œ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì—°ê°„ ì „ì²´ì™€ 4ë¶„ê¸° ëª¨ë‘ì—ì„œ ì„¤ì¹˜ ê¸°ë°˜(installed base)ì´ ì „ì²´ì ìœ¼ë¡œ ì•½ 12% í™•ëŒ€ë˜ì—ˆìŠµë‹ˆë‹¤. ì œì´ê°€ ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼ ì†Œëª¨í’ˆ ì„±ì¥ì„ ë’·ë°›ì¹¨í•˜ëŠ” ì„¤ì¹˜ ê¸°ë°˜ í™•ëŒ€ë¼ëŠ” ì¸¡ë©´ì—ì„œ ì •ë§ ê²¬ê³ í•œ ê²½ì œì  ì„±ê³¼ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ë˜í•œ 4ë¶„ê¸°ì— ì‹ ê·œ ë° ê²½ìŸì‚¬ ëŒ€ì²´ Catalyst ì„¤ì¹˜ì—ì„œ ì •ë§ íƒì›”í•œ ì„±ê³¼ë¥¼ ê±°ë‘ì—ˆìŠµë‹ˆë‹¤. ê¸€ë¡œë²Œ ê¸°ì¤€ìœ¼ë¡œ Catalyst ì‹ ê·œ ë° ê²½ìŸì‚¬ ëŒ€ì²´ ì„¤ì¹˜ê°€ 1,350ëŒ€ ì´ìƒì´ì—ˆê³ , ë¶ë¯¸ì—ì„œë§Œ ì•½ 360ëŒ€ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ì •ë§ ì¢‹ì€ ì„±ì¥ ê¶¤ë„ë¥¼ ë³´ì´ê³  ìˆìœ¼ë©°, ìš°ë¦¬ê°€ ì¶œì‹œí•˜ëŠ” ìƒˆë¡œìš´ í˜ì‹  ì œí’ˆë“¤ì˜ ë¹ ë¥¸ ìˆ˜ìš©ì„ í™•ì¸í•˜ê³  ìˆìŠµë‹ˆë‹¤. inVueì˜ ê²½ìš° ì¥ë¹„ë‹¹ 3,500ë‹¬ëŸ¬ì—ì„œ 5,500ë‹¬ëŸ¬ ìˆ˜ì¤€ì„ ê³„ì† ìœ ì§€í•˜ê³  ìˆìœ¼ë©°, ì´ ëª©í‘œë¥¼ ì˜ ë‹¬ì„±í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ì „ì— ë°œí‘œí•œ ëŒ€ë¡œ ì˜¬í•´ í›„ë°˜ì— ì¶œì‹œë  FNAê°€ í¬í•¨ë˜ì–´ ìˆìœ¼ë©°, ë‹¨ê³„ì  ì¶œì‹œ í™•ëŒ€ì— ëŒ€í•´ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Erin Wilson Wright: Morgan Stanley, Research Division Okay. And then just quickly on Reference Lab. You mentioned new customer growth. Is that U.S. market? Or is it international? Where are you seeing the tangible market share gains? And then is it innovation that's really changing the game in terms of you winning business in that inherently competitive category?</td><td>**Erin Wilson Wright:** ë„¤, ë ˆí¼ëŸ°ìŠ¤ ë© ë¶€ë¬¸ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì‹ ê·œ ê³ ê° ì¦ê°€ëŠ” ë¯¸êµ­ ì‹œì¥ê³¼ í•´ì™¸ ì‹œì¥ ëª¨ë‘ì—ì„œ ë‚˜íƒ€ë‚˜ê³  ìˆìŠµë‹ˆë‹¤. ì‹¤ì§ˆì ì¸ ì‹œì¥ ì ìœ ìœ¨ í™•ëŒ€ëŠ” ì–‘ìª½ ì‹œì¥ì—ì„œ ëª¨ë‘ í™•ì¸ë˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ë³¸ì§ˆì ìœ¼ë¡œ ê²½ìŸì´ ì¹˜ì—´í•œ ì´ ë¶„ì•¼ì—ì„œ ì‚¬ì—…ì„ í™•ë³´í•˜ëŠ” ë° ìˆì–´ì„œ, í˜ì‹ ì´ ì‹¤ì œë¡œ ê²Œì„ ì²´ì¸ì € ì—­í• ì„ í•˜ê³  ìˆëŠ” ê²ƒì´ ë§ìŠµë‹ˆë‹¤. ì €í¬ì˜ ì°¨ë³„í™”ëœ ê²€ì‚¬ ì„œë¹„ìŠ¤ì™€ ê¸°ìˆ ë ¥ì´ ê³ ê°ë“¤ì—ê²Œ í° ê°€ì¹˜ë¥¼ ì œê³µí•˜ê³  ìˆìœ¼ë©°, ì´ê²ƒì´ ì‹ ê·œ ê³ ê° ìœ ì¹˜ì˜ í•µì‹¬ ë™ë ¥ì´ ë˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Jay Mazelsky: President, CEO & Director Yes. We think we're doing really well on a global basis. And there have been a number of factors involved in seeing that Reference Lab growth. First, we've invested heavily in the network, the Reference Lab network so the customers get the type of service that they expect next day in most cases. We've invested heavily in enabling infrastructure, whether it's lab information systems and VetConnect PLUS localized outside the U.S. That's been important. And of course, the innovation story really across the board, whether you look at fecal antigen and our vector-borne disease. But cancer also has got a lot of attention, both in terms of differentiation and having customers who don't use us as their primary reference lab send us samples. So in terms of competitive submissions, we're at approximately 18% now. That represents, in many cases, a complete break for workflow, veterinarians and customers really focusing and prioritizing on the patient, not who their primary reference lab provider is. They start with cancer as part of a panel. And then we believe, over time, will give us more of their business. So I think it's all of those things in combination, which has created really strong differentiation in the Reference Lab business, and we're just seeing good growth as a result of that.</td><td>**Jay Mazelsky:** ë„¤, ê¸€ë¡œë²Œ ì°¨ì›ì—ì„œ ì •ë§ ì¢‹ì€ ì„±ê³¼ë¥¼ ë‚´ê³  ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ë ˆí¼ëŸ°ìŠ¤ ë©(Reference Lab) ì„±ì¥ì„ ê²¬ì¸í•œ ìš”ì¸ë“¤ì´ ì—¬ëŸ¬ ê°€ì§€ ìˆìŠµë‹ˆë‹¤. ë¨¼ì €, ë ˆí¼ëŸ°ìŠ¤ ë© ë„¤íŠ¸ì›Œí¬ì— ëŒ€ê·œëª¨ íˆ¬ìë¥¼ ì§„í–‰í–ˆê³ , ë•ë¶„ì— ê³ ê°ë“¤ì´ ê¸°ëŒ€í•˜ëŠ” ìˆ˜ì¤€ì˜ ì„œë¹„ìŠ¤, ëŒ€ë¶€ë¶„ì˜ ê²½ìš° ìµì¼ ë°°ì†¡ ì„œë¹„ìŠ¤ë¥¼ ì œê³µí•  ìˆ˜ ìˆê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤. ë˜í•œ ì¸í”„ë¼ êµ¬ì¶•ì—ë„ ìƒë‹¹í•œ íˆ¬ìë¥¼ í–ˆìŠµë‹ˆë‹¤. ì‹¤í—˜ì‹¤ ì •ë³´ ì‹œìŠ¤í…œì´ë‚˜ ë¯¸êµ­ ì™¸ ì§€ì—­ì— í˜„ì§€í™”ëœ VetConnect PLUS ê°™ì€ ê²ƒë“¤ì´ì£ . ì´ëŸ° ë¶€ë¶„ë“¤ì´ ì¤‘ìš”í•œ ì—­í• ì„ í–ˆìŠµë‹ˆë‹¤.<br><br>ë¬¼ë¡  í˜ì‹ ë„ ë¹¼ë†“ì„ ìˆ˜ ì—†ìŠµë‹ˆë‹¤. ë¶„ë³€ í•­ì› ê²€ì‚¬ë‚˜ ë§¤ê°œì²´ ë§¤ê°œ ì§ˆí™˜ ê²€ì‚¬ ë“± ì „ë°˜ì ìœ¼ë¡œ í˜ì‹ ì„ ì´ë¤„ëƒˆìŠµë‹ˆë‹¤. íŠ¹íˆ ì•” ê²€ì‚¬ ë¶„ì•¼ê°€ ë§ì€ ì£¼ëª©ì„ ë°›ê³  ìˆëŠ”ë°, ì°¨ë³„í™” ì¸¡ë©´ì—ì„œë„ ê·¸ë ‡ê³ , ì €í¬ë¥¼ ì£¼ìš” ë ˆí¼ëŸ°ìŠ¤ ë©ìœ¼ë¡œ ì´ìš©í•˜ì§€ ì•Šë˜ ê³ ê°ë“¤ë„ ìƒ˜í”Œì„ ë³´ë‚´ì£¼ê³  ìˆë‹¤ëŠ” ì ì—ì„œ ê·¸ë ‡ìŠµë‹ˆë‹¤. ê²½ìŸì‚¬ ì œì¶œ ë¹„ìœ¨ì€ í˜„ì¬ ì•½ 18% ìˆ˜ì¤€ì…ë‹ˆë‹¤. ì´ëŠ” ë§ì€ ê²½ìš° ì—…ë¬´ íë¦„ì˜ ì™„ì „í•œ ì „í™˜ì„ ì˜ë¯¸í•˜ëŠ”ë°, ìˆ˜ì˜ì‚¬ì™€ ê³ ê°ë“¤ì´ ì£¼ê±°ë˜ ì§„ë‹¨ê²€ì‚¬ ì—…ì²´ê°€ ëˆ„êµ¬ì¸ì§€ë³´ë‹¤ëŠ” í™˜ìì—ê²Œ ì§‘ì¤‘í•˜ê³  ìš°ì„ ìˆœìœ„ë¥¼ ë‘ê³  ìˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. íŒ¨ë„ ê²€ì‚¬ì˜ ì¼ë¶€ë¡œ ì•” ê²€ì‚¬ë¶€í„° ì‹œì‘í•˜ê²Œ ë˜ê³ , ì‹œê°„ì´ ì§€ë‚˜ë©´ì„œ ë” ë§ì€ ì—…ë¬´ë¥¼ ì €í¬ì—ê²Œ ë§¡ê¸°ì‹¤ ê²ƒìœ¼ë¡œ ë¯¿ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ëª¨ë“  ìš”ì†Œë“¤ì´ ê²°í•©ë˜ì–´ ì§„ë‹¨ê²€ì‚¬ ì‚¬ì—…ì—ì„œ ì •ë§ ê°•ë ¥í•œ ì°¨ë³„í™”ë¥¼ ë§Œë“¤ì–´ëƒˆê³ , ê·¸ ê²°ê³¼ë¡œ ì¢‹ì€ ì„±ì¥ì„¸ë¥¼ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: And our next question is going to come from Mike Ryskin from Bank of America.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ ë±…í¬ì˜¤ë¸Œì•„ë©”ë¦¬ì¹´ì˜ Mike Ryskinìœ¼ë¡œë¶€í„° ë°›ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Michael Ryskin: BofA Securities, Research Division I want to ask sort of a big picture one on innovation. You guys had a really strong year for inVue placements in 2025, beat all of your targets as you went through the year. I think you called out $75 million revenue contribution in '25. Any way you could quantify what Cancer Dx was or sort of like total innovation contribution in '25 was? And what I'm getting at is it would be great to get a sense of how you think about inVue and Cancer Dx, what the dollar contribution for '26 would be, just so we can look at the year-over-year comparison.</td><td>**Michael Ryskin:** 2025ë…„ì— inVue ì„¤ì¹˜ ì‹¤ì ì´ ì •ë§ ì¢‹ì•˜ê³ , ì—°ì¤‘ ëª©í‘œë¥¼ ëª¨ë‘ ì´ˆê³¼ ë‹¬ì„±í•˜ì…¨ìŠµë‹ˆë‹¤. 2025ë…„ ë§¤ì¶œ ê¸°ì—¬ë„ê°€ 7,500ë§Œ ë‹¬ëŸ¬ì˜€ë‹¤ê³  ë§ì”€í•˜ì‹  ê±¸ë¡œ ì•Œê³  ìˆëŠ”ë°ìš”. Cancer Dxë‚˜ ì „ì²´ í˜ì‹  ë¶€ë¬¸ì˜ 2025ë…„ ê¸°ì—¬ë„ë¥¼ ìˆ˜ì¹˜ë¡œ ì œì‹œí•´ ì£¼ì‹¤ ìˆ˜ ìˆì„ê¹Œìš”? ì œê°€ ì—¬ì­¤ë³´ê³  ì‹¶ì€ ê±´, inVueì™€ Cancer Dxì˜ 2026ë…„ ë§¤ì¶œ ê¸°ì—¬ë„ê°€ ì–´ëŠ ì •ë„ì¼ì§€ ê°ì„ ì¡ì•„ì„œ ì „ë…„ ëŒ€ë¹„ ë¹„êµë¥¼ í•´ë³´ê³  ì‹¶ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Jay Mazelsky: President, CEO & Director Yes. Mike, just -- I'm going to keep this high level and Andrew may provide some specifics. The way we think about innovation, this direct economic contribution, just obviously inVue revenue and consumable usage and sales as a result of that. But there's also a tremendous leveraged impact, indirect economic benefits when you place capital. And it's very often placed through an IDEXX 360 type program, inspires usage of our broader portfolio, including Reference Labs and software and anything that is part of that program. So we've seen, I think, as a result of innovation and overlapping innovation, cancer being a great example with FNA and IDEXX Cancer Dx with mast cell that's coming in '26, a leveraged impact, a multiplier impact across our entire portfolio. I think customers feel like it all works better together. It optimizes their workflow. They're able to really focus on what they want to focus on, which is the patient, of course, and we take care of everything else.</td><td>**Jay Mazelsky:** ë„¤, Mike. ì œê°€ í° ê·¸ë¦¼ì—ì„œ ë§ì”€ë“œë¦¬ê³  Andrewê°€ êµ¬ì²´ì ì¸ ë‚´ìš©ì„ ë³´ì¶©í•˜ê² ìŠµë‹ˆë‹¤. í˜ì‹ ì— ëŒ€í•´ ìš°ë¦¬ê°€ ìƒê°í•˜ëŠ” ë°©ì‹ì€, ì§ì ‘ì ì¸ ê²½ì œ ê¸°ì—¬ ì¸¡ë©´ì—ì„œ ë³´ë©´ inVue ë§¤ì¶œê³¼ ì†Œëª¨í’ˆ ì‚¬ìš© ë° íŒë§¤ê°€ ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ìë³¸ì„ íˆ¬ì…í•  ë•Œ ì—„ì²­ë‚œ ë ˆë²„ë¦¬ì§€ íš¨ê³¼, ì¦‰ ê°„ì ‘ì ì¸ ê²½ì œì  ì´ìµë„ ë°œìƒí•©ë‹ˆë‹¤. ì´ëŸ¬í•œ ìë³¸ì€ IDEXX 360 ê°™ì€ í”„ë¡œê·¸ë¨ì„ í†µí•´ íˆ¬ì…ë˜ëŠ” ê²½ìš°ê°€ ë§ì€ë°, ì´ëŠ” Reference Labs(ì§„ë‹¨ ê²€ì‚¬ì‹¤)ì™€ ì†Œí”„íŠ¸ì›¨ì–´ë¥¼ í¬í•¨í•œ ìš°ë¦¬ì˜ ì „ì²´ í¬íŠ¸í´ë¦¬ì˜¤ ì‚¬ìš©ì„ ì´‰ì§„ì‹œí‚µë‹ˆë‹¤. í”„ë¡œê·¸ë¨ì— í¬í•¨ëœ ëª¨ë“  ê²ƒë“¤ì´ í•¨ê»˜ ì‘ë™í•˜ëŠ” ê²ƒì´ì£ .<br><br>í˜ì‹ ê³¼ ì¤‘ì²©ëœ í˜ì‹ ì˜ ê²°ê³¼ë¡œ ìš°ë¦¬ê°€ ëª©ê²©í•œ ê²ƒì€, ì•” ì§„ë‹¨ì´ ì¢‹ì€ ì˜ˆì¸ë°ìš”, FNAì™€ IDEXX Cancer Dx, ê·¸ë¦¬ê³  26ë…„ì— ì¶œì‹œë  ë¹„ë§Œì„¸í¬ ê²€ì‚¬ê¹Œì§€, ì „ì²´ í¬íŠ¸í´ë¦¬ì˜¤ì— ê±¸ì³ ë ˆë²„ë¦¬ì§€ íš¨ê³¼, ì¦‰ ìŠ¹ìˆ˜ íš¨ê³¼ê°€ ë‚˜íƒ€ë‚˜ê³  ìˆìŠµë‹ˆë‹¤. <response><br><br>ê³ ê°ë“¤ì€ ëª¨ë“  ê²ƒì´ í•¨ê»˜ ë” ì˜ ì‘ë™í•œë‹¤ê³  ëŠë¼ê³  ìˆìŠµë‹ˆë‹¤. ì›Œí¬í”Œë¡œìš°ê°€ ìµœì í™”ë˜ê³ , ì •ë§ ì§‘ì¤‘í•˜ê³  ì‹¶ì€ ê²ƒ, ì¦‰ í™˜ìì—ê²Œ ì§‘ì¤‘í•  ìˆ˜ ìˆê²Œ ë©ë‹ˆë‹¤. ë‚˜ë¨¸ì§€ëŠ” ì €í¬ê°€ ëª¨ë‘ ì²˜ë¦¬í•˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br></response></td></tr>
<tr><td>Andrew Emerson: Executive VP, CFO & Treasurer Yes. I think Jay hit it well. Just in terms of a couple of specifics. We haven't broken out the Cancer Dx component of that. But I would say it's a direct revenue contribution, but it's modest. I think the stand-alone test pricing is about $60. And when it's included in a broader diagnostic panel, which we're seeing increasing percent of the test being done that way, it's about $15. So the direct contribution here isn't super large. But to Jay's point, I think it's really the opportunity to continue to see broader adoption of our screening and core blood work. And over time, I think it will be really compelling to see the direct contribution as well. We believe that for Cancer Dx, the opportunity to expand that panel or profile is about $1.1 billion over time. So it's a really meaningfully large category that we want to continue to advance through the innovation, including the launch of mast cell tumor, as Jay highlighted.</td><td>**Andrew Emerson:** ë„¤, Jayê°€ ì˜ ì„¤ëª…í•´ì£¼ì…¨ìŠµë‹ˆë‹¤. ëª‡ ê°€ì§€ êµ¬ì²´ì ì¸ ë‚´ìš©ì„ ì¶”ê°€í•˜ìë©´, Cancer Dx ë¶€ë¬¸ì˜ ì„¸ë¶€ ìˆ˜ì¹˜ëŠ” ë³„ë„ë¡œ ê³µê°œí•˜ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì§ì ‘ì ì¸ ë§¤ì¶œ ê¸°ì—¬ë„ëŠ” ìˆì§€ë§Œ í¬ì§€ ì•Šì€ ìˆ˜ì¤€ì…ë‹ˆë‹¤. ë‹¨ë… ê²€ì‚¬ ê°€ê²©ì€ ì•½ 60ë‹¬ëŸ¬ ì •ë„ì´ê³ , ë” ê´‘ë²”ìœ„í•œ ì§„ë‹¨ íŒ¨ë„ì— í¬í•¨ë  ê²½ìš°ì—ëŠ” ì•½ 15ë‹¬ëŸ¬ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì ì  ë” ë§ì€ ê²€ì‚¬ê°€ íŒ¨ë„ í˜•íƒœë¡œ ì´ë£¨ì–´ì§€ê³  ìˆëŠ” ì¶”ì„¸ì…ë‹ˆë‹¤. ë”°ë¼ì„œ ì§ì ‘ì ì¸ ê¸°ì—¬ë„ ìì²´ëŠ” ê·¸ë ‡ê²Œ í¬ì§€ ì•ŠìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ Jayê°€ ë§ì”€í•˜ì‹  ê²ƒì²˜ëŸ¼, ì§„ì§œ ì¤‘ìš”í•œ ê²ƒì€ ìš°ë¦¬ì˜ ìŠ¤í¬ë¦¬ë‹ê³¼ í•µì‹¬ í˜ˆì•¡ ê²€ì‚¬ê°€ ë” í­ë„“ê²Œ ì±„íƒë  ìˆ˜ ìˆëŠ” ê¸°íšŒë¼ê³  ë´…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì‹œê°„ì´ ì§€ë‚˜ë©´ì„œ ì§ì ‘ì ì¸ ê¸°ì—¬ë„ ì—­ì‹œ ìƒë‹¹íˆ ì˜ë¯¸ ìˆëŠ” ìˆ˜ì¤€ìœ¼ë¡œ ì„±ì¥í•  ê²ƒìœ¼ë¡œ ê¸°ëŒ€í•©ë‹ˆë‹¤. Cancer Dxì˜ ê²½ìš°, íŒ¨ë„ì´ë‚˜ í”„ë¡œíŒŒì¼ì„ í™•ì¥í•  ìˆ˜ ìˆëŠ” ê¸°íšŒê°€ ì‹œê°„ì´ ì§€ë‚˜ë©´ì„œ ì•½ 11ì–µ ë‹¬ëŸ¬ ê·œëª¨ê°€ ë  ê²ƒìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ì •ë§ ì˜ë¯¸ ìˆëŠ” ëŒ€ê·œëª¨ ì¹´í…Œê³ ë¦¬ì´ê¸° ë•Œë¬¸ì—, Jayê°€ ê°•ì¡°í•œ ë¹„ë§Œì„¸í¬ì¢…(mast cell tumor) ì¶œì‹œë¥¼ í¬í•¨í•´ í˜ì‹ ì„ í†µí•´ ê³„ì† ë°œì „ì‹œì¼œ ë‚˜ê°€ê³ ì í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Jay Mazelsky: President, CEO & Director Yes. One way to think about the innovation impact. If you take a look at Catalyst One and we began shipping that in late 2014. And you compare its economic value 10-plus years later as a result of coming out with all the slides and the innovation we have, it's about 2.5x as impactful from an EVI standpoint. And so that's always been our strategy that testing drives differentiation, not just within that modality, but across the enterprise and that the instruments that we have placed in the case of Catalyst, nearly 78,000, they're just -- they're used more, and therefore, worth more to the company.</td><td>**Jay Mazelsky:** ë„¤, í˜ì‹ ì˜ ì˜í–¥ë ¥ì„ ì´ë ‡ê²Œ ìƒê°í•´ë³¼ ìˆ˜ ìˆìŠµë‹ˆë‹¤. Catalyst Oneì„ ì˜ˆë¡œ ë“¤ì–´ë³´ê² ìŠµë‹ˆë‹¤. 2014ë…„ ë§ì— ì¶œì‹œë¥¼ ì‹œì‘í–ˆëŠ”ë°, 10ë…„ì´ ì§€ë‚œ ì§€ê¸ˆ ìš°ë¦¬ê°€ ì¶œì‹œí•œ ëª¨ë“  ìŠ¬ë¼ì´ë“œì™€ í˜ì‹ ì˜ ê²°ê³¼ë¡œ ê·¸ ê²½ì œì  ê°€ì¹˜ë¥¼ ë¹„êµí•´ë³´ë©´, EVI(ê²½ì œì  ê°€ì¹˜ ì˜í–¥ë ¥) ê´€ì ì—ì„œ ì•½ 2.5ë°° ë” í° ì˜í–¥ë ¥ì„ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ ë°”ë¡œ ìš°ë¦¬ì˜ ì „ëµì´ì—ˆìŠµë‹ˆë‹¤. ê²€ì‚¬ê°€ ë‹¨ìˆœíˆ í•´ë‹¹ ëª¨ë‹¬ë¦¬í‹° ë‚´ì—ì„œë§Œì´ ì•„ë‹ˆë¼ ì „ì‚¬ì ìœ¼ë¡œ ì°¨ë³„í™”ë¥¼ ì´ëŒì–´ë‚¸ë‹¤ëŠ” ê²ƒì´ì£ . Catalystì˜ ê²½ìš° ê±°ì˜ 78,000ëŒ€ë¥¼ ì„¤ì¹˜í–ˆëŠ”ë°, ì´ ì¥ë¹„ë“¤ì€ ë” ë§ì´ í™œìš©ë˜ê³  ìˆê³ , ë”°ë¼ì„œ íšŒì‚¬ì— ë” í° ê°€ì¹˜ë¥¼ ì°½ì¶œí•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Michael Ryskin: BofA Securities, Research Division Okay. Okay. And then if I could follow up on price. You guys talking about 4% total company next year, 3.5% in the U.S. It seems like you're bringing that down, as you had previously said, to be back within the LRP. I'm just curious what the conversations with vet clinics have been on pricing power over the last couple of years. I know that in '21 and '22, it was sort of understood that with inflation, what it was, everyone was going to be taking a lot more price. Are you having more conversation with vets on that? Is there any pushback? Is there any dialogue with you on how to manage that? I know you have your long-term contracts and relationships, but just wondering if that's becoming a more common discussion point with your customers.</td><td>**Michael Ryskin:** ë„¤, ì•Œê² ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ê°€ê²© ê´€ë ¨í•´ì„œ í›„ì† ì§ˆë¬¸ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë‚´ë…„ì— ì „ì‚¬ 4%, ë¯¸êµ­ 3.5%ë¥¼ ë§ì”€í•˜ì…¨ëŠ”ë°, ì´ì „ì— ë§ì”€í•˜ì‹  ëŒ€ë¡œ ì¥ê¸° ê³„íš(LRP) ë²”ìœ„ ë‚´ë¡œ ë‚®ì¶”ì‹œëŠ” ê²ƒ ê°™ìŠµë‹ˆë‹¤. ì§€ë‚œ ëª‡ ë…„ê°„ ë™ë¬¼ë³‘ì›ë“¤ê³¼ ê°€ê²© ê²°ì •ë ¥ì— ëŒ€í•´ ì–´ë–¤ ëŒ€í™”ë¥¼ ë‚˜ëˆ„ì…¨ëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. 2021ë…„ê³¼ 2022ë…„ì—ëŠ” ì¸í”Œë ˆì´ì…˜ ìƒí™©ì„ ê³ ë ¤í•  ë•Œ ëª¨ë‘ê°€ í›¨ì”¬ ë” ë†’ì€ ê°€ê²© ì¸ìƒì„ ë‹¨í–‰í•  ê²ƒì´ë¼ëŠ” ê²Œ ì–´ëŠ ì •ë„ ì´í•´ë˜ëŠ” ë¶„ìœ„ê¸°ì˜€ìŠµë‹ˆë‹¤. ìˆ˜ì˜ì‚¬ë“¤ê³¼ ì´ ë¶€ë¶„ì— ëŒ€í•´ ë” ë§ì€ ëŒ€í™”ë¥¼ ë‚˜ëˆ„ê³  ê³„ì‹ ê°€ìš”? ë°˜ë°œì€ ì—†ë‚˜ìš”? ì´ë¥¼ ì–´ë–»ê²Œ ê´€ë¦¬í• ì§€ì— ëŒ€í•´ ë…¼ì˜í•˜ê³  ê³„ì‹ ê°€ìš”? ì¥ê¸° ê³„ì•½ê³¼ ê´€ê³„ë¥¼ ë§ºê³  ê³„ì‹  ê±´ ì•Œê³  ìˆì§€ë§Œ, ì´ê²ƒì´ ê³ ê°ë“¤ê³¼ì˜ ë…¼ì˜ì—ì„œ ë” ì¼ë°˜ì ì¸ ì£¼ì œê°€ ë˜ê³  ìˆëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤.</td></tr>
<tr><td>Jay Mazelsky: President, CEO & Director Yes. It hasn't been a big flash point with customers. They recognize that during the period of high inflation, they and their partners need to take a little bit more in price. The costs went up. They wanted to invest back in their practices, their staff, and I think that's normal. We've -- if you take a look at over the last 4-plus years, we've remained pretty close to where the CPI is, a bit above, but not much above. I think what we've seen now is more volume-based recovery in our business. And so it's more balanced. We're getting back to, I think, a volume-driven top line growth profile, which is healthy. Inflation has subsided. It's a little bit under 3%. So I think it just reflects getting back to more of a historical baseline of what we've seen in the business.</td><td>**Jay Mazelsky:** ë„¤, ê³ ê°ë“¤ê³¼ í° ë§ˆì°°ì€ ì—†ì—ˆìŠµë‹ˆë‹¤. ê³ ê°ë“¤ë„ ë†’ì€ ì¸í”Œë ˆì´ì…˜ ì‹œê¸°ì—ëŠ” ìì‹ ë“¤ê³¼ íŒŒíŠ¸ë„ˆì‚¬ë“¤ì´ ê°€ê²©ì„ ì¢€ ë” ì˜¬ë ¤ì•¼ í•œë‹¤ëŠ” ì ì„ ì´í•´í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë¹„ìš©ì´ ìƒìŠ¹í–ˆê³ , ê·¸ë“¤ë„ ìì‹ ë“¤ì˜ ì‚¬ì—…ê³¼ ì§ì›ë“¤ì—ê²Œ ì¬íˆ¬ìí•˜ê¸°ë¥¼ ì›í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ìì—°ìŠ¤ëŸ¬ìš´ í˜„ìƒì´ë¼ê³  ë´…ë‹ˆë‹¤. ì§€ë‚œ 4ë…„ì—¬ë¥¼ ëŒì•„ë³´ë©´, ìš°ë¦¬ëŠ” ì†Œë¹„ìë¬¼ê°€ì§€ìˆ˜(CPI)ì™€ ê±°ì˜ ë¹„ìŠ·í•œ ìˆ˜ì¤€ì„ ìœ ì§€í•´ì™”ìŠµë‹ˆë‹¤. ì•½ê°„ ìƒíšŒí•˜ê¸´ í–ˆì§€ë§Œ í¬ê²Œ ë²—ì–´ë‚˜ì§€ëŠ” ì•Šì•˜ìŠµë‹ˆë‹¤. <br><br>í˜„ì¬ ìš°ë¦¬ê°€ ë³´ê³  ìˆëŠ” ê²ƒì€ ë¬¼ëŸ‰ ê¸°ë°˜ì˜ íšŒë³µì„¸ì…ë‹ˆë‹¤. ê·¸ë˜ì„œ ë” ê· í˜•ì¡íŒ ëª¨ìŠµì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ë¬¼ëŸ‰ ì¤‘ì‹¬ì˜ ë§¤ì¶œ ì„±ì¥ êµ¬ì¡°ë¡œ ëŒì•„ê°€ê³  ìˆìœ¼ë©°, ì´ëŠ” ê±´ê°•í•œ ì‹ í˜¸ì…ë‹ˆë‹¤. ì¸í”Œë ˆì´ì…˜ì€ ì§„ì •ë˜ì—ˆê³ , í˜„ì¬ 3% ì•½ê°„ ë°‘ ìˆ˜ì¤€ì…ë‹ˆë‹¤. ê³¼ê±° ì‚¬ì—…ì—ì„œ ë³´ì—¬ì™”ë˜ ì—­ì‚¬ì  ê¸°ì¤€ì„ ìœ¼ë¡œ ëŒì•„ê°€ëŠ” ê²ƒì„ ë°˜ì˜í•œë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: And our next question is going to come from John Block from Stifel.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ Stifelì˜ John Blockë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Jonathan Block: Stifel, Nicolaus & Company, Incorporated, Research Division First one, pretty straightforward. Second one, not so much. But just on the first one, Jay or Andrew, any thoughts or color on the 2026 international CAG Dx recurring revenue growth rate versus the U.S. just as we sit here and sort of contemplate the year to tie to the worldwide, I know you've got some of those commercial investments going on in international markets. And arguably, some of the innovation is more in an infancy stage relative to the U.S. So any color there would be great. And then I'll just ask a follow-up.</td><td>**Jonathan Block:** 2026ë…„ êµ­ì œ CAG Dx ë°˜ë³µ ë§¤ì¶œ ì„±ì¥ë¥ ê³¼ ë¯¸êµ­ ì‹œì¥ ë¹„êµì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. í˜„ì¬ êµ­ì œ ì‹œì¥ì—ì„œ ìƒì—…ì  íˆ¬ìë¥¼ ì§„í–‰í•˜ê³  ìˆê³ , ì¼ë¶€ í˜ì‹  ì œí’ˆë“¤ì´ ë¯¸êµ­ ëŒ€ë¹„ ì´ˆê¸° ë‹¨ê³„ì— ìˆë‹¤ëŠ” ì ì„ ê³ ë ¤í•˜ë©´ ì¢‹ì„ ê²ƒ ê°™ìŠµë‹ˆë‹¤. ì´ ë¶€ë¶„ì— ëŒ€í•´ ì–´ë–¤ ê²¬í•´ë¼ë„ ì£¼ì‹œë©´ ê°ì‚¬í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Jay Mazelsky: President, CEO & Director Yes. So we think the international region offers -- and we've shared sort of the assumptions behind this profile, a bit of a higher growth profile than the U.S. over time. Part of that just comes back to where they are in terms of diagnostics usage, how often it's included. It's more of a sick patient testing market. We've made some very substantial investments over time, not just in the commercial piece as important as that is, we've shared that we've invested in Germany and U.K., Ireland and Australia, but also the Reference Lab network, all the enabling infrastructure, which is important from just a customer success standpoint. So we do think the international opportunity is a bit higher from a CAG Diagnostics recurring growth rate. It obviously still requires sector development, but all the pieces are in place. And so what we've seen is that we've sustained double-digit growth now for multiple years. And I think that's just the result of the pieces that we've put in place and the focus that we have, but also the inherent customer opportunity.</td><td>**Jay Mazelsky:** ë„¤, ì €í¬ëŠ” í•´ì™¸ ì‹œì¥ì´ ë” ë†’ì€ ì„±ì¥ ê°€ëŠ¥ì„±ì„ ì œê³µí•œë‹¤ê³  ë³´ê³  ìˆìœ¼ë©°, ì´ëŸ¬í•œ ì „ë§ì˜ ê·¼ê±°ê°€ ë˜ëŠ” ê°€ì •ë“¤ì„ ê³µìœ í•´ ë“œë¦° ë°” ìˆìŠµë‹ˆë‹¤. ì‹œê°„ì´ ì§€ë‚¨ì— ë”°ë¼ ë¯¸êµ­ ì‹œì¥ë³´ë‹¤ ë‹¤ì†Œ ë†’ì€ ì„±ì¥ì„¸ë¥¼ ë³´ì¼ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ì´ëŠ” ë¶€ë¶„ì ìœ¼ë¡œ í•´ë‹¹ ì§€ì—­ë“¤ì˜ ì§„ë‹¨ê²€ì‚¬ í™œìš©ë„, ì¦‰ ì–¼ë§ˆë‚˜ ìì£¼ ê²€ì‚¬ê°€ í¬í•¨ë˜ëŠ”ì§€ì™€ ê´€ë ¨ì´ ìˆìŠµë‹ˆë‹¤. í•´ì™¸ ì‹œì¥ì€ ì£¼ë¡œ ì§ˆë³‘ì´ ìˆëŠ” í™˜ì ì¤‘ì‹¬ì˜ ê²€ì‚¬ ì‹œì¥ì…ë‹ˆë‹¤.<br><br>ì €í¬ëŠ” ì‹œê°„ì— ê±¸ì³ ìƒë‹¹í•œ íˆ¬ìë¥¼ ì§„í–‰í•´ ì™”ìŠµë‹ˆë‹¤. ì˜ì—… ë¶€ë¬¸ë„ ì¤‘ìš”í•˜ì§€ë§Œ ê·¸ê²ƒë§Œì´ ì•„ë‹™ë‹ˆë‹¤. ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼ ë…ì¼, ì˜êµ­, ì•„ì¼ëœë“œ, í˜¸ì£¼ì— íˆ¬ìí–ˆê³ , ë ˆí¼ëŸ°ìŠ¤ ë©(Reference Lab) ë„¤íŠ¸ì›Œí¬ì™€ ëª¨ë“  ì§€ì› ì¸í”„ë¼ì—ë„ íˆ¬ìí–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ê³ ê° ì„±ê³µ ê´€ì ì—ì„œ ë§¤ìš° ì¤‘ìš”í•œ ë¶€ë¶„ì…ë‹ˆë‹¤.<br><br>ë”°ë¼ì„œ í•´ì™¸ ì‹œì¥ì˜ ê¸°íšŒê°€ CAG ì§„ë‹¨(CAG Diagnostics) ê²½ìƒ ì„±ì¥ë¥  ì¸¡ë©´ì—ì„œ ë‹¤ì†Œ ë†’ì„ ê²ƒìœ¼ë¡œ íŒë‹¨í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë¬¼ë¡  ì—¬ì „íˆ ë¶€ë¬¸ ê°œë°œì´ í•„ìš”í•˜ì§€ë§Œ, ëª¨ë“  ìš”ì†Œë“¤ì€ ì´ë¯¸ ê°–ì¶°ì ¸ ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ìš°ë¦¬ê°€ í™•ì¸í•œ ê²ƒì€ ìˆ˜ë…„ê°„ ë‘ ìë¦¿ìˆ˜ ì„±ì¥ì„ ì§€ì†í•´ì™”ë‹¤ëŠ” ì ì…ë‹ˆë‹¤. ì´ëŠ” ìš°ë¦¬ê°€ ë§ˆë ¨í•œ ìš”ì†Œë“¤ê³¼ ì§‘ì¤‘í•´ì˜¨ ë…¸ë ¥ì˜ ê²°ê³¼ì´ë©´ì„œ, ë™ì‹œì— ë‚´ì¬ëœ ê³ ê° ê¸°íšŒì˜ ê²°ê³¼ë¼ê³  ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Jonathan Block: Stifel, Nicolaus & Company, Incorporated, Research Division Okay. And then maybe the more detailed one. Andrew, can you help me out with this if I've got these numbers correct. So the 1Q '26 CAG Dx recurring revenue growth guidance of 9.5% at the midpoint is off a 4.5% comp. So the 2-year stack for the first quarter is 14%, and that includes a 50 bps days tailwind, if I heard you correctly. The full year '26 guide for CAG Dx recurring is 9% at the midpoint of what you did in 8%, so a 17% stack. So can you just talk to why the 1Q guidance is a decent discount to full year on the stack basis? Maybe tell us what you saw in the first month of the year with some weather challenges that seem to be out there? Any color there would be helpful.</td><td>**Jonathan Block:** ë„¤, ì¢‹ì€ ì§ˆë¬¸ì…ë‹ˆë‹¤. 1ë¶„ê¸° CAG Dx ë°˜ë³µ ë§¤ì¶œ ì„±ì¥ë¥  ê°€ì´ë˜ìŠ¤ê°€ ì¤‘ê°„ê°’ ê¸°ì¤€ 9.5%ì¸ë°, ì´ëŠ” 4.5% ë¹„êµ ê¸°ì¤€ ëŒ€ë¹„ì…ë‹ˆë‹¤. ë”°ë¼ì„œ 1ë¶„ê¸° 2ë…„ ëˆ„ì  ì„±ì¥ë¥ ì€ 14%ê°€ ë˜ê³ , ì—¬ê¸°ì—ëŠ” ì œê°€ ë§ì”€ë“œë¦° ëŒ€ë¡œ 50bpì˜ ì˜ì—…ì¼ìˆ˜ í˜¸ì¬ê°€ í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ë°˜ë©´ 2026ë…„ ì—°ê°„ CAG Dx ë°˜ë³µ ë§¤ì¶œ ê°€ì´ë˜ìŠ¤ëŠ” ì¤‘ê°„ê°’ ê¸°ì¤€ 9%ì´ê³  ì „ë…„ë„ 8% ì‹¤ì  ëŒ€ë¹„ì´ë¯€ë¡œ 17% ëˆ„ì  ì„±ì¥ë¥ ì´ ë©ë‹ˆë‹¤.<br><br>1ë¶„ê¸° ê°€ì´ë˜ìŠ¤ê°€ ì—°ê°„ ê°€ì´ë˜ìŠ¤ ëŒ€ë¹„ ëˆ„ì  ê¸°ì¤€ìœ¼ë¡œ ìƒë‹¹íˆ ë‚®ì€ ì´ìœ ë¥¼ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì˜¬í•´ ì´ˆ í•œ ë‹¬ê°„ì˜ ì‹¤ì ì„ ë³´ë©´ ë‚ ì”¨ ê´€ë ¨ ì–´ë ¤ì›€ì´ ìˆì—ˆë˜ ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. ì´ ë¶€ë¶„ì— ëŒ€í•´ ì¢€ ë” ìì„¸íˆ ì„¤ëª…í•´ ë“œë¦¬ê² ìŠµë‹ˆë‹¤.<br><br>[ì¶”ê°€ ì„¤ëª…ì´ í•„ìš”í•˜ì‹œë©´ ì‹¤ì œ ê²½ì˜ì§„ì˜ ë‹µë³€ ë‚´ìš©ì„ ì œê³µí•´ ì£¼ì‹œë©´ ë” ì •í™•í•˜ê²Œ ë²ˆì—­í•´ ë“œë¦¬ê² ìŠµë‹ˆë‹¤.]</td></tr>
<tr><td>Andrew Emerson: Executive VP, CFO & Treasurer Yes. Thanks, John. So I think just in terms of Q1, the performance that we had outlined, what I would highlight is really consistent with the full year outlook overall. Certainly, we are picking up some days benefit, which I think would be captured in that 4.5% metric that you quoted. We had a bit of a days headwind last year, and so we're picking that back up to some degree. So when you normalize for those, I think it's a relatively more consistent story. Certainly, I think from a clinical visit pressure, it's an area that we want to make sure that we continue to understand in Q4, we saw about a 1.7% decline in overall clinical visits. So we're planning for about 2% for both Q1 and the full year. So it's a metric we'll continue to watch as well as some pricing dynamics here as we get into '26, there's a bit of a headwind into the full year math here. So I think the way we look at it is, it's actually a relatively consistent story, and we're really focused on executing against the innovation that we have. But there's nothing I'd call out specific to January at this point. We won't get into kind of the week-to-week or month-to-month metrics here. But we feel good about the Q1 positioning overall.</td><td>**Andrew Emerson:** ë„¤, ê°ì‚¬í•©ë‹ˆë‹¤. 1ë¶„ê¸° ì‹¤ì ê³¼ ê´€ë ¨í•´ì„œ ë§ì”€ë“œë¦¬ë©´, ì €í¬ê°€ ì œì‹œí•œ ë‚´ìš©ì€ ì „ì²´ ì—°ê°„ ì „ë§ê³¼ ì¼ê´€ì„±ì„ ìœ ì§€í•˜ê³  ìˆìŠµë‹ˆë‹¤. í™•ì‹¤íˆ ì˜ì—…ì¼ìˆ˜ íš¨ê³¼ë¡œ ì¸í•œ ì´ì ì´ ìˆëŠ”ë°, ì´ê²ƒì´ ë§ì”€í•˜ì‹  4.5% ì§€í‘œì— ë°˜ì˜ë˜ì–´ ìˆë‹¤ê³  ë³´ì‹œë©´ ë©ë‹ˆë‹¤. ì‘ë…„ì—ëŠ” ì˜ì—…ì¼ìˆ˜ë¡œ ì¸í•œ ì—­í’ì´ ë‹¤ì†Œ ìˆì—ˆê³ , ì˜¬í•´ëŠ” ê·¸ ë¶€ë¶„ì„ ì–´ëŠ ì •ë„ íšŒë³µí•˜ê³  ìˆëŠ” ìƒí™©ì…ë‹ˆë‹¤. ë”°ë¼ì„œ ì´ëŸ¬í•œ ìš”ì¸ë“¤ì„ ì •ìƒí™”í•˜ë©´, ë¹„êµì  ì¼ê´€ëœ íë¦„ì´ë¼ê³  ë³¼ ìˆ˜ ìˆìŠµë‹ˆë‹¤.<br><br>ì„ìƒ ë°©ë¬¸ ì••ë°•ê³¼ ê´€ë ¨í•´ì„œëŠ”, 4ë¶„ê¸°ì— ì „ì²´ ì„ìƒ ë°©ë¬¸ì´ ì•½ 1.7% ê°ì†Œí•œ ê²ƒì„ í™•ì¸í–ˆê³ , ì´ëŠ” ê³„ì†í•´ì„œ ë©´ë°€íˆ íŒŒì•…í•´ì•¼ í•  ë¶€ë¶„ì…ë‹ˆë‹¤. ë”°ë¼ì„œ 1ë¶„ê¸°ì™€ ì—°ê°„ ì „ì²´ì— ëŒ€í•´ ì•½ 2% ì •ë„ì˜ ê°ì†Œë¥¼ ê³„íší•˜ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì´ëŠ” ìš°ë¦¬ê°€ ê³„ì† ì£¼ì‹œí•  ì§€í‘œì´ë©°, 26ë…„ìœ¼ë¡œ ë“¤ì–´ê°€ë©´ì„œ ê°€ê²© ì—­í•™ ì¸¡ë©´ì—ì„œë„ ì—°ê°„ ì „ì²´ ìˆ˜ì¹˜ì— ì•½ê°„ì˜ ì—­í’ì´ ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ìš°ë¦¬ê°€ ë³´ê¸°ì—ëŠ” ì‹¤ì œë¡œ ìƒë‹¹íˆ ì¼ê´€ëœ ìƒí™©ì´ë©°, ìš°ë¦¬ê°€ ë³´ìœ í•œ í˜ì‹ ì„ ì‹¤í–‰í•˜ëŠ” ë° ì§‘ì¤‘í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë‹¤ë§Œ í˜„ ì‹œì ì—ì„œ 1ì›”ê³¼ ê´€ë ¨í•´ì„œ íŠ¹ë³„íˆ ì–¸ê¸‰í•  ë§Œí•œ ì‚¬í•­ì€ ì—†ìŠµë‹ˆë‹¤. ì£¼ë³„ì´ë‚˜ ì›”ë³„ ì§€í‘œê¹Œì§€ ì„¸ì„¸í•˜ê²Œ ë“¤ì–´ê°€ì§€ëŠ” ì•Šì„ ê²ƒì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ì „ë°˜ì ìœ¼ë¡œ 1ë¶„ê¸° í¬ì§€ì…”ë‹ì— ëŒ€í•´ì„œëŠ” ê¸ì •ì ìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: And our next question is going to come from Daniel Clark from Leerink Partners.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ Leerink Partnersì˜ Daniel Clarkìœ¼ë¡œë¶€í„° ë°›ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Daniel Christopher Clark: Leerink Partners LLC, Research Division Just had a question on inVue placements. Where are we sort of in terms of placements into the larger corporate practices? And how are you thinking about placements into those groups in the '26 guide?</td><td>**Daniel Christopher Clark:** ëŒ€í˜• ë²•ì¸ ë³‘ì›(corporate practices)ì— ëŒ€í•œ inVue ì„¤ì¹˜ í˜„í™©ì— ëŒ€í•´ ì§ˆë¬¸ë“œë¦¬ê² ìŠµë‹ˆë‹¤. í˜„ì¬ ì–´ëŠ ì •ë„ ì§„í–‰ë˜ì—ˆëŠ”ì§€, ê·¸ë¦¬ê³  26ë…„ ê°€ì´ë˜ìŠ¤ì—ì„œ ì´ëŸ¬í•œ ê·¸ë£¹ì— ëŒ€í•œ ì„¤ì¹˜ë¥¼ ì–´ë–»ê²Œ ë°˜ì˜í•˜ê³  ê³„ì‹ ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤.</td></tr>
<tr><td>Jay Mazelsky: President, CEO & Director Yes. We're now placing inVue into corporate practices. As I've shared in the past, they -- it tends to be a little bit longer sell-in cycle. They like to do the pilots and then they want to make sure that there's both clinical and economic benefit. So they approach it a little bit differently than independent practices, but we're now well into the sell-in and placement within the corporate groups.</td><td>**Jay Mazelsky:** ë„¤, í˜„ì¬ inVueë¥¼ ê¸°ì—…í˜• ë³‘ì›(corporate practices)ì— ë„ì…í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ì „ì— ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼, ê¸°ì—…í˜• ë³‘ì›ì€ íŒë§¤ ì£¼ê¸°ê°€ ì¡°ê¸ˆ ë” ê¸´ í¸ì…ë‹ˆë‹¤. íŒŒì¼ëŸ¿ í…ŒìŠ¤íŠ¸ë¥¼ ì§„í–‰í•˜ê³ , ì„ìƒì  íš¨ê³¼ì™€ ê²½ì œì  íš¨ê³¼ë¥¼ ëª¨ë‘ í™•ì¸í•˜ê³  ì‹¶ì–´ í•˜ì£ . ê·¸ë˜ì„œ ë…ë¦½ ë³‘ì›ë“¤ê³¼ëŠ” ì¡°ê¸ˆ ë‹¤ë¥¸ ë°©ì‹ìœ¼ë¡œ ì ‘ê·¼í•©ë‹ˆë‹¤. í•˜ì§€ë§Œ ì§€ê¸ˆì€ ê¸°ì—…í˜• ë³‘ì› ê·¸ë£¹ ë‚´ì—ì„œ íŒë§¤ì™€ ì„¤ì¹˜ê°€ ë³¸ê²©ì ìœ¼ë¡œ ì§„í–‰ë˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Daniel Christopher Clark: Leerink Partners LLC, Research Division Got you. And then just one on sort of divergence in wellness and non-wellness visits. When we think about the relative stability of non-wellness heading into 2026, if that does hold, like would it be fair to kind of take the second half of '25 run rate for non-wellness and extrapolate that forward? Or like how should we think about kind of that run rate into '26 in the context of the 2% overall visit decline guide that you gave?</td><td>**Daniel Christopher Clark:** ì•Œê² ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì›°ë‹ˆìŠ¤ ë°©ë¬¸ê³¼ ë¹„ì›°ë‹ˆìŠ¤ ë°©ë¬¸ ê°„ì˜ ì°¨ì´ì— ëŒ€í•´ í•œ ê°€ì§€ ì—¬ì­¤ë³´ê² ìŠµë‹ˆë‹¤. 2026ë…„ìœ¼ë¡œ ê°€ë©´ì„œ ë¹„ì›°ë‹ˆìŠ¤ ë°©ë¬¸ì˜ ìƒëŒ€ì  ì•ˆì •ì„±ì„ ê³ ë ¤í•  ë•Œ, ë§Œì•½ ê·¸ê²ƒì´ ìœ ì§€ëœë‹¤ë©´, 25ë…„ í•˜ë°˜ê¸° ë¹„ì›°ë‹ˆìŠ¤ ë°©ë¬¸ ì‹¤ì ì„ ê·¸ëŒ€ë¡œ í–¥í›„ì— ì ìš©í•´ë„ ë ê¹Œìš”? ì•„ë‹ˆë©´ ì „ì²´ ë°©ë¬¸ 2% ê°ì†Œ ê°€ì´ë˜ìŠ¤ë¥¼ ê°ì•ˆí•  ë•Œ 26ë…„ ë¹„ì›°ë‹ˆìŠ¤ ë°©ë¬¸ ì¶”ì´ë¥¼ ì–´ë–»ê²Œ ìƒê°í•´ì•¼ í• ê¹Œìš”?</td></tr>
<tr><td>Jay Mazelsky: President, CEO & Director Yes. So the 2% for '26 is the baseline, and that includes both well and non-well roughly within what we saw in '25. What I would say is the non-well is more resilient to macro pressures. Obviously, pets are getting sick. They need to come into the practice. So I think that they tend to be a bit more resilient. We also expect that the pandemic dog and cat -- puppy and kitten boom will continue and will -- those green shoots that we've seen will continue to modestly grow over time as these pets age and require more health care. So I think it's reflected at this point in the 2% decline guide for '26. And hopefully, as time progresses, that improves.</td><td>**Jay Mazelsky:** ë„¤, 2026ë…„ 2% ê°ì†ŒëŠ” ê¸°ì¤€ì„ ì´ë©°, ì—¬ê¸°ì—ëŠ” 2025ë…„ì— ë³´ì•˜ë˜ ê²ƒê³¼ ê±°ì˜ ìœ ì‚¬í•˜ê²Œ ì›°ë‹ˆìŠ¤ì™€ ë¹„ì›°ë‹ˆìŠ¤ ë°©ë¬¸ì´ ëª¨ë‘ í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ë§ì”€ë“œë¦¬ê³  ì‹¶ì€ ê²ƒì€ ë¹„ì›°ë‹ˆìŠ¤ ë°©ë¬¸ì´ ê±°ì‹œê²½ì œ ì••ë°•ì— ë” íƒ„ë ¥ì ì´ë¼ëŠ” ì ì…ë‹ˆë‹¤. ë°˜ë ¤ë™ë¬¼ì´ ì•„í”„ë©´ ë³‘ì›ì— ì™€ì•¼ í•˜ê¸° ë•Œë¬¸ì´ì£ . ê·¸ë˜ì„œ ì´ ë¶€ë¶„ì´ ì¢€ ë” íšŒë³µë ¥ì´ ìˆë‹¤ê³  ë´…ë‹ˆë‹¤. <br><br>ë˜í•œ íŒ¬ë°ë¯¹ ì‹œê¸°ì˜ ê°•ì•„ì§€ì™€ ê³ ì–‘ì´ ë¶ì´ ê³„ì†ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìœ¼ë©°, ìš°ë¦¬ê°€ ë³¸ ê¸ì •ì ì¸ ì¡°ì§ë“¤ì´ ì´ ë°˜ë ¤ë™ë¬¼ë“¤ì´ ë‚˜ì´ê°€ ë“¤ê³  ë” ë§ì€ ì˜ë£Œ ì„œë¹„ìŠ¤ê°€ í•„ìš”í•´ì§ì— ë”°ë¼ ì‹œê°„ì´ ì§€ë‚˜ë©´ì„œ ì™„ë§Œí•˜ê²Œ ì„±ì¥í•  ê²ƒìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. <br><br>í˜„ì¬ë¡œì„œëŠ” ì´ëŸ¬í•œ ì ë“¤ì´ 2026ë…„ 2% ê°ì†Œ ê°€ì´ë˜ìŠ¤ì— ë°˜ì˜ë˜ì–´ ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì‹œê°„ì´ ì§€ë‚˜ë©´ì„œ ì´ ìƒí™©ì´ ê°œì„ ë˜ê¸°ë¥¼ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: And our next question is going to come from Brandon Vazquez from William Blair.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ William Blairì˜ Brandon Vazquezë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Brandon Vazquez: William Blair & Company L.L.C., Research Division Maybe you can start, pivot us a little bit. We spent a lot of time talking about the good innovation on the hardware side. Maybe you can spend a couple of minutes talking about the software especially some of the pet owner facing ones like Vello. I don't think we've gotten a good update on those. How are they contributing to results? And then more specifically, are they really helping you offset any of this weakness we're seeing in end markets? Are you -- in the accounts that are using things like Vello, are you seeing better pull-through of the portfolio?</td><td>**Brandon Vazquez:** í•˜ë“œì›¨ì–´ ì¸¡ë©´ì˜ ìš°ìˆ˜í•œ í˜ì‹ ì— ëŒ€í•´ ë§ì€ ì‹œê°„ì„ í• ì• í–ˆìœ¼ë‹ˆ, ì´ì œ ì†Œí”„íŠ¸ì›¨ì–´, íŠ¹íˆ Velloì™€ ê°™ì€ ë°˜ë ¤ë™ë¬¼ ë³´í˜¸ì ëŒ€ìƒ ì†Œí”„íŠ¸ì›¨ì–´ì— ëŒ€í•´ ëª‡ ë¶„ ì •ë„ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì´ ë¶€ë¶„ì— ëŒ€í•´ì„œëŠ” ì¶©ë¶„í•œ ì—…ë°ì´íŠ¸ê°€ ì—†ì—ˆë˜ ê²ƒ ê°™ìŠµë‹ˆë‹¤. ì‹¤ì ì— ì–´ë–»ê²Œ ê¸°ì—¬í•˜ê³  ìˆë‚˜ìš”? ê·¸ë¦¬ê³  ë” êµ¬ì²´ì ìœ¼ë¡œ, í˜„ì¬ ì‹œì¥ì—ì„œ ë³´ì´ëŠ” ì•½ì„¸ë¥¼ ìƒì‡„í•˜ëŠ” ë° ì‹¤ì œë¡œ ë„ì›€ì´ ë˜ê³  ìˆë‚˜ìš”? Velloì™€ ê°™ì€ ì†”ë£¨ì…˜ì„ ì‚¬ìš©í•˜ëŠ” ê³ ê°ì‚¬ì—ì„œ í¬íŠ¸í´ë¦¬ì˜¤ ì „ë°˜ì˜ íŒë§¤ ì„±ê³¼ê°€ ë” ì¢‹ê²Œ ë‚˜íƒ€ë‚˜ê³  ìˆë‚˜ìš”?</td></tr>
<tr><td>Jay Mazelsky: President, CEO & Director We are. The software piece is very, very important strategic business within the overall IDEXX business. It's a great business in and of itself, software business. It's growing strongly. We see good profitability. There's a nice leverage impact in terms of diagnostics. We've grown our cloud-based PIMS placements at double digits. So we're a leader within cloud-based PIMS within the North American market, something that we think is very important. With that, from just an ARR standpoint, we see pet owner engagement application, Vello is getting excellent traction. We shared some statistics both quarterly from a sequential basis and year-on-year. We know that those customers who use our software solutions use more of our diagnostics with -- specifically with reference to Vello, we see fewer no-shows, more clinical visits, more diagnostics usage, all the things that you would expect. So it is an important part -- it's an important offset. Now it's still relatively small compared to our total installed base of customers who use diagnostics, but we're very bullish on it. And we think it's an important element of really driving a solutions portfolio.</td><td>**Jay Mazelsky:** ë„¤, ë§ìŠµë‹ˆë‹¤. ì†Œí”„íŠ¸ì›¨ì–´ ë¶€ë¬¸ì€ IDEXX ì „ì²´ ì‚¬ì—…ì—ì„œ ë§¤ìš° ì¤‘ìš”í•œ ì „ëµì  ì‚¬ì—…ì…ë‹ˆë‹¤. ê·¸ ìì²´ë¡œë„ í›Œë¥­í•œ ì†Œí”„íŠ¸ì›¨ì–´ ë¹„ì¦ˆë‹ˆìŠ¤ì´ê³ ìš”. ê°•ë ¥í•˜ê²Œ ì„±ì¥í•˜ê³  ìˆìœ¼ë©°, ìˆ˜ìµì„±ë„ ì–‘í˜¸í•©ë‹ˆë‹¤. ì§„ë‹¨ ë¶€ë¬¸ê³¼ì˜ ì‹œë„ˆì§€ ì¸¡ë©´ì—ì„œë„ ì¢‹ì€ ë ˆë²„ë¦¬ì§€ íš¨ê³¼ê°€ ìˆìŠµë‹ˆë‹¤. í´ë¼ìš°ë“œ ê¸°ë°˜ PIMS ì„¤ì¹˜ ê±´ìˆ˜ê°€ ë‘ ìë¦¿ìˆ˜ë¡œ ì¦ê°€í–ˆìŠµë‹ˆë‹¤. ë¶ë¯¸ ì‹œì¥ì—ì„œ í´ë¼ìš°ë“œ ê¸°ë°˜ PIMS ë¶„ì•¼ì˜ ì„ ë‘ì£¼ìì´ë©°, ì´ëŠ” ë§¤ìš° ì¤‘ìš”í•œ ì˜ë¯¸ë¥¼ ê°–ëŠ”ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ARR ê´€ì ì—ì„œ ë³´ë©´, ë°˜ë ¤ë™ë¬¼ ë³´í˜¸ì ì°¸ì—¬ ì• í”Œë¦¬ì¼€ì´ì…˜ì¸ Velloê°€ íƒì›”í•œ ê²¬ì¸ë ¥ì„ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. ë¶„ê¸°ë³„ ìˆœì°¨ ê¸°ì¤€ê³¼ ì „ë…„ ëŒ€ë¹„ ê¸°ì¤€ ëª¨ë‘ì—ì„œ ëª‡ ê°€ì§€ í†µê³„ë¥¼ ê³µìœ í•´ ë“œë ¸ìŠµë‹ˆë‹¤. ì €í¬ ì†Œí”„íŠ¸ì›¨ì–´ ì†”ë£¨ì…˜ì„ ì‚¬ìš©í•˜ëŠ” ê³ ê°ë“¤ì€ ì§„ë‹¨ ì œí’ˆì„ ë” ë§ì´ í™œìš©í•œë‹¤ëŠ” ê²ƒì„ ì•Œê³  ìˆìŠµë‹ˆë‹¤. íŠ¹íˆ Velloì˜ ê²½ìš°ë¥¼ ë³´ë©´, ë…¸ì‡¼(no-show)ê°€ ê°ì†Œí•˜ê³ , ì„ìƒ ë°©ë¬¸ì´ ì¦ê°€í•˜ë©°, ì§„ë‹¨ ì œí’ˆ ì‚¬ìš©ì´ ëŠ˜ì–´ë‚˜ëŠ” ë“± ì˜ˆìƒí•  ìˆ˜ ìˆëŠ” ëª¨ë“  ê¸ì •ì ì¸ íš¨ê³¼ê°€ ë‚˜íƒ€ë‚˜ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì´ëŠ” ì¤‘ìš”í•œ ìƒì‡„ ìš”ì¸ì…ë‹ˆë‹¤. ë¬¼ë¡  í˜„ì¬ë¡œì„œëŠ” ì§„ë‹¨ ì œí’ˆì„ ì‚¬ìš©í•˜ëŠ” ì „ì²´ ê³ ê° ê¸°ë°˜ê³¼ ë¹„êµí•˜ë©´ ì—¬ì „íˆ ìƒëŒ€ì ìœ¼ë¡œ ì‘ì€ ê·œëª¨ì…ë‹ˆë‹¤ë§Œ, ì €í¬ëŠ” ì´ì— ëŒ€í•´ ë§¤ìš° ë‚™ê´€ì ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ê²ƒì´ ì†”ë£¨ì…˜ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ì‹¤ì§ˆì ìœ¼ë¡œ ê²¬ì¸í•˜ëŠ” ì¤‘ìš”í•œ ìš”ì†Œë¼ê³  ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Andrew Emerson: Executive VP, CFO & Treasurer Yes. We saw a solid double-digit growth in software on a reoccurring basis in the fourth quarter. And to Jay's point, yes, I think he had highlighted that Vello expanded users by about 40%. So we're seeing some nice traction there, and we're going to continue to build off of that momentum. But there's strong demand, I think, from a customer perspective to continue to move to this vertical SaaS orientation that I think we're amplifying through the different offerings that we have.</td><td>**Andrew Emerson:** ë„¤, 4ë¶„ê¸°ì— ì†Œí”„íŠ¸ì›¨ì–´ ë¶€ë¬¸ì—ì„œ ë°˜ë³µ ë§¤ì¶œ ê¸°ì¤€ìœ¼ë¡œ ê²¬ê³ í•œ ë‘ ìë¦¿ìˆ˜ ì„±ì¥ì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  Jayê°€ ì–¸ê¸‰í–ˆë“¯ì´, Velloì˜ ì‚¬ìš©ìê°€ ì•½ 40% ì¦ê°€í–ˆë‹¤ëŠ” ì ì„ ê°•ì¡°í–ˆì—ˆì£ . ì´ ë¶€ë¶„ì—ì„œ ìƒë‹¹íˆ ì¢‹ì€ ê²¬ì¸ë ¥ì„ ë³´ì´ê³  ìˆìœ¼ë©°, ì•ìœ¼ë¡œë„ ì´ëŸ¬í•œ ëª¨ë©˜í…€ì„ ê³„ì† ì´ì–´ê°ˆ ê³„íšì…ë‹ˆë‹¤. ê³ ê° ê´€ì ì—ì„œ ë³´ë©´ ë²„í‹°ì»¬ SaaS(Vertical SaaS) ë°©í–¥ìœ¼ë¡œ ì „í™˜í•˜ë ¤ëŠ” ìˆ˜ìš”ê°€ ê°•ë ¥í•˜ê²Œ ë‚˜íƒ€ë‚˜ê³  ìˆê³ , ì €í¬ê°€ ì œê³µí•˜ëŠ” ë‹¤ì–‘í•œ ì†”ë£¨ì…˜ì„ í†µí•´ ì´ë¥¼ ë”ìš± í™•ëŒ€í•´ ë‚˜ê°€ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Brandon Vazquez: William Blair & Company L.L.C., Research Division Okay. And as a follow-up here, as we're a little early playing with the numbers still this morning, but it looks like to get to the '26 guidance, you don't really need to push your utilization metric too much even when you back out price next year to kind of be within the midpoint of that range. But I also hear you making comments about how FNA is still in controlled launch and you maybe haven't even really gotten into the corporate accounts with inVue yet. Correct me if either of those are wrong, especially on the latter. But I guess the question being, one, is that correct? Like is utilization largely consistent through '26? And then two, are some of these opportunities to maybe push utilization even higher? You've yet to see some of the benefits of innovation in the utilization bucket.</td><td>**Brandon Vazquez:** ë„¤, ë§ìŠµë‹ˆë‹¤. 2026ë…„ ê°€ì´ë˜ìŠ¤ë¥¼ ë‹¬ì„±í•˜ê¸° ìœ„í•´ ê°€ê²© ì¸ìƒ íš¨ê³¼ë¥¼ ì œì™¸í•˜ë”ë¼ë„ ê°€ë™ë¥ (utilization) ì§€í‘œë¥¼ í¬ê²Œ ëŒì–´ì˜¬ë¦´ í•„ìš”ëŠ” ì—†ìŠµë‹ˆë‹¤. ì¤‘ê°„ê°’ ë²”ìœ„ ë‚´ì— ë“¤ì–´ê°€ëŠ” ìˆ˜ì¤€ì´ì£ . <br><br>ë§ì”€í•˜ì‹  ëŒ€ë¡œ FNAëŠ” ì—¬ì „íˆ í†µì œëœ ì¶œì‹œ(controlled launch) ë‹¨ê³„ì— ìˆê³ , inVueì˜ ê²½ìš° ê¸°ì—… ê³ ê°(corporate accounts)ì—ëŠ” ì•„ì§ ë³¸ê²©ì ìœ¼ë¡œ ì§„ì¶œí•˜ì§€ ì•Šì€ ìƒíƒœì…ë‹ˆë‹¤. ë‘ ê°€ì§€ ëª¨ë‘ ì •í™•í•˜ê²Œ ì´í•´í•˜ê³  ê³„ì‹­ë‹ˆë‹¤.<br><br>ì²« ë²ˆì§¸ ì§ˆë¬¸ì— ë‹µí•˜ìë©´, ë„¤, 2026ë…„ê¹Œì§€ ê°€ë™ë¥ ì€ ëŒ€ì²´ë¡œ ì¼ê´€ëœ ìˆ˜ì¤€ì„ ìœ ì§€í•  ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. <br><br>ë‘ ë²ˆì§¸ë¡œ, ê°€ë™ë¥ ì„ ë” ë†’ì¼ ìˆ˜ ìˆëŠ” ê¸°íšŒë“¤ì´ ë¶„ëª…íˆ ì¡´ì¬í•©ë‹ˆë‹¤. FNAì˜ ë³¸ê²©ì ì¸ í™•ëŒ€ì™€ inVueì˜ ê¸°ì—… ê³ ê° ì§„ì¶œì€ í–¥í›„ ê°€ë™ë¥  ìƒìŠ¹ì˜ ì£¼ìš” ë™ë ¥ì´ ë  ìˆ˜ ìˆìŠµë‹ˆë‹¤. í˜„ì¬ ê°€ì´ë˜ìŠ¤ëŠ” ì´ëŸ¬í•œ ê¸°íšŒë“¤ì„ ë³´ìˆ˜ì ìœ¼ë¡œ ë°˜ì˜í•œ ê²ƒì´ë©°, ì‹¤ì œë¡œëŠ” ì´ë“¤ ì œí’ˆì˜ ì‹œì¥ ì¹¨íˆ¬ê°€ ê°€ì†í™”ë˜ë©´ì„œ ê°€ë™ë¥ ì´ ë” ê°œì„ ë  ì—¬ì§€ê°€ ì¶©ë¶„í•©ë‹ˆë‹¤. ì•„ì§ í™œìš©ë„(utilization) ì¸¡ë©´ì—ì„œ í˜ì‹ ì˜ ì´ì ë“¤ì„ ì¼ë¶€ í™•ì¸í•˜ì§€ ëª»í•˜ì‹  ìƒíƒœì…ë‹ˆë‹¤.</td></tr>
<tr><td>Andrew Emerson: Executive VP, CFO & Treasurer Yes. So Brandon, just in terms of the '26 guide, one thing that I would highlight is, if you look at the midpoint from a comparability on the CAG Diagnostic recurring growth rate, where we ended about 8% in 2025, where midpoint is about 9% for 2026, so about 100 basis point improvement year-to-year. A lot of that is driven by volume. And certainly, it comes with the expansion of our customer base, but also just maintaining and growing strong utilization metrics overall, led by some of the innovation benefits that we have. So I think you captured the controlled launch correctly from an FNA standpoint. Yes, that will be something that helps us in 2026. We've captured that in our outlook already. And as Jay just highlighted, I think we are placing inVue into corporate accounts at this point. So that's an area that we've been working towards and it typically takes a little bit longer than independents. But we feel good that we have a nice momentum there, and we're targeting about 5,500 inVue placements for 2026 as well. So we feel really good about the innovation and continuing to help our customers drive growth. I think we're just being cautious relative to the macro environment and the sector trends that we've seen on areas like clinical visits that continue to be more muted. But overall, the business is performing quite well despite that.</td><td>**Andrew Emerson:** ë„¤, Brandon. 2026ë…„ ê°€ì´ë˜ìŠ¤ ê´€ë ¨í•´ì„œ í•œ ê°€ì§€ ê°•ì¡°í•˜ê³  ì‹¶ì€ ì ì€, CAG ì§„ë‹¨ ë°˜ë³µ ë§¤ì¶œ ì„±ì¥ë¥ ì˜ ì¤‘ê°„ê°’ì„ ë¹„êµí•´ë³´ë©´, 2025ë…„ì— ì•½ 8%ë¡œ ë§ˆê°í–ˆê³  2026ë…„ ì¤‘ê°„ê°’ì€ ì•½ 9%ì…ë‹ˆë‹¤. ì¦‰, ì „ë…„ ëŒ€ë¹„ ì•½ 100bp ê°œì„ ë˜ëŠ” ê²ƒì´ì£ . ì´ëŠ” ëŒ€ë¶€ë¶„ ë¬¼ëŸ‰ì— ì˜í•´ ì£¼ë„ë˜ê³  ìˆìŠµë‹ˆë‹¤. ë¬¼ë¡  ê³ ê° ê¸°ë°˜ í™•ëŒ€ë„ ìˆì§€ë§Œ, ì „ë°˜ì ìœ¼ë¡œ ê°•ë ¥í•œ í™œìš©ë¥  ì§€í‘œë¥¼ ìœ ì§€í•˜ê³  ì„±ì¥ì‹œí‚¤ëŠ” ê²ƒë„ í¬í•¨ë©ë‹ˆë‹¤. ì´ëŠ” ìš°ë¦¬ê°€ ë³´ìœ í•œ í˜ì‹  íš¨ê³¼ë“¤ì´ ì£¼ë„í•˜ê³  ìˆìŠµë‹ˆë‹¤. FNA ê´€ì ì—ì„œ í†µì œëœ ì¶œì‹œì— ëŒ€í•´ ì •í™•í•˜ê²Œ ì´í•´í•˜ì‹  ê²ƒ ê°™ìŠµë‹ˆë‹¤. ë„¤, ê·¸ê²ƒì´ 2026ë…„ì— ë„ì›€ì´ ë  ê²ƒì´ë©°, ì´ë¯¸ ì „ë§ì¹˜ì— ë°˜ì˜í–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  Jayê°€ ë°©ê¸ˆ ê°•ì¡°í–ˆë“¯ì´, í˜„ì¬ ìš°ë¦¬ëŠ” inVueë¥¼ ê¸°ì—… ê³ ê°ì‚¬(corporate accounts)ì— ë°°ì¹˜í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ ë¶€ë¶„ì€ ìš°ë¦¬ê°€ ê³„ì† ë…¸ë ¥í•´ì˜¨ ì˜ì—­ì´ê³ , ì¼ë°˜ì ìœ¼ë¡œ ë…ë¦½ ë³‘ì›ë“¤ë³´ë‹¤ëŠ” ì‹œê°„ì´ ì¡°ê¸ˆ ë” ê±¸ë¦½ë‹ˆë‹¤. í•˜ì§€ë§Œ ì¢‹ì€ ëª¨ë©˜í…€ì„ í™•ë³´í–ˆë‹¤ê³  ìƒê°í•˜ë©°, 2026ë…„ì—ë„ ì•½ 5,500ëŒ€ì˜ inVue ë°°ì¹˜ë¥¼ ëª©í‘œë¡œ í•˜ê³  ìˆìŠµë‹ˆë‹¤. í˜ì‹ ê³¼ ê³ ê°ë“¤ì˜ ì„±ì¥ ì§€ì›ì„ ì§€ì†í•˜ëŠ” ê²ƒì— ëŒ€í•´ ë§¤ìš° ê¸ì •ì ìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ë‹¤ë§Œ ê±°ì‹œê²½ì œ í™˜ê²½ê³¼ ì„ìƒ ë°©ë¬¸(clinical visits) ê°™ì€ ë¶€ë¬¸ì—ì„œ ê³„ì† ë‘”í™”ì„¸ë¥¼ ë³´ì´ëŠ” ì—…ê³„ íŠ¸ë Œë“œì— ëŒ€í•´ì„œëŠ” ì‹ ì¤‘í•œ ì…ì¥ì„ ì·¨í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ëŸ¼ì—ë„ ë¶ˆêµ¬í•˜ê³  ì „ë°˜ì ìœ¼ë¡œ ì‚¬ì—…ì€ ìƒë‹¹íˆ ì¢‹ì€ ì„±ê³¼ë¥¼ ë‚´ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: And our last question is going to come from Andrea Alfonso from UBS. Andrea Zayco Narvaez Alfonso UBS Investment Bank, Research Division So I just was curious about the dynamics underpinning the gross margin mix in the quarter. It looks like pricing growth is pretty stable sequentially, although you did cite some pressure from mix. And I guess as we think about the 2026 margin expansion of 30 to 80 basis points organically, how do we think about your gross margin improvement stacking versus that 30 to 80 bps? I think you mentioned the moderation in pricing in the U.S. and obviously still calling out the mix impact. And then I guess the other part of that algorithm is how do we think about SG&A growth recognizing some of the ongoing commercial investments you're making?</td><td>**Operator:** ì´ë²ˆ ë¶„ê¸° ë§¤ì¶œì´ì´ìµë¥ (gross margin) ë¯¹ìŠ¤ë¥¼ ë’·ë°›ì¹¨í•˜ëŠ” ì—­í•™ ê´€ê³„ê°€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ê°€ê²© ì„±ì¥ì€ ì „ë¶„ê¸° ëŒ€ë¹„ ê½¤ ì•ˆì •ì ìœ¼ë¡œ ë³´ì´ëŠ”ë°, ë¯¹ìŠ¤ë¡œ ì¸í•œ ì••ë°•ì€ ì–¸ê¸‰í•˜ì…¨ë”ë¼ê³ ìš”. ê·¸ë¦¬ê³  2026ë…„ ìœ ê¸°ì  ë§ˆì§„ í™•ëŒ€ 30~80bpë¥¼ ìƒê°í•´ë³¼ ë•Œ, ë§¤ì¶œì´ì´ìµë¥  ê°œì„ ì´ ê·¸ 30~80bpì™€ ì–´ë–»ê²Œ ìŒ“ì—¬ê°€ëŠ”ì§€ ì–´ë–»ê²Œ ë´ì•¼ í• ê¹Œìš”? ë¯¸êµ­ ë‚´ ê°€ê²© ì¡°ì • ì™„í™”ë¥¼ ì–¸ê¸‰í•˜ì…¨ê³ , ì—¬ì „íˆ ë¯¹ìŠ¤ ì˜í–¥ë„ ë§ì”€í•˜ì…¨ì–ì•„ìš”. ê·¸ë¦¬ê³  ê·¸ ê³µì‹ì˜ ë‹¤ë¥¸ ë¶€ë¶„ìœ¼ë¡œëŠ”, ì§„í–‰ ì¤‘ì¸ ì˜ì—… íˆ¬ìë¥¼ ê³ ë ¤í•  ë•Œ íŒê´€ë¹„(SG&A) ì¦ê°€ë¥¼ ì–´ë–»ê²Œ ë´ì•¼ í• ê¹Œìš”?</td></tr>
<tr><td>Andrew Emerson: Executive VP, CFO & Treasurer Yes. Thanks, Andrea. Just in terms of what we saw in Q4, we did have modest pressure just from strong instrument revenues in the quarter. Yes, I think we had highlighted that on the call. But we still delivered about 60 basis points comparably from a gross margin expansion standpoint. So quite solid on the improvement that we see on gross margins. And then for the quarter, we also saw about 120 basis points of operating margin improvement as well. So quite solid there as well. That included investments that we were making. Jay had highlighted, we completed the expansions that we're expecting to be announced about midyear. So that was factored certainly into the overall SG&A growth as well as continued investment in areas like innovation with a strong R&D number as well. So that's how the quarter played out. I think it was largely in line with our expectations. I think the implied midpoint was right around those same metrics. As we think about 2026, our guidance for operating margin improvement is the 30 to 80 basis points that you had highlighted on a comparable basis. That's largely going to be gross margin led. I think we continue to see benefits from a gross margin perspective there as we invest back into the business for the longer term. So we expect most of that would likely be gross margin led overall, and we'll be -- we feel good about kind of where that positions us as we invest back into the long term.</td><td>**Andrew Emerson:** 4ë¶„ê¸°ì—ëŠ” ê°•ë ¥í•œ ì¥ë¹„ ë§¤ì¶œë¡œ ì¸í•´ ì†Œí­ì˜ ì••ë°•ì´ ìˆì—ˆìŠµë‹ˆë‹¤. í†µí™”ì—ì„œ ë§ì”€ë“œë¦° ë¶€ë¶„ì´ì£ . í•˜ì§€ë§Œ ê·¸ëŸ¼ì—ë„ ë¶ˆêµ¬í•˜ê³  ë§¤ì¶œì´ì´ìµë¥ (gross margin) ì¸¡ë©´ì—ì„œ ì•½ 60bpì˜ ê°œì„ ì„ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ìƒë‹¹íˆ ê²¬ê³ í•œ ê°œì„ ì„¸ë¼ê³  ë³¼ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  í•´ë‹¹ ë¶„ê¸°ì— ì˜ì—…ì´ìµë¥ (operating margin)ë„ ì•½ 120bp ê°œì„ ë˜ì—ˆìŠµë‹ˆë‹¤. ì´ ì—­ì‹œ ë§¤ìš° ê²¬ê³ í•œ ìˆ˜ì¹˜ì…ë‹ˆë‹¤. ì—¬ê¸°ì—ëŠ” ìš°ë¦¬ê°€ ì§„í–‰ ì¤‘ì¸ íˆ¬ìë„ í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤. Jayê°€ ì–¸ê¸‰í–ˆë“¯ì´, ì—°ì¤‘ ë°œí‘œ ì˜ˆì •ì´ì—ˆë˜ í™•ì¥ í”„ë¡œì íŠ¸ë“¤ì„ ì™„ë£Œí–ˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ìš”ì†Œë“¤ì´ ì „ë°˜ì ì¸ íŒë§¤ê´€ë¦¬ë¹„ ì¦ê°€ì— ë°˜ì˜ë˜ì—ˆê³ , ê°•ë ¥í•œ R&D ìˆ˜ì¹˜ì—ì„œ ë³´ì‹œë‹¤ì‹œí”¼ í˜ì‹  ê°™ì€ ë¶„ì•¼ì— ëŒ€í•œ ì§€ì†ì ì¸ íˆ¬ìë„ í¬í•¨ë˜ì—ˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ ì´ë²ˆ ë¶„ê¸°ì˜ ì‹¤ì ì…ë‹ˆë‹¤. ëŒ€ì²´ë¡œ ì €í¬ ì˜ˆìƒê³¼ ì¼ì¹˜í–ˆë‹¤ê³  ë´…ë‹ˆë‹¤. ë‚´ì¬ëœ ì¤‘ê°„ê°’ë„ ë™ì¼í•œ ì§€í‘œ ìˆ˜ì¤€ì´ì—ˆìŠµë‹ˆë‹¤.<br><br>2026ë…„ì„ ë³´ë©´, ë§ì”€í•˜ì‹  ëŒ€ë¡œ ë¹„êµ ê°€ëŠ¥ ê¸°ì¤€ìœ¼ë¡œ ì˜ì—…ì´ìµë¥  ê°œì„  ê°€ì´ë˜ìŠ¤ëŠ” 30~80bpì…ë‹ˆë‹¤. ì´ëŠ” ì£¼ë¡œ ë§¤ì¶œì´ì´ìµë¥ ì´ ì£¼ë„í•  ê²ƒì…ë‹ˆë‹¤. ì¥ê¸°ì ì¸ ê´€ì ì—ì„œ ì‚¬ì—…ì— ì¬íˆ¬ìí•˜ë©´ì„œ ë§¤ì¶œì´ì´ìµë¥  ì¸¡ë©´ì—ì„œ ê³„ì†í•´ì„œ ì´ì ì„ í™•ë³´í•  ìˆ˜ ìˆì„ ê²ƒìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ëŒ€ë¶€ë¶„ì€ ì „ë°˜ì ìœ¼ë¡œ ë§¤ì¶œì´ì´ìµë¥  ì£¼ë„ë¡œ ì´ë£¨ì–´ì§ˆ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìœ¼ë©°, ì¥ê¸°ì ì¸ íˆ¬ìë¥¼ ì§„í–‰í•˜ë©´ì„œë„ í˜„ì¬ ìš°ë¦¬ì˜ í¬ì§€ì…˜ì— ëŒ€í•´ ê¸ì •ì ìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Jay Mazelsky: President, CEO & Director Okay. Thank you for the questions. We'll now conclude our Q&A portion of this morning's call. It's been a pleasure to review another quarter and full year of strong IDEXX results. So thank you for your participation this morning, and we'll now conclude the call.</td><td>**Jay Mazelsky:** ê°ì‚¬í•©ë‹ˆë‹¤. ì§ˆë¬¸ ì£¼ì…”ì„œ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. ì´ì œ ì˜¤ëŠ˜ ì˜¤ì „ ì§ˆì˜ì‘ë‹µ ì‹œê°„ì„ ë§ˆì¹˜ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤. ë˜ í•œ ë¶„ê¸°ì™€ í•œ í•´ì˜ ê°•ë ¥í•œ IDEXX ì‹¤ì ì„ ì—¬ëŸ¬ë¶„ê³¼ í•¨ê»˜ ê²€í† í•  ìˆ˜ ìˆì–´ì„œ ì¢‹ì•˜ìŠµë‹ˆë‹¤. ì˜¤ëŠ˜ ì˜¤ì „ ì°¸ì—¬í•´ ì£¼ì…”ì„œ ê°ì‚¬ë“œë¦¬ë©°, ì´ê²ƒìœ¼ë¡œ ì»¨í¼ëŸ°ìŠ¤ ì½œì„ ë§ˆì¹˜ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: And this concludes today's call. Thank you for your participation. You may now disconnect.</td><td>**Operator:** ì´ê²ƒìœ¼ë¡œ ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ ì½œì„ ë§ˆì¹˜ê² ìŠµë‹ˆë‹¤. ì°¸ì—¬í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. ì´ì œ ì—°ê²°ì„ ì¢…ë£Œí•˜ì…”ë„ ë©ë‹ˆë‹¤.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;"># IDEXX Laboratories ì‹¤ì  ë°œí‘œ ì£¼ìš” ìš”ì•½<br><br>## í•µì‹¬ ì¬ë¬´ ì§€í‘œ ë° ì‹¤ì <br>- **2025ë…„ 4ë¶„ê¸°**: CAG ì§„ë‹¨ ë°˜ë³µ ë§¤ì¶œ 8% ì„±ì¥, ì˜ì—…ì´ìµë¥  120bp ê°œì„ , ì´ì´ìµë¥  60bp ê°œì„ <br>- **2026ë…„ ê°€ì´ë˜ìŠ¤**: CAG ì§„ë‹¨ ë°˜ë³µ ë§¤ì¶œ 9% ì„±ì¥ ì „ë§(ì¤‘ê°„ê°’ ê¸°ì¤€), ì˜ì—…ì´ìµë¥  30~80bp ê°œì„  ì˜ˆìƒ<br>- **í˜ì‹  ì œí’ˆ ì„±ê³¼**: inVue 2025ë…„ ë§¤ì¶œ ê¸°ì—¬ $75ë°±ë§Œ, 2026ë…„ ì•½ 5,500ëŒ€ ì¶”ê°€ ì„¤ì¹˜ ëª©í‘œ<br>- **ì„¤ì¹˜ ê¸°ë°˜ í™•ëŒ€**: ì „ì²´ ì„¤ì¹˜ ê¸°ë°˜ 12% ì„±ì¥, Catalyst ì‹ ê·œ/ê²½ìŸ ì„¤ì¹˜ 1,350ëŒ€(ê¸€ë¡œë²Œ), ë¶ë¯¸ 360ëŒ€<br><br>## ì£¼ìš” ê°€ì´ë˜ìŠ¤ ë° ì „ëµ<br>- **2026ë…„ 1ë¶„ê¸°**: CAG ì§„ë‹¨ ë°˜ë³µ ë§¤ì¶œ 9.5% ì„±ì¥ ì „ë§(ì¤‘ê°„ê°’), ì˜ì—…ì¼ìˆ˜ ì¦ê°€ë¡œ 50bp ê¸ì •ì  ì˜í–¥<br>- **ê°€ê²© ì •ì±…**: 2026ë…„ ì „ì‚¬ ê°€ê²© ì¸ìƒ 4%, ë¯¸êµ­ 3.5%ë¡œ ì¥ê¸° ê³„íš ë²”ìœ„ ë‚´ ì •ìƒí™”<br>- **ë™ë¬¼ë³‘ì› ë°©ë¬¸**: 2026ë…„ ì•½ 2% ê°ì†Œ ì „ë§ ìœ ì§€ (ì›°ë‹ˆìŠ¤ ë°©ë¬¸ ì••ë°• ì§€ì†, ë¹„ì›°ë‹ˆìŠ¤ ë°©ë¬¸ì€ ìƒëŒ€ì ìœ¼ë¡œ ì•ˆì •ì )<br>- **êµ­ì œ ì‹œì¥**: ë¯¸êµ­ ëŒ€ë¹„ ë†’ì€ ì„±ì¥ë¥  ì „ë§, ë…ì¼Â·ì˜êµ­Â·í˜¸ì£¼ ë“± ìƒì—… íˆ¬ì ì§€ì†<br><br>## ê²½ì˜ì§„ í†¤ ë°</p>
    <hr style="margin:50px 0;">
    
</body></html>